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1. The immune response 
The immune system is highly complex and comprises molecules, cells and tissues 
responsible for combating external and internal insults. An intact immune system is 
essential for maintaining our health, and its dysfunction is associated with increased 
susceptibility to infection or the development of inflammation, autoimmunity, allergy 
or cancer. In general, there are two kinds of immunity, i.e. the innate immunity and 
the adaptive immunity (1). Microbes as small as viruses/bacteria, but also larger 
organisms such as worms, can invade humans. Collectively these organisms are 
called pathogens when they cause disease in the host. The first line of defense 
includes outer barriers, like the skin and mucous membranes. When pathogens 
breach the outer barriers, non-specific innate immunity including complement 
activation, phagocytosis and opsonization will be activated. The innate immunity 
relies on the recognition of pathogen-associated molecular patterns (PAMPs) that are 
common to many pathogens, but are absent in the host. Monocytes, macrophages, 
dendritic cells (DCs), granulocytes, mast cells and natural killer (NK) cells are the 
most important effector cell types of the innate immune system (2, 3). In contrast 
to the innate immune response which is activated mainly at sites of infection, the 
adaptive immune response is activated in peripheral lymphoid organs and provides 
specific and long-lasting protection against the particular pathogens. The major 
mediators of the adaptive immune response consist of B cells, T cells, and antigen 
presenting cells (APCs) such as DCs (4).
T lymphocytes carry out multiple functions in the adaptive immune response. T cells 
develop from hematopoietic stem cells (HSC) in the bone marrow and mature in 
the thymus, where they are educated via negative selection and positive selection 
processes (5, 6). The surviving T cell population will have the potential capacity to 
recognize foreign antigens with sufficient affinity to result in T cell activation. Based 
on the subtypes of T cell receptor (TCR) expressed, there exist aβ T cells and gδ T 
cells (7). The aβ T cells, based on the glycoprotein expressed on the cell surface, 
can be further divided into two broad subsets, CD4+ T cells, also called T helper 
cells, and CD8+ cytotoxic cells. In this thesis, the main focus is on CD4+ T cells.
2. CD4+ T Lymphocytes
CD4+ T helper cells play a crucial role in establishing and maximizing the capabilities 
of the acquired immune response. They express a TCR that recognizes antigen 
bound to class II major histocompatibility complex (MHC) molecules. T cells are 
engaged when an APC displays the antigen derived peptide to which the T cell is 
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specific. The cytokine milieu present during naïve T cell activation guides them to 
differentiate into memory and effector T helper (Th) subsets including Th1, Th2, 
Th17, TFH (follicular helper cells) and others (8) (Figure 1). This differentiation process 
is dependent on the strength of the TCR signal, as well as additional costimulatory 
and cytokine signals that the cell receives during cell-cell contact. The Th cell 
subtypes express different profiles of cell surface markers and a characteristic 
cytokine signature that determines their effector cell capacity. 
Th1 cells promote cellular immunity against viruses and intracellular bacteria. 
Cytokines like IL-12, which thereafter induces the phosphorylation of STAT1/4 
(9, 10), play a major role in the generation of Th1 cells in both mice and humans 
(11). Th1 cells can be discriminated from other T helper phenotypes based on the 
expression of the nuclear transcription factor T-bet and chemokine receptors CXCR3 
and CCR5 (12). An additional hall mark of Th1 differentiation is the ability to produce 
IFNγ. Several Th1 dominant autoimmune diseases including multiple sclerosis, 
diabetes, and rheumatoid arthritis have been reported.In contrast to Th1 cells, Th2 
cells promote immunity against extracellular pathogens and are involved in allergic 
inflammation. Th2 cells differentiation is mainly driven by IL-4 which in turn leads 
to the phosphorylation of STAT6 (13-15). The lineage marker of Th2 cells is the 
expression of nuclear transcription factor GATA-3 (16). Interestingly, the low signal 
via the TCR is important for the initial expression of GATA-3 (17). The characterized 
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Figure 1: CD4+ T cell subsets and the critical cytokines and transcription factors that are essential 
for their differentiations.
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cytokines produced by Th2 cells include IL-4, IL-5, IL-6, IL-10, and IL-13.
Th17 cells are involved in inflammatory autoimmune diseases such as psoriasis and 
rheumatoid arthritis(RA) (18), as well as in protection from fungal infection (19, 20). 
TGFβ combined with cytokines such as IL-6, and/or IL-21, via the phosphorylation 
of STAT3, are required for Th17 differentiation (19, 21). The maintenance of Th17 
requires IL-23 which drives rapid cell proliferation via IL-23 receptor (22). Th17 
cells are characterized by the expression of the nuclear transcription factor RORgt 
(23), and the expression of the surface marker CCR6 (24). The signature cytokines 
produced by Th17 include IL-17A, IL-17F, IL-21, and IL-22 (25-27).
Follicular helper T (TFH) cells are recently established as an independent T cell 
lineage. The differentiation and maturation process of TFH cells is more complicated 
than that of other subsets, and composes of three phases: firstly initial differentiation 
towards the TFH lineage, secondly, migration to B cell follicles and interaction with 
B-cells, and finally, maturation in germinal centers. In humans, IL-12, IL-23, and 
TGFβ have dominant roles in the generation of TFH cells (28, 29). TFH express CXCR5 
and display a superior capacity to induce B cells to produce immunoglobulins in vitro 
(30).
Finally, regulatory T cells (Treg) are crucial for maintaining self tolerance and 
putting a brake on excessive immune responses. The lineage marker of Treg is the 
transcription factor FOXP3, and the high expression of the IL-2 receptor alpha chain 
(CD25) is another important feature. Additional characteristic features of Treg will be 
discussed in a separate section.
2.1. T cell activation
T cells require several signals to become fully activated (31). The first signal occurs 
upon ligation of the TCR by MHC molecules expressed on APCs, presenting 
peptides from either endogenously encoded self-molecules or exogenously encoded 
pathogen derived molecules (signal 1). Other signals are offered by subsequent 
engagement of costimulatory molecules such as CD28 (signal 2) and/or cytokines 
(signal 3) (32). Generally, the second signal has two important features; (i) it has no 
relation with antigen specificity, and (ii) it can be produced by a number of distinct 
molecular interactions that may occur between an APC and a T cell (33). TCR ligation 
alone is insufficient to elicit T cell effector functions such as the release of IL-2, but 
does result in T cell unresponsiveness to subsequent stimulation, a phenomenon 
known as anergy (34). Activation of T cells results in the translocation of  nuclear 
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transcription factors like NFAT, NFκB and AP-1,  thus leading to the clonal expansion, 
the upregulation of activation markers, the differentiation into effector cells, and the 
induction of cytotoxicity or cytokine secretion. 
Following triggering of the TCR, the Src family kinase Lck is recruited to the TCR 
complex resulting in the downstream activation and phosphorylation of ZAP70 
kinase. This phosphorylation results in conformational changes in ZAP70 that 
promotes its kinase activity, leading to the activation of its target molecules including 
LAT (linker for activation of T cells). Phosphorylated tyrosine residues of LAT recruit 
multiple downstream adaptor and signaling molecules including SLP76 (SH2-domain 
containing leukocyte protein of 76 kDa) and PLCγ (phospholipase Cγ). Activated PLCγ 
triggers the formation of the two second messengers IP3 (inositol triphosphate) and 
DAG (diacyglycerols), which ultimately lead to the release of endoplasmic reticulum 
(ER) stored Ca2+ resulting in the elevation of cytosolic calcium and the activation of 
Ca2+ dependent serine/threonine phosphatase calcineurin (35, 36) (Figure 2). This 
lead to the nuclear translocation of the transcription factor NFAT which kick-starts the 
activation and/or differentiation of the resting T cells.
2.2. CD28 costimulation
The membrane receptor CD28 is one of the most extensively investigated 
costimulatory molecules, which is constitutively expressed on the surface of 
Figure 2: Schematic overview of TCR/CD28 signaling pathways. Adapted from Isakov, J Clin Cell 
Immunol 2012, S12.
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approximately 95% of peripheral CD4+ cells (both resting and activated T cells). The 
physiologic ligands of CD28 are B7.1 (CD80) and B7.2 (CD86) that are highly 
expressed on activated mature APCs (37, 38). CD28 signals are mediated through 
phosphorylated tyrosine and proline rich motifs present in its short cytoplasmic tail 
(39). Phosphorylated tyrosine serves as a binding site for the SH2-domain containing 
proteins like p85, a regulatory subunit of PI3K (40, 41), Grb2 and GADS (42, 43). 
The two proline-rich motifs serve as a binding site for the SH3-domain containing 
proteins such as Itk kinase (44, 45), Grb2 and GADS adaptor proteins (46), LcK and 
Fyn protein tyrosine kinases (47-50), PKCθ (51), and filamin A (52), an actin binding 
protein and a scaffold for lipid raft formation (Figure 3). 
In contrast to TCR triggering, CD28 engagement does not induce the activation of 
protein complex ZAP70/LAT/SLP76 and the Ca2+ responses (53), but enhances 
TCR mediated increase of the intracellular calcium concentration through regulating 
PLCg1 kinase activity (54, 55). Ligation of CD28 alone is sufficient for activation 
of PI3K/Akt and inactivation of GSK-3 in human T cells (56). Following CD28 
costimulation, a number of transcription factors are activated including NFκB (57), 
NFAT (58), and AP-1 (59) (Figure 2). CD28 costimulation leads to the generation of 
cytokines including IL-2 and the expression of Bcl-xL protein thus contributing to T 
cell growth and survival. CD28 is also indispensable for thymic Treg development 
Figure 3: Cytoplasmic tail of human CD28 and its binding proteins. The amino acid sequence of human 
CD28 cytoplasmic domain is shown in its dimeric form. Phosphorylated tyrosine residues of the Tyr-
Met-Asn-Met (YMNM) motif binds directly to the p85 subunit of PI3K, and the Asn residue is involved 
in the phosphorylation of VAV1. Proline rich regions of CD28 are responsible for the binding of LcK, 
PKCγ, ITK, Fyn, Grb2, GADS, as well as filamin-A. Phosphorylation of Tyr 191 within the PYAP motif 
creates a docking site for SH2 domain of Lck kinase and enables PKCθ to interact via its V3 domain with 
LcK. Studies suggest that Tyr191 is important for CD28 and PKCθ localization to the immune synapse. 
Adapted from Isakov et al, Front Immunol 2012, 3:273.
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and homeostasis. CD28-/- mice or B7.1/2 deficient mice show a marked reduction of 
Treg both in the thymus and periphery (60, 61). CD28-mediated Lck signals and the 
activation of the downstream NFκB family member c-Rel are linked to thymic Treg 
differentiation (62). Effective proliferation of human Treg also requires a strong CD28 
signal that cannot be substituted by IL-2 (63).
2.3. Protein Kinase C in T cells 
The protein kinase C (PKC) family of serine/therionine kinases contributes to signal 
transduction networks that coordinate almost all aspects of immune cell functions. 
PKCθ, a novel PKC of which activation is dependent on DAG, but independent on 
Ca2+ (64), is most abundant in hematopoietic cells (65). PKCθ plays a crucial role 
in integration of TCR-CD28 signals required for optimal NFκB activation (66). PKCθ 
is also the only isoform selectively recruited to the immune synapse in conventional 
effector T cells (67). Interestingly, both PKCθ and CD28 are localized to a spatially 
unique compartment that plays a central role in coordinating the signal pathways 
downstream of the TCR (68). PKCθ physically associates with the cytoplasmic tail of 
CD28 following TCR/CD28 stimulation (Figure 3). It is proposed that the localization 
of PKC in the immune synapse is determined by the PKCθ regulatory V3 domain, 
through which it associates with CD28, and requires Lck kinase (51). However, in 
contrast to its location in effector T cells, PKCθ is sequestered away from the immune 
synapse of activated Treg (69). The mechanism leading to such difference between 
effector T cells and Treg is not known yet.
Fully activated PKCθ leads to the activation of transcription factors NFκB (70), AP-1 
(71), and NFAT (72). PKCθ functions differently in distinct T cell subpopulations and 
during the induction of selected types of immune responses. It is essential for the 
induction of Th2 type immune responses to allergens or helminthes infection (73, 74), 
and the induction of Th17-mediated experimental autoimmune encephalomyelitis 
(EAE) (75). In contrast, Th1 dependent resistance to virus infection is intact in 
PKCθ knockout mice (73, 76, 77). Also cytotoxic T lymphocytes mediated protective 
antiviral responses do not rely on PKCθ (78). Interestingly, PKCθ is required for 
T cell mediated allo-reactivity and graft-versus-host diseases (GvHD), but not 
for graft-versus-leukemia (GvL) responses (77, 79). In mice lacking PKCθ, Treg 
development in the thymus is impaired, whereas the conventional naïve CD4+ and 
CD8+ T cell population appears grossly normal (72, 80-82). These data predict that 
PKCθ inhibition could be a useful approach in treatment of allogeneic transplantation 
of solid organs or HSCs, and autoimmune diseases. The recent success of small 
molecule inhibitors of PKC in a phase I clinical trial for psoriasis raises the possibility 
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of therapeutically targeting PKCθ to interfere with the balance between Tconv and 
Treg in patients (83).
3. Regulatory T Cells 
In this thesis,  the term Treg is used to refer to a CD4+ T cell lineage marked by the 
expression of transcription factor forkhead box protein 3 (FOXP3) and constitutive 
expression of the high affinity interleukin-2 receptor alpha chain CD25. 
Treg are first identified in mice (84), and later in human (85). Treg constitute 1-5% 
of the total peripheral CD4+ T cell pool, where they function to maintain homeostatic 
balance in the immune system. The loss of Treg, as a result of failed development or 
experimental depletion, leads to multi-organ autoimmune diseases (86). Augmenting 
Treg has been shown to prevent, and in certain autoimmune settings, reverse 
ongoing diseases (87). 
The majority of Treg are generated from CD4 single positive thymocytes (88). A two-
step model of Treg thymic development has been proposed, in which a high functional 
TCR ligation results in the upregulation of CD25, i.e. forming the CD25+FOXP3- 
Treg precursor, and a subsequent increase in the responsiveness of these Treg 
precursor to common γ chain cytokines (predominantly IL-2) signals that facilitates 
FOXP3 induction (89, 90) (Figure 4). The primary role of CD28 is to enhance either 
the efficiency of Treg development and/or the survival of thymocytes undergoing 
Treg differentiation (60 , 91-93). There also exists a redundancy contribution between 
CD28 and IL-2 to Treg generation considering the observation that IL-2-/- and CD28-
/-  double knockout mice demonstrate a more significant decline in Treg cell numbers 
compared to single knockout ones (94). 
CD4+
CD25-
FOXP3-
CD4+
CD25+
FOXP3-
CD4+
CD25++
FOXP3+
TCR
 CD28
IL-2, IL-15
CD28
Positive selection
of thymocytes
Treg precursor Thymus derived
Treg (tTreg)
Figure 4: A two steps model for thymic Treg development. Initially, thymocytes expressing high affinity 
of TCRs undergo TCR/CD28 dependent positive selection that gives rise to the CD4+CD25+FOXP3- Treg 
precursors; A subsequent TCR-independent but IL-2/IL-15-dependent step results in FOXP3 expression.
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Identification of Treg is not straightforward, and it is even more complex in humans 
than in mice because the Treg lineage marker FOXP3 is transiently expressed on 
activated conventional T cells (95, 96). Treg are initially defined by high expression 
of CD25, while other cell surface markers are also used to further characterize Treg. 
For example, Treg have been identified based on CD4+CD25+CD127low (97), or 
CD4+CD25+CD49d-CD127low (98). The molecules like CD45RA (99), HLA-DR 
(100), CD103 (101), CD27 (102), CD39 (103), CD62L (104), LAG-3 and CD49b 
(105), OX40 and 4-1BB (106), GITR (107), CTLA-4 (108), Helios (109), neuropilin-1 
(110), and TIGIT (111, 112), are used to define various Treg subsets as well. Despite 
the essential role of FOXP3 in Treg, it has become clear that FOXP3 alone is neither 
strictly necessary nor sufficient for Treg suppressive function. In humans, activated T 
cells transiently upregulate FOXP3 expression without acquiring suppressive function 
(96, 113). To establish a suppressive Treg phenotype, FOXP3 has to cooperate with 
other transcription factors, cis-regulatory elements and epigenetic mechanisms.
3.1. Treg Subtypes
Treg are a phenotypically and functionally heterogeneous population. Based on 
the specific developmental processes involved in Treg generation, there exist the 
so-called naturally occurring thymus-derived Treg (nTreg) that are generated in 
the thymus as a functionally mature and distinct T cell subpopulation (114), and 
peripheral induced Treg (iTreg) that developed from conventional CD4+CD25- cells 
in peripheral sites under appropriate environmental cues. Helios and neurophilin-1 
are considered to be useful markers to distinguish nTreg and iTreg (109, 115). 
However, a lack of Helios expression does not exclusively identify human iTreg, as 
Helios+ and Helios- nTreg coexist in human peripheral blood (116). A recent study 
suggested that the TIGIT/FCRL3 combination allowed reliable identification of nTreg 
cells even in highly activated conditions (111). In general, the majority of freshly 
isolated FOXP3+ Treg are actually nTreg.
Similar to conventional T cells (Tconv) that consist of naïve and memory subsets, 
Treg can also be divided into naïve Treg and memory Treg based on the expression 
of CD45RA. Human peripheral CD45RA+FOXP3+ naïve Treg are typically positive 
for CCR7 and CD62L, homing markers for lymph nodes (117). Upon in vitro 
expansion, only naïve Treg give rise to a homogeneous population of FOXP3+ cells 
that produce no inflammatory cytokines and maintain a robust suppressive activity 
(99). In contrast, it is suggested that CD45RA-FOXP3+ memory Treg easily lose 
FOXP3 and convert into proinflammatory cytokine producing cells (118-120).
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3.2. Epigenetic regulation of Treg
Epigenetic mechanism such as DNA methylation, histone modification as well as 
microRNAs are essential for control fof gene expression. Methylated DNA sequence 
are silenced while opening of the gene for transcription is linked to demethylation 
of DNA and acetylation of histones. FOXP3 gene is controlled by promoter and 
three conserved non-coding sequences (CNS): CNS1/2 located in the first intron, 
and CNS3 is in the second intron (121). The epigenetic modification of these sites 
determine chromatin structure, thus altering the accessibility of the gene locus to 
transcription factors. Known transcription factors binding and epigenetic modification 
are shown in Figure 5.
 
Treg and resting Tconv show differences in the epigenetic modification of the FOXP3 
promoter in both mice and humans: the CpG motifs in the FOXP3 promoter are 
almost completely demethylated in Treg, whereas they are weakly demethylated in 
resting Tconv. Furthermore, the FOXP3 promoter shows a stronger association with 
acetylated histones in Treg than in Tconv (122, 123), suggesting that the FOXP3 
promoter is more accessible in Treg. The most striking differences regarding the 
methylation pattern at the FOXP3 locus lies in CNS2, which is referred to as the Treg 
specific demethylated region (TSDR). Complete demethylation of CpG motifs within 
TSDR is required to stabilize both FOXP3 expression and suppressive capacity 
(122). The existence of a latent Treg population that has lost FOXP3 expression, but 
retains epigenetic memory of FOXP3 expression and suppressive functions (124), 
suggest that FOXP3+ T cells are not completely identical to Treg, and that DNA 
methylation status is a more stable parameter than FOXP3 protein expression for 
identifying a Treg population. Interestingly, the Treg-specific CpG hypermethylation 
pattern, which requires the TCR stimulation, is found not only in the FOXP3 gene, but 
Figure 5: The FOXP3 epigenome and transcription factor binding sites. FOXP3 promoter and three 
other CNSs are susceptible to epigenetic modification. Known transcription factor binding sites and 
the signals required for access to each region are also shown. CNS1: the TGF-β sensor/enhancer, 
CNS2: Treg-specific demethylation region (TSDR), and CNS3: a FOXP3 pioneer element. Adapted from 
Povoleri et al, Front. Immunol., 2013, 4: 169.
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also in other Treg-associated genes such as Il2ra (encoding CD25), Ctla4 (encoding 
CTLA4), Tnfrsf 18 (encoding GITR), Ikzf2 (encoding Helios), and Ikzf4 (encoding 
Eos) (125). The combination of CpG hypomethylation of Treg cell signature genes 
and the stable expression of FOXP3 protein complement each other to support Treg 
suppressive activity and lineage stability (126). 
3.3.  Plasticity of Treg 
Treg cell lineage stability, plasticity and conversion to effector T cells has been largely 
documented based on expression of the FOXP3 protein. Our group, in the first time, 
has reported that human FOXP3+ T cells could produce IL-17 (118), and this result 
is further confirmed by other groups (119, 120). The issue of whether every FOXP3+ 
Treg may lose FOXP3 expression (ex-Tregs) under certain circumstances remains 
to be determined. In humans, CD45RA+CD25+FOXP3+ thymus-derived Treg 
represent a population of bona fide naïve Treg, while CD45RA− memory Treg are a 
mixed population that contain antigen-experienced Treg of both thymic and peripheral 
origin (99). Similar to CD4+ Tconv, Treg respond to lineage defining cytokines 
resulting in differentiation into subsets that seem to mirror classical T helper cell 
subsets (127). Th1-, Th2-, and Th17-like peripheral memory Treg can be identified in 
human peripheral blood based on the expression of the chemokine receptors CXCR3, 
CCR4, and CCR6, respectively (128). The main question is whether these effector-
like Treg subsets are protective or pathogenic. In patients with type 1 diabetes, Th1-
like FOXP3+ Treg that express T-bet, CXCR3 and produce IFNγ appear to lose their 
suppressive function (129, 130). Th17-like Treg are enriched at inflammatory sites, 
indicating a potential role in disease pathogenesis (131, 132). In psoriasis patients, 
peripheral Treg were shown to easily differentiate into IL-17 producing cells, and 
were found in lesional skin (133). On the other hand, there is also evidence that 
IL-17 producing human peripheral Treg retain suppressive function (118, 120). The 
conditions that induce human FOXP3+ Treg to secrete different effector cytokines 
and the role of these cells in infections, cancer, and autoimmune diseases remains 
to be fully established.
3.4. Mechanisms for Treg-mediated suppression
Treg potently suppress the activation, proliferation, and/or effector functions of 
other CD4+ and CD8+ T cells, as well as possibly NK cells, NKT cells, B cells, 
and DCs. Although the molecular basis of their suppressive activity has not been 
fully elucidated yet, in vitro and in vivo studies suggest that both cell-cell contact 
dependent and independent mechanisms contribute to Treg-mediated suppression 
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(134). Constitutive high expression of CD25 on Treg could deprive effector T cells of 
IL-2 required for their  growth and proliferation (135). Treg can deliver suppressive 
factors like cAMP to conventional T cells via gap junctions(136-138). Adenosine 
signaling initiated by Treg not only directly inhibits the proliferation of effector T 
cells, but also negatively affects the function of dendritic cells. Treg also modulate 
APC function through negative signaling by CTLA-4 (139, 140), LAG-3 (141), or 
TIGIT (142). Moreover, Treg secrets granzyme B or perforin to kill the areget cells 
directly (143), or inhibitory cytokines like  IL-10 (144), IL-35 (145), IL-9 and TGFβ 
(146). More recently, attention has been directed toward the capacity of Treg to limit 
tissue inflammation directly by influencing biochemical pathways (147, 148). It is 
noteworthy that these number of inhibitory mechanisms are not mutually exclusive. 
Instead they are mostly compatible with each other and work simultaneously to fulfill 
the Treg suppressive function. 
4. Immunosuppressive Agents
Immunosuppressive agents selectively inhibit activity of the immune system thus 
preventing rejectioof the allograft, GvHD, or autoimmune diseases such as Rheumatoid 
arthritis, multiple sclerosis and systemic lupus erythematosus. Immunosuppressive 
drugs (ISDs) currently used in the clinic include calcineurin inhibitors (CNIs), mTOR 
inhibitors, proliferation inhibitors, and corticosteroids. Additionally biologicals (poly 
or monoclonal antibodies) and small molecule inhibitors are used with increasing 
success. Below, some of these immunosuppressive agents are described briefly.
4.1. Calcineurin inhibitors
CNIs are widely used in organ transplantation to prevent acute rejection, and in 
bone marrow transplantation to prevent/treat GvHD. The most often used CNIs 
after transplantation are cyclosporine A (CsA) and tacrolimus (FK506). The latter is 
ten times more potent than CsA. Biochemically, CsA binds to cyclophilin whereas 
tacrolimus binds to the FKBP12 binding protein (149). Although CsA and tacrolimus 
have an entirely different molecular structure, their immunosuppressive properties 
are remarkably similar. The binding of CsA–cyclophilin and tacrolimus–FKBP12 to 
calcineurin inhibits the phosphatase activity of calcineurin and thereby prevents the 
dephosphorylation and nuclear translocation of the transcription factor NFAT (150), 
which is important for the production of pro-inflammatory cytokines like IL-2, IL-4, 
IFNγ and TNFα (151). Therefore, the net consequence of CNIs treatment is the 
blockade of cytokine gene transcription and the prevention of T cell activation and 
proliferation.
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Because inhibition of the calcineurin–NFAT pathway by CNIs is not specific 
to immune cells, it is obvious that CNIs result in many side-effects in addition to 
immunosuppressive effects. These include nephrotoxicity, hypertension, neurological 
disorders, new-onset diabetes, enhanced skin cancer and increased viral infections 
(152). Patient studies showed that CsA withdrawal resulted in improved renal function 
in stable renal transplant recipients receiving MMF/CsA/corticosteroids triple drugs 
(153). Recently, trials on CNIs avoidance have been performed in kidney transplant 
patients, using belatacept as a fusion protein that targets the CD28-CD80/CD86 
pathway. A phase III trial has compared two doses of belatacept (more and less 
intensive) to full-dose CsA, with the addition of MMF plus steroids (154). 
4.2. mTOR inhibitors
mTOR interacts with several proteins to form two different complexes, named mTOR 
complex 1 and 2 (mTORC1 and mTORC2) (155, 156). It functions as the central 
regulator for cell proliferation and survival as well as for the differentiation of helper T 
cells . The differentiation of Th1 and Th17 subsets is selectively regulated by mTORC1, 
whereas the generation of Th2 cells and the stability of Treg relies on mTORC2 (157, 
158). The mTOR inhibitor rapamycin (also named as sirolimus) and everolimus have 
shown their efficacy in solid organ and HSC transplantation patients. Th1 cells become 
anergic when activated in the presence of rapamycin (159). However, FOXP3+ Treg 
display a selective advantage to proliferation in the presence of rapamycin because 
activation of Treg preferentially leads to phosphorylation of STAT5 but not the PI3K-
Akt-mTOR pathway (160, 161). Additionally, rapamycin induces epigenetic changes 
at the FOXP3 promoter, thus favouring its expression (162, 163). Many approaches 
have focused on employing rapamycin to generate stable Treg ex vivo or in vivo 
for treatment of type 1 diabetes and GvHD (164-166). The main and most common 
side effects of mTOR inhibitors include thrombocytopenia, hypercholesterolemia, 
diarrhoea, leukopenia, and anemia (167). The rare but potentially most severe 
adverse effect is non-infectious pneumonitis, also called interstitial pneumonia (168).
4.3. Proliferation inhibitors
Anti-proliferative ISDs include azathioprine and mycophenolate mofetil (MMF). 
Azathioprine is metabolized to 6-mercaptopurine (6-MP), which is incorporated into 
replicating DNA and thereby halts replication. It also blocks the de novo pathway of 
purine synthesis, thus specifically acting on lymphocytes which is lack of a salvage 
pathway for purine synthesis (151). The evidence for the efficacy of azathioprine 
in transplantation comes from pioneering studies in the 1960s (169). The principle 
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side effect of azathioprine is the dose-related bone marrow suppression but it may 
also cause occasional liver impairment and cholestatic jaundice. Hypersensitivity 
reactions such as appearance of rash has also been reported.
MMF is a parent drug of the active compound mycophenolic acid (MPA). MPA targets 
on inosine monophosphate dehydrogenase (IMPDH), the rate-limiting enzyme in the 
de novo synthesis of guanosine nucleotides, thus depleting cellular level of GTP and 
dGTP. Guanosine nucleotides can be generated by most cells via either the IMPDH-
dependent de novo pathway or the IMPDH-independent salvage pathway. Because 
lymphocytes do not possess such a salvage pathway, blockade of IMPDH using 
MPA results in relatively selective inhibition of lymphocytes proliferation. However, 
MMF is not potent enough to be used as a sole immunosuppressant. By combination 
with CNIs it allows immunesuppression to be maintained while minimizing the 
dose of CNIs, thus reducing the risk of CNI-induced renal toxicity (170). The most 
common adverse effect of MMF is diarrhoea, nausea, vomiting and abdominal pain. 
Enhanced severity of viral infections such as cytomegalovirus, candida and herpes 
simplex are also reported (171). 
4.4. Corticosteroids
Corticosteroids exhibit a wide range of effects on almost every phase of the immune 
responses in animals and humans due to the ubiquitous expression of corticosteroid 
receptors. Prednisone is the most widely used steroid and is metabolized in the liver, 
primarily to prednisolone, its major active metabolite. Steroids can cross the cell 
membrane and bind to cytoplasmic glucocorticoid receptors, which in turn translocate 
to the cell nucleus and influence the gene transcription. The net result is a decrease 
in pro-inflammatory cytokine production including IL-1, IL-2, IL-6, IFNγ and TNFα, 
inhibition of lymphocytes proliferation, and changes of cell migration. Corticosteroids 
also impair monocytes or macrophages function and decrease the number of 
circulating CD4+ T cells (172). Over the last 50 years, most routine, postoperative 
and maintenance transplant immunosuppression protocols have included steroids, 
although they have been given in lower and lower doses. The side effects of steroid 
treatment are numerous such as metabolic effects (fat redistribution, diabetogenesis, 
and central obesity), adrenal suppression, hypertension, and impaired wound 
healing (173).
4.5. Polyclonal antibodies
Polyclonal antibodies used as immunosuppressive agents include anti-thymocyte 
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globulin (ATG) and anti-lymphocyte globulin (ALG). They are prepared by inoculating 
rabbits or horses with human lymphocytes or thymocytes. The purified IgG fraction 
contains antibodies directed against many different cell surface molecules that are 
expressed on T-, B-, NK-cells and macrophages (174). Therefore, administration 
of these polyclonal antibodies results in a rapid and profound lymphopenia in the 
majority of patients. To minimize the so-called “first dose reaction” that is caused 
by the presence of xenogeneic proteins or the initial activation of T cells following 
engagement of cell surface receptors and cytokine release (175), and other adverse 
effects like skin rash, pruritus and thrombocytopenia, a combination of steroids, 
anti-histamines and paracetamol are give routinely 30-60 min before starting the 
antibody therapy.
4.6. Monoclonal antibodies
Monoclonal antibodies (mAbs) target against specific proteins expressed on cell 
surface (e.g. CD3, CD25, CD52). OKT3 is an immunoglobulin that targets on CD3, 
a part of T cell receptor that expressed on circulating human T cells. Thus, OKT3 
blocks the activation of T cells and  depletes them from the circulation. OKT3 
has been used to treat acute rejection (176) and steroid-resistant rejection (177). 
Basiliximab and daclizumab bind to CD25 and interrupt the cellular events leading to 
cell growth, proliferation and cytokine release. These anti-CD25 mAb is often used 
as a induction therapy to reduce the incidence of acute rejection (178, 179). There 
are other widely used mAbs in clinic such as rituximab (anti-CD20), alemtuzuman 
(anti-CD52), eculizuman (targeting on the complement protein C5), and so on (also 
seen Figure 6).
4.7. New immunosuppressive agents
Current immunosuppressive therapies are highly successful for regulating acute 
allograft rejection and inducing transplanted organ survival. However, currently 
available medications are also associated with many drug toxicities including 
nephrotoxicity, hypertension, hyperlipidemia and glucose intolerance. Moreover, 
recent findings suggest that chronic allo-immune responses play the dominant role 
in late allograft loss. Thus improvement in long-term allograft outcomes may depend 
on new agents with novel mechanisms of actions. An increased understanding of the 
molecular pathways involved in the immune activation has led to the development 
of new classes of immunosuppressive agents that may provide potent immune 
suppression but with few side-effects (Figure 6). Targets of T cell-mediated activation 
include antibodies and fusion proteins interfering with LFA1/ICAM-1, LFA3/CD2, 
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CD40/CD154, and CD28/B7 interactions. Targets of intracellular signal pathways 
include PKC, JAK, and calcineurin.
4.7.1. PKC inhibitor
One strategy to block T cell activation is the inhibition of PKC kinase that is 
critical to downstream TCR/CD28 signaling (180). The small molecular weight 
immunosuppressant sotrastaurin, also named AEB071, inhibits multiple PKC 
isoforms, resulting in inhibition of neutrophils (181) and diminished T cell activation 
via a calcineurin independent way (182, 183). It decreases allograft rejection in 
preclinical studies (184, 185) and exhibits few toxic effects on transplanted organs 
(186). In a phase II trial (187) sotrastaurin at a dose of at least 200 mg/d plus 
tacrolimus had comparable efficacy to MPA plus tacrolimus in prevention of rejection 
with no significant difference in renal function between the groups. Interestingly, in 
two other phase II trials using calcineurin inhibitor free regimens, including either 
MPA (188) or everolimus (189), sotrastaurin showed improved renal allograft 
function, albeit higher efficacy failure compared to a CsA-based therapy. The 
Figure 6: Mutltiple targets for novel immunosuppressive agents. Alefacept and efalizumab target 
T-cell adhesion to APCs by inhibiting LFA-3/CD2 and LFA-1/ICAM-1 interactions, respectively. Belatacept 
is a CTLA-4–Ig fusion protein that competitively inhibits costimulation via CD28-B7 interactions. 
4D11 (anti-CD40) prevents costimulation by blocking CD40/CD154 interactions. Basiliximab (anti-
CD25) prevents T-cell activation by blocking IL-2 signals. Several targets of immunotherapies involve 
downstream intracellular pathways, including calcineurin (inhibited by voclosporin), mTOR (inhibited 
by everolimus), PKC (inhibited by sotrastaurin), and JAK3 (inhibited by tofacitinib). Reprinted from 
Lunsford et al Curr Opin Organ Transplant., 2011, 16(4),390-397, with the permission of reuse in this 
thesis.
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beneficial effect of sotrastaurin on Treg stability and function has been observed in 
patients after kidney transplantation (190). These results suggest that further well-
controlled studies using alternative sotrastaurin regimens should be conducted to 
evaluate its effect in solid organ transplant patients. Furthermore, psoriasis patients 
receiving 750 mg single dose of sotrastaurin treatment also show reduced severity 
of psoriasis symptoms (83, 191), suggesting its potential application in the treatment 
of autoimmune diseases.
4.7.2. Belatacept
Costimulation blockade represents another strategy for immunosuppression. 
CTLA-4 (CD152), a T cell surface receptor that shares sequence homology with 
CD28, but provides inhibitory instead of stimulating signals for T cell activation (37). 
Belatacept is a fusion protein combining the modified extracellular domain of CTLA-
4 with the constant human IgG1 domain (CTLA-4-Ig). This fusion protein binds 
B7.1/B7.2 molecules expressed on APC thereby blocking costimulatory interaction 
with CD28 (192). Belatacept has been approved for use in adult kidney transplant 
recipients. After 5 years post-transplantation, recipients receiving belatacept had 
significantly improved graft survival and allograft function, although this was at the 
expense of significantly increased acute-rejection rates during the first year of post-
transplantation (193).
5. Cell-based immunotherapy
Achieving allograft tolerance while avoiding the need for ongoing immunosuppression 
thus achieving  immune tolerance is the main goal of current studies. There are 
different lymphoid cell types with regulatory capacity that can promote tolerance 
induction such as regulatory T cells (CD4+ Treg, CD8+ Treg, NKT cells, gδ T cells), 
regulatory B cells and macrophages, tolerogenic DCs, mesenchymal stromal cells 
(MSCs), and myeloid derived suppressor cells (195). Of these cells, the most widely 
studied is the CD4+FOXP3+ Treg cell subset. The underlying rationale for using Treg 
as a cell-based therapy is to move the balance from predominantly pro-inflammatory 
cells to a cell population enriched with Treg aiming to minimize immune responses. 
In animal models, transfer of Treg, with or without manipulation ex vivo, has proved 
to be a very effective strategy for controlling acute (196-199) and chronic (200, 201) 
allograft rejection and for preventing GvHD (104). These studies provide proof-of 
concept data to support the clinical translation of this approach in humans. Clinical 
application of Treg to ameliorate GvHD (166, 202, 203), as well as to treat type 
1 diabetes (204, 205) have been reported. More recently, the ONE study, a multi 
30
Chapter 1
1
center Phase I/IIa clinical trial designed to test the safety and production feasibility of 
seven different regulatory cell populations in living solid organ transplantation, has 
begun (206, www.onestudy.org).
It is now possible to purify Treg from human peripheral blood (207, 208) and umbilical 
cord blood (166). For the purpose of cell-based therapy, it is crucial to isolate Treg 
under good manufacturing practice (GMP) procedures. Flow cytometry based 
techniques allow a more complex phenotype to be defined and greater purities to 
be achieved. However, such therapeutic Treg flow-sorting is restricted to a few clinic 
centres worldwide. In contrast, magnetic beads isolation of CD4+CD25+ Treg using 
a GMP compliant closed system has achieved acceptable levels of purity (209). As 
described in the previous section, Treg lack a specific surface marker and its lineage 
marker FOXP3 is an intracellular molecule. Thus, the combination of several cell 
surface markers is commonly used for the isolation of Treg. Although human Treg 
were initially defined based on the constitutively high expression of CD25, the fact 
that CD4+CD25+CD127low cells showed approximately 5 times more potency than 
CD4+CD25hi cells (200) indicates that CD127low is a valuable additional marker for 
Treg isolation. Also, CD45RA is useful to distinguish naïve versus memory human 
Treg (210). 
The low frequency of Treg indicates that these cells require expansion prior to the 
clinical usage. Most successful protocols for ex vivo expansion of Treg use anti-CD3 
mAb attached to beads (166, 200, 202) or artificial APCs expressing high affinity Fc 
receptors (211, 212) together with exogenously added  recombinant human IL-2. 
Allogenic APCs are also used to expand Treg resulting in an antigen-specific Treg, 
showing a greater potency (165, 198, 213). CD28 costimulation is also required for 
successful expansion of Treg (214). Rapamycin can be added to the cultures that 
are less pure to minimize the outgrowth of potentially contaminating non-Treg (215, 
216). So far, clinical studies support the concept that ex vivo expanded Treg are 
safe in HSC transplantation. However, several important issues must be addressed 
before shaping larger clinical trials. 
1) What is the most appropriate source of Treg for immunotherapy? As discussed 
previously, human Treg can be isolated from both peripheral blood and umbilical cord 
blood. There are also several different Treg subpopulations like CD45RA+FOXP3+ 
naïve and CD45RA-FOXP3+ memory Treg. Regarding to the suppressive capacity, 
in general, antigen-specific Treg are more potent than polyclonal ones. It remains 
to decide which cell subsets following ex vivo expansion will be a safe and effective 
product. 
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2) What is the optimal ex vivo expansion protocols to achieve sufficient number of 
potent Treg? Due to the lack of unique Treg markers, the isolation of human Treg 
based on CD4, CD25 and/or CD127 is challenging because non-Treg will also be 
present in the eventual cell product. Considering the hypo-proliferative capability of 
Treg in vitro and the functional plasticity of Treg, it is essential to optimize Treg ex 
vivo expansion protocols for achieving enough numbers of potent Treg. Considering 
that the most reliable way to define Treg is by function rather than by phenotype, it 
should be crucial to perform quality control of expanded Treg before their infusion to 
the patients.
3) Will Treg be stable enough in patients that received Treg-based cell therapy? 
Ample evidences demonstrated that Treg, especially TGFβ/IL-2-generated induced 
Treg, might lose FOXP3 expression and their suppressive function (118-120). 
Loss of FOXP3 expression correlated with partial TSDR demethylation (122), and 
the unstable FOXP3 expression can result in pathogenic cells. Therefore, careful 
evaluation of Treg cell stability (probably via checking the demethylation of TSDR) 
and survival will guide future clinic related protocols. 
6. Aims and outline of this thesis
Based on our previous findings that human Treg exhibit plasticity, with putative 
detrimental effects for therapeutic potential, we set out to further unravel the 
mechanisms behind this transformation into IL-17A producing cells, define the cell 
population at risk, and find ways to preserve a stable Treg phenotype to be used for 
clinical applications.
In chapter 1 we give a short introduction on the immune responses with a focus on 
regulatory T cells and on immunosuppressive drugs currently used in transplantation 
and autoimmunity.
Subsequently in chapter 2 we reveal the cell signalling transduction pathways in 
T cells and define the importance of TCR verse CD28 costimulation. PMA/CD3 
stimulation enhances a Th1-like response in an Lck and PKCθ dependent fashion, 
whereas PMA/CD28 stimulation results in a Th2-like phenotype independent of the 
proximal TCR-tyrosine kinase Lck.
Then, in chapter 3 we describe the novel insights into the mechanisms underlying 
MPA-mediated suppression of human CD4+ T cells, which will contribute to 
optimization of protocols for MPA-based forms of therapy in transplantation and 
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autoimmunity.
The costimulatory molecule CD28 is required for  thymic Treg development and 
proliferation. In chapter 4 we show enhanced activation of CD28 stimulation 
boosts a stable and efficient ex vivo expansion of human Treg, indicating it is of 
interest to include CD28 superagonist in the Treg expansion protocol for Treg-based 
immunotherapy.
We continue our research by focusing on the delicate selection of pharmaceutical 
agents thus supporting the efficient cell proliferation and the stability of human 
Treg. In chapter 5 we describe the usage of TNFR2-agonist to facilitate ex vivo 
expansion of human Treg. We show that the protocol containing TNFR2-agonist 
leads to an efficient Treg expansion. The resultant Treg reveal potent suppressor 
function and less IFNγ and IL-17A producing potential. Importantly, this expansion 
protocol enables the use of less pure, but more easily obtainable MACS-isolated 
Treg fractions, indicating its potential for ex vivo expansion of clinic grade Treg. 
Intriguing by the observation that CD28 signals are crucial for Treg proliferation and 
function (chapter 4), and the knowledge that PKCθ  is one of the main downstream 
targets of CD28 (chapter 2), we further reveal that selective inhibition of PKC using 
sotrastaurin blocks effector T cell responses, but preserves a stable Treg phenotype 
in chapter 6. Therefore, pharmacological inhibition of PKC may serve as a powerful 
tool to concurrently inhibit effector T cells and to facilitate Treg, thereby showing 
therapeutic potential for the treatment of autoimmune diseases such as psoriasis. 
In chapter 7, we describe a modified method for the isolation of leucocytes from 
human skin biopsies. The acquired cells is ready to use for phenotypic analysis 
using flow cytometry or ex vivo cell culture.
Finally, the results presented in this thesis and future perspectives are summarized 
and discussed in chapter 8.
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Abstract
Background: T lymphocytes are orchestrators of adaptive immunity. Naïve T 
cells may differentiate into the Th1, Th2, Th17 or iTreg phenotype, depending on 
environmental co-stimulatory signals. To identify genes and pathways involved 
in differentiation of Jurkat T cells towards Th1 and Th2 subtypes we performed 
comprehensive transcriptome analyses of Jurkat T cells stimulated with various 
stimuli and pathway inhibitors. Results from these experiments where validated in a 
primary human experimental setting using whole blood or purified CD4+ Tcells
Results: Calcium-dependent activation of T cells using CD3/CD28 and PMA/CD3 
stimulation induced a Th1 expression profile reflected by increased expression of 
T-bet, RUNX3, IL-2, and IFNγ, whereas calcium-independent activation via PMA/
CD28 induced a Th2 expression profile which included GATA3, RXRA, CCL1 
and Itk. Knock down with siRNA and gene expression profiling in the presence of 
selective kinase inhibitors showed that proximal kinases Lck and PKCθ are crucial 
signaling hubs during T helper cell activation, revealing a clear role for Lck in Th1 
development and for PKCθ in both Th1 and Th2 development. Medial signaling 
via MAPkinases appeared to be less important in these pathways, since specific 
inhibitors of these kinases displayed a minor effect on gene expression. Translation 
towards a primary, whole blood setting  and purified human CD4+ T cells revealed 
that PMA/CD3 stimulation induced a more pronounced Th1 specific, Lck and PKCθ 
dependent IFNγ production, whereas PMA/CD28 induced Th2 specific IL-5 and IL-
13 production independent of Lck activation. PMA/CD3-mediated skewing towards a 
Th1 phenotype was also reflected in the mRNA expression of the master transcription 
factor Tbet, whereas PMA/CD28 stimulation enhanced GATA3 mRNA expression in 
primary human CD4+ Tcells.
Conclusions: This study identifies stimulatory pathways and associated gene 
expression profiles for in vitro skewing of T helper cell activation. PMA/CD3 stimulation 
enhances a Th1-like response in a Lck and PKCθ dependent fashion, whereas PMA/
CD28 stimulation results in a more Th2-like phenotype independent of the proximal 
TCR-tyrosine kinase Lck. The assays and stimuli described offer a robust and fast 
translational cellular in vitro system for skewed T helper cell responses, in jurkat T 
cells, primary human CD4+ Tcells but also in a more complex matrix such as human 
whole blood.
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Background
Activation of T helper 0 (Th0) cells leads to differentiation into several lineages. These 
lineages include the Th1 and Th2 subsets as well as the more recently described 
subsets such as induced T regulatory cells and Th17 cells. The Th1 cells protect 
against intracellular pathogens and are in general characterized by their ability to 
produce IFNγ, IL-2 and TNFα and express the Th1-specific transcription factor T-bet. 
The Th2 subset, which is involved in the defense against extracellular pathogens, 
is characterized by the production of IL-4, IL-5 and IL-13 and is controlled by the 
master transcription factor GATA3 [1-2].
In a proper functioning immune system, these different T helper subsets are 
well-balanced and co-operate to eliminate invading pathogens and to maintain 
homeostasis. Hyper activation of one T helper subset, however, can tip the balance 
from health towards disease, in which Th2-overshoot can lead to inappropriate 
immune responses leading to diseases like allergy and asthma. Alternatively, 
overshoot towards a Th1 or Th17-phenotype can cause autoimmune diseases, like 
rheumatoid arthritis and multiple sclerosis [3-4]. 
For effective CD4 T cell activation, the antigen-presenting cell (APC) provides a 
key contact point to facilitate T cell activation and polarization towards different 
T helper subsets. A crucial event in this process is the interaction between the 
antigen presented via the MHCII receptor and the TCR receptor (signal 1). The 
nature of activation, defined by the strength of the TCR stimulation, can affect T 
helper cell polarization towards Th1 or Th2, in which a high affinity interaction favors 
Th1 development and low affinity drives Th2 development [5-8]. Besides the TCR 
signal transduction, an additional signal is provided by the APC in the form of a 
co-stimulatory signal (signal 2). This signal is  provided via CD28-B7 interaction 
and has been shown to be important for effective T cell activation [9]. Furthermore, 
CD28-mediated co-stimulation has been implicated in effective polarization of T cells 
towards a Th2 phenotype [10-11]. Also other co-stimulatory molecules, including 
ICOS and OX40, have been positively correlated with Th2 differentiation [12-13]. 
The results from these studies underline the importance of both signal 1 and signal 
2, but also underline the complexity of these integrated signaling pathways. 
The cascade of biochemical events, linking cell surface receptor engagement to 
cellular responses has been a focus of many studies. Detailed investigation of these 
signal transduction events has led to identification and functional characterization of 
many kinases and phosphatases downstream of the TCR and CD28-receptor. TCR 
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ligation results in the recruitment of p56Lck (Lck), a proximal TCR Src family kinase, 
which kick-starts the signal transduction cascade leading to phosphorylation of the 
ITAM motifs in the TCR, which recruits and activates ZAP70 [14]. This initial step 
leads to the activation of PLCγ that hydrolyzes PIP2 into IP3, which is the second 
messenger molecule responsible for the sustained intracellular calcium flux in T cells. 
CD28-ligation on T cells results in the recruitment of PI3K, with PIP2 and PIP3, which 
serve as pleckstrin homology (PH) domain membrane anchors. Via this mechanism 
PDK1 and PKB/Akt are recruited and regulate several pathways that increase 
cellular metabolism [15]. Additionally, CD28-signaling has been shown to initiate 
NFκB signaling, via a mechanism that is functionally linked through recruitment of 
PKCθ to CD28 in the immunological synapse [16-18].
Members of the Mitogen-activated protein kinase family, which can be activated via 
TCR signaling, also play a role in the differentiation of Th1 and Th2 subsets. In 
a thorough review by Dong et al, the role of p38, JNK and ERK in T helper cell 
differentiation has been outlined [19]. ERK is important for Th2 differentiation, 
whereas p38 and JNK2 appear to be involved in Th1 development. 
TCR/CD3 stimulation and CD28 stimulation alone are weak activators of T cell 
signaling. It is generally conceived that CD28 signaling merely acts as a signal 
potentiator on top of the initiator signal mediated via the TCR/CD3. Ledbetter and 
June et al. described that CD28 stimulation in the absence of cross-linking on top 
of PMA stimulation can activate T cells, without increasing calcium flux [20-21]. This 
suggests that co-stimulatory pathways when powerful enough can directly activated 
T cells without the need of TCR stimulation. Whether CD28 ligation, in the absence 
of TCR signaling, leads to activation and differentiation has not been fully explored.
These findings show that effective T cell activation and differentiation towards 
effector subsets is the result of precise integration of multiple signaling routes. To 
explore the pathways underlying these distinct routes towards T cell activation 
and differentiation we used comprehensive biochemical characterization and gene 
expression profiling of Jurkat T cells that were activated with various co-stimulatory 
signals in the presence of various inhibitors of specific signaling routes.  With this 
approach we identified specific PMA/CD3 and PMA/CD28 signal transduction and 
genomic fingerprints. PMA/CD3 stimulation was more enhanced a Th1 activation 
phenotype, dependent on both Lck and PKCθ, whereas PMA/CD28 stimulation, 
which is independent of TCR-mediated activation of Lck, resulted in a profound 
activation of T cells, skewing towards a more profound T helper 2 phenotype.
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Results and Discussion
Activation of Jurkat T cells by various stimuli leads to differential signaling 
fingerprints
Jurkat T cells were activated by anti-CD3, anti-CD28, PMA, or ionomycin or 
combinations of these single stimuli, in order to map the contribution of these stimuli 
Figure 1 
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Figure 1: Signal transduction in Jurkat T cells. Jurkat T cells were stimulated with different combinations 
of stimuli in order to elucidate the different signal transduction pathways. A; Jurkat T cells were 
stimulated as indicated and intracellular Ca2+ release was monitored over time. B; Intracellular 
signal transduction routes were charted via phospho-analysis using western blot. Jurkat T cells were 
stimulated for 15 min using different stimulations. Proximal (Lck, ZAP70, PKCθ and the PKC substrate 
MARCKs), medial (MAPK phosphorylation) and distal (c-Jun and ATF2) signaling were monitored based 
on the phosphorylation status of the described proteins. C; Nuclear translocation of the transcription 
factors NFAT, NFkB and c-Jun was evaluated 15 minutes after stimulation.
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towards the activation of proximal, medial and distal signal transduction pathways. 
As shown in figure 1A, CD3-stimulation and ionomycin/PMA were able to increase 
intracellular levels of Ca2+. Interestingly, neither CD28 nor PMA stimulation alone, 
affected intracellular Ca2+ levels. As expected, CD3-signaling resulted in an Lck-
dependent phosphorylation of ZAP70 (figure 1B). Stimuli containing PMA directly 
activated the MAPK pathway, which is reflected by the phosphorylation of ERK, P38 
and JNK (figure 1B). Furthermore, PMA addition directly activated PKC which was 
not reflected in the autophosphorylation of PKCθ, but was clearly detectable on the 
phosphorylation of the PKC substrate MARCKS (figure 1B). CD3-mediated 
stimulations and PMA-induced stimulations resulted both in the activation of AP1 
family transcription factors c-Jun and ATF2 (figure 1B). Analysis of nuclear 
translocation of NFATc1 and c-Jun (AP1) / NFκB p65, as part of the distal signaling 
events revealed that indeed CD3-mediated signaling induced both NFAT and c-Jun/
NFκB, of which the latter pathways were potentiated by CD28-mediated signaling 
(figure 1C). In line with the calcium release from the ER, PMA or PMA/CD28-
mediated signaling did not induce NFAT nuclear translocation but highly activated 
the CD28 responsive element transcription factors c-Jun and NFκB p65 (figure 1C). 
These results indicate that two distinct co-stimulatory profiles can be identified. A 
CD3/28 and PMA/CD3 stimulus that signals via Lck, increasing intracellular Ca2+ and 
activating NFAT, and a PMA/CD28 calcium independent (co)-stimulatory activation 
signaling via PKCθ and MARCKS. Next, the molecular mechanisms involved in 
these signaling pathways were further explored in genomics studies.
Figure 2 
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CD3_PMA 338 1.00 0.53 0.83
PMA_CD28 194 0.92 1.00 0.89
CD3_CD28 319 0.88 0.54 1.00
T= 8 hrs
CD3_PMA 1567 1.00 0.72 0.42
PMA_CD28 1853 0.60 1.00 0.30
CD3_CD28 786 0.84 0.70 1.00
Figure 2: PMA/CD3 and CD3/28 stimulations differ from PMA/CD28 stimulation. The table shows 
the number of regulated probe sets and their overlap at 1 and 8 hrs following stimulation with CD3/
PMA, PMA/CD28 and CD3/CD28 (using a fold change cut off of 2 and a p-value cut off of <1.10-6. The 
right panel shows a hierarchical clustering of the data using the data for the regulated probe sets. Most 
of the variation is caused by the time difference (1hr vs 8 hrs). At both time points the PMA/CD28 
stimulus was clearly different from the CD3/CD28 and CD3/PMA stimulus. Repeating this analysis with 
different values for the fold change and p–value cut off yielded essentially the same results for the 
multivariate analysis.
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Differential regulation of genes after PMA/CD3 and CD3/28 vs PMA/CD28 
stimulation.
In order to further characterize the different signal transduction events induced by 
different (co)-stimulatory signals, we performed a first gene expression experiment 
with Jurkat T cells that were stimulated for 1 or 8 hours with PMA/CD3, CD3/28 and 
PMA/CD28. It appeared that after 1 hour a limited response on transcription level 
was seen, whereas after 8 hours of stimulation, several hundreds of genes were 
regulated. Furthermore, PMA/CD3 and PMA/CD28 regulate more genes compared 
to CD3/28, reflecting the strength of the stimuli used (Figure 2). Multivariate analysis 
by principal component analysis and hierarchical clustering showed that the 3 
stimuli lead to clearly distinct gene expression profiles. At both time points the profile 
induced by PMA/CD28 is clearly distinct from the profiles induced by PMA/CD3 and 
CD3/28 (figure 2).
Differentially regulated genes CCL1 and IL-2 are profile-specific secreted 
proteins
Gene profiles of the differential stimuli were ranked on the level of induction and 
evaluated on whether or not the translated protein is secreted. This resulted in the 
identification of the PMA/CD28-specific transcript CCL1 (figure 3A), the CD3-specific 
transcripts IL-2 (figure 3B) and XCL1/2 (data not shown). Small but significant 
inductions of these genes were observed after 1 hour of stimulation for both CCL1 
and IL-2. However, both genes were highly induced after 8 hours of stimulation. 
The secretion of the protein 24 hours after stimulation reveals an identical profile 
compared to the mRNA (figure 3A/B, right hand panel).
Pathway profiling with multiple stimuli and inhibitors
To investigate the contribution of proximal, medial and distal signaling events 
on the CD3/28, PMA/CD3 and PMA/CD28 stimuli, we performed a second gene 
expression profiling experiment with different selective inhibitors, including proximal 
kinase inhibitors Lck (A420983), PKCθ (AEB071), medial MAPK inhibitors PD98059 
(MEK/ERK), SP600125 (pan JNK), Org 48762-0 (P38) and the distal Calcineurin 
(Cn) inhibitor Cyclosporin A (CsA). Jurkat T cells were stimulated with PMA, CD28 
and CD3 alone and combinations thereof in the presence of the above mentioned 
inhibitors. Based on the results of the first gene expression profiling experiment, we 
chose evaluated gene expression after 8 hours of stimulation. A principal component 
analysis on the ratio data set is shown in figure 4. It appeared that the PMA/CD28, 
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CD3/CD28 and PMA/CD3 co-stimuli induced several hundreds of genes, whereas 
the effect of a single stimulus was smaller, with the exception of the PMA single 
stimulus (supplemental figure S1, Additional file 2: table S1). The gene set induced 
by a PMA stimulus showed a larger overlap with the genes induced by the PMA/
CD28 stimulus than with the CD3/PMA induced gene set. Whereas PMA and CD3 
as a single stimulus induce a large number of genes, CD28 elicits only a minor 
effect. It can be observed that CsA, AEB071 and A420983 induce the largest effects 
on gene regulation whereas the inhibitors of the MAPK pathway only have a minor 
effect on gene expression. This finding is corroborated by the number of regulated 
genes, showing that the MAPK inhibitors only regulate a small number of genes 
whereas A420983, CsA and AEB071 regulate many genes (table S1). A420983 and 
CsA only show a significant effect on the PMA/CD3 and CD3/CD28 pathways, in 
which the effect of CsA is smaller than the effect of A420983. AEB071 is the only 
compound that shows also a significant effect on the PMA/CD28 induced pathway. 
These analyses were rerun with different settings for the thresholds used for gene 
selection. In all cases similar results were obtained indicating that the results were 
not critical dependent on the thresholds settings that were used. 
Inspection of the profiles of CCL1 and IL-2 revealed that CCL1 mRNA is highly 
induced via the PMA/CD28 pathway. This induction is depending on PKC signaling 
and negatively regulated via Lck signaling. Apparently this effect was upstream of 
Cn, since the inhibitor CsA did not increase CCL1 mRNA induction (figure 4A).
Figure 3 
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Figure 3: Differential regulation of IL-2 
and CCL1. Jurkat T cells were activated 
for 1 and 8 hours using different stimuli 
(as indicated). Differentially regulated 
genes of which the proteins were 
secreted were identified and the 
highest ranking genes were selected. A; 
regulation of the CCL1 mRNA is highly 
and differentially regulated after PMA/
CD28 stimulation. Right panel shows 
the validation of the mRNA levels on 
protein level, secreted by activated 
Jurkat T cells. B; regulation of IL-2 mRNA 
is highly and differentially regulated 
after CD3/28 and PMA/CD3 stimulation. 
Right panel shows the validation of the mRNA levels on protein, secreted by activated Jurkat T cells.
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As expected, PMA/CD3 and CD3/28 stimuli and to a lesser extent PMA/CD28 
resulted in a marked expression of IL-2, which is highly depending on the Lck/Cn 
signal transduction pathway, and the PKC pathway. Interestingly inhibition of MAPK 
signaling (with the exception of the MEK/ERK pathway) does not affect IL-2 mRNA 
induction (figure 4B). These effects on CCL1 and IL-2 production by inhibitors of the 
Lck/Cn and PKC pathway were further substantiated in a full dose-response 
experiment. Figure 5A shows that indeed AEB071 dose-dependently inhibited PMA/
CD28-induced CCL1 production, which is slightly enhanced in the presence of an 
Lck inhibitor and which is not affected by Cn inhibition via CsA. IL-2 production can 
be blocked by inhibition of both the Lck/Cn and PKC pathway (figure 5B). The 
involvement of Lck in the CD3-mediated pathway and PKC in the CD3 and CD28-
mediated pathways was further confirmed by the knock-down of both kinases under 
the distinct stimuli. Knock-down of Lck did not affect PMA/CD28-induced CCL1 
production, whereas knock-down of PKCθ resulted in significant inhibition of both 
IL-2 and CCL1 (figure 5C). These results clearly show that PMA/CD28-induced gene 
Figure 4: Involvement of signal transduction 
pathways on differentially regulated genes. Jurkat T 
cells were stimulated as indicated previously and the 
involvement of different signaling pathways on gene 
regulation was elucidated using inhibitors of specific 
pathways, including Lck (1 mM), PKC (10 mM), 
Calcineurin (1 mM), and MAPKs p38, JNK, and MEK/
ERK (all 10 mM). A; Regulation of CCL1 mRNA in 
Jurkat T cells after stimulation with PMA/CD28-, 
CD3/28- or PMA/CD3-and co-incubated and cultured 
for 8 hours in the presence or absence of signal 
transduction pathway inhibitors. B; Regulation of 
IL-2 mRNA in Jurkat T cells after stimulation with 
PMA/CD28-, CD3/28- and PMA/CD3- and co-
incubated and cultured for 8 hours in the presence 
or absence of signal transduction pathway inhibitors. 
The height of the bars represent the average 
intensity of 3 biological replicates, the error bars 
indicate the variation (min and max values). 
Significance of changes in expression level between 
the stimulated sample and the sample that was 
stimulated in the presence of the pathway inhibitor 
is indicated as follows; *** P value < 0.0001; ** 0.01 < P value >0.001, * 0.05 < P value >0.01.
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profiles are highly depending on PKCθ signaling pathways but are independent of 
Lck/Cn and MAPK signaling pathways, whereas CD3-mediated signaling pathways 
are dependent on both Lck/Cn and PKCθ signal transduction and independent on 
MAPK signaling events. 
PMA/CD3, PMA/CD28 and CD3/CD28 induce distinct genomic fingerprints
The above analysis indicated that treating Jurkat T-cells with multiple combinations 
of stimuli and inhibitors highlights pathways that are regulated by specific 
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Figure 5: PMA/CD28-induced CCL1 production is not dependent on the Lck/Cn pathway. Jurkat T 
cells were stimulated using PMA/CD3 and PMA/CD28 in the presence of Lck (A420983), Cn (CsA) and 
PKC (AEB071) pathway inhibitors for 24 hours. Dose-response effects of the inhibitors were evaluated 
on the production of CCL1, after PMA/CD28 stimulation (A) and IL-2 after PMA/CD3 stimulation (B) in 
supernatant of the cell cultures. The data are representative for 3 independent experiments. C; Knock 
down of Lck and PKCθ resulted in a clear dose-dependent reduction of the protein (500, 100, 20 nM 
siRNA). 24 hour culture supernatants were collected after stimulation with PMA/CD28 and PMA/CD3 
and the effect of knock down on respectively CCL1 and IL-2 was determined. Data of two independent 
experiments are presented as mean + SEM. Significance of differences are indicated by ** p<0.01, 
*p<0.05, # no difference using a one-way ANOVA with a Bonferroni’s post-hoc test.
Figure 6: Heatmap of stimulation dependent gene clusters. Top panel: CCL1 cluster characterized by 
induction of genes exclusively following CD28/PMA stimulation and subsequent repression by AEB071. 
Middle panel: IL-2 cluster characterized by induction of genes by all stimulations, and down-regulated 
by A420983 and AEB071 and to a lesser extent by CsA. Lower panel: EGR1 cluster characterized by 
induction of genes by all stimulations, but down-regulated only by AEB071 when stimulated with 
PMA/CD28 or PMA/CD3. A red color denotes a down-regulation, a green color an up-regulation. The 
MAPK inhibitors induced very little regulation and have been omitted from this figure for clarity. The 
gene lists shown in this figure, with extended annotation and their distance to the CCL1, IL-2 and EGR1 
profiles are provided in supplemental files 1,2 and 3.
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profiles are highly depending on PKCθ signaling pathways but are independent of 
Lck/Cn and MAPK signaling pathways, whereas CD3-mediated signaling pathways 
are dependent on both Lck/Cn and PKCθ signal transduction and independent on 
MAPK signaling events. 
PMA/CD3, PMA/CD28 and CD3/CD28 induce distinct genomic fingerprints
The above analysis indicated that treating Jurkat T-cells with multiple combinations 
of stimuli and inhibitors highlights pathways that are regulated by specific 
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Figure 5: PMA/CD28-induced CCL1 production is not dependent on the Lck/Cn pathway. Jurkat T 
cells were stimulated using PMA/CD3 and PMA/CD28 in the presence of Lck (A420983), Cn (CsA) and 
PKC (AEB071) pathway inhibitors for 24 hours. Dose-response effects of the inhibitors were evaluated 
on the production of CCL1, after PMA/CD28 stimulation (A) and IL-2 after PMA/CD3 stimulation (B) in 
supernatant of the cell cultures. The data are representative for 3 independent experiments. C; Knock 
down of Lck and PKCθ resulted in a clear dose-dependent reduction of the protein (500, 100, 20 nM 
siRNA). 24 hour culture supernatants were collected after stimulation with PMA/CD28 and PMA/CD3 
and the effect of knock down on respectively CCL1 and IL-2 was determined. Data of two independent 
experiments are presented as mean + SEM. Significance of differences are indicated by ** p<0.01, 
*p<0.05, # no difference using a one-way ANOVA with a Bonferroni’s post-hoc test.
Figure 6: Heatmap of stimulation dependent gene clusters. Top panel: CCL1 cluster characterized by 
induction of genes exclusively following CD28/PMA stimulation and subsequent repression by AEB071. 
Middle panel: IL-2 cluster characterized by induction of genes by all stimulations, and down-regulated 
by A420983 and AEB071 and to a lesser extent by CsA. Lower panel: EGR1 cluster characterized by 
induction of genes by all stimulations, but down-regulated only by AEB071 when stimulated with 
PMA/CD28 or PMA/CD3. A red color denotes a down-regulation, a green color an up-regulation. The 
MAPK inhibitors induced very little regulation and have been omitted from this figure for clarity. The 
gene lists shown in this figure, with extended annotation and their distance to the CCL1, IL-2 and EGR1 
profiles are provided in supplemental files 1,2 and 3.
combinations of stimulus and inhibitor, revealing the involvement of certain kinases 
as signaling hub under specific stimulatory conditions. In order to identify additional 
genes in the pathways that are exemplified by CCL1 and IL-2, we searched for 
genes with similar profiles to these pathway genes. Figure 6 shows genes related to 
CCL1, identified by a strong up regulation following PMA/CD28 stimulation only and 
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a down regulation by AEB071. Interestingly, besides CCL1, which is a chemo 
attractant for Th2 cells, many Th2-associated genes co-clustered with CCL1, 
including GATA3, Itk, RXRA, c-FLIP (CFLAR), ICOS and the IL-31 receptor and also 
other genes that are associated with Th2 development (See figure 6; CCL1 gene 
cluster).
Likewise a very specific IL-2 profile can be constructed by selecting genes that are up 
regulated under all three conditions and down regulated by all three inhibitors, and 
by which CsA is the weakest inhibitor (see figure 6; IL-2 cluster). In this gene cluster 
appeared to be Th1-associated genes, including the Th1 master transcription factor 
Tbet (TBX21), Th1 chemokine XCL1/2, IFNγ, granzyme, RUNX3, FASL, OX40L 
(TNFRSF4), CD27, and the IL-21 receptor. Of note, inhibition of both Lck and Cn 
 Figure 8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A 
Control PMA/CD3 PMA/CD28
0
500
1000
1500
2000
2500
3000
3500 * p=0.028
[IF
N
γγ γγ] 
pg
/m
l
Control PMA/CD3 PMA/CD28
0
20
40
60
80
100
120
140
** p=0.001
[IL
-1
7] 
pg
/m
l
B 
Control PMA/CD3 PMA/CD28
0
500
1000
1500
2000
* p=0.013
[IL
-
13
] p
g/
m
l
Control PMA/CD3 PMA/CD28
0
100
200
300
400
500
600
700
800
* p=0.033
[IL
-
5] 
pg
/m
l
C 
c
o
n
tr
o
l
A
-4
20
98
3
A
EB
-0
71
0
1000
2000
3000
*
*
[IF
N
γγ γγ] 
pg
/m
l
co
n
tr
o
l
A
-
42
09
83
A
EB
-0
71
0
250
500
750
1000
1250
ns
*
[IL
-1
3] 
pg
/m
l
D 
Figure 7: PMA/CD3 and PMA/CD28 
stimulation differentially modulate 
primary T cell cytokine responses 
in human healthy donor blood. 
Healthy donor blood was stimulated 
with PMA/CD3 and PMA/CD28 and 
cultured for 24 hours in the presence 
or absence of pathway inhibitors for 
Lck and PKC. Culture supernatants 
were analyzed on A; IFNγ, IL-17 
(Th1/17 cytokines) and B; IL-13 and 
IL-5 (Th2 cytokines).  Figure C shows 
the involvement of Lck (420983; 1 
mM) and PKC (AEB071; 1 mM) signal 
transduction on PMA/CD3-induced 
IFNγ production. Figure D shows 
the effect of Lck (A-420983; 1 mM)) 
and PKC (AEB071; 1 mM) signal 
transduction pathways on PMA/
CD28-induced IL-13 production. 
Data are presented as results from 
3 donors measured as biological 
duplicates. Significance of differences 
are presented as followed; * p<0.05, 
**p<0.01 using a one-way ANOVA 
with Dunnett’s post hoc testing.
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under PMA/CD3 stimulation enhanced the expression of Th2 master transcription 
factors GATA3 and RXRA, but also peptidoglycan recognition protein 4 (PGLYRP4) 
and G protein-coupled receptor 84 (GPR84). 
A third example is provided by genes clustering together with EGR1, which show an 
up regulation by all stimuli but are specifically regulated by AEB071 in all conditions 
and only by A420983 after CD3/CD28 stimulus.  Although IL-2 and EGR1 show a 
similar regulation by the stimuli used, the profiles can clearly be discriminated by the 
effects of the various inhibitors on their expression. The list of genes that are shown 
in Figure 7 together with their annotation and the correlation score to the CCL, IL-2 
and EGR1 profiles are shown in Supplemental Table 2-4. This analysis shows that 
by applying multiple stimuli and selective compound treatments, pathways can be 
unraveled at high resolution.
Translation of PMA/CD3 and PMA/CD28 stimulations; differential modulation 
of primary T cell cytokine responses in human donor blood.
In order to assess whether the stimulation profiles and signal transduction profiles 
identified in Jurkat T-cells were also relevant in a primary human setting, the 
stimulation protocols were adapted and a primary assay was established using 
healthy human donor whole blood. The effect of differential stimulation was evaluated 
using IFNγ and IL-17 as Th1- and Th17-associated read-outs respectively and both 
IL-5 and IL-13 as Th2-associated read-outs. Stimulation of human whole blood cells 
with CD3/CD28 was unsuccessful: no cytokine release was detected. However, 
PMA/CD3 stimulation of human blood cells, resulted in a high production of IFNγ 
(Figure 8A). Interestingly, INFγ production levels were significantly lower after PMA/
CD28 stimulation. A similar observation was seen when analyzing IL-17 production. 
Thus, higher production levels of both IFNγ and IL-17 were seen following PMA/CD3 
stimulation when compared to PMA/CD28 stimulation. Furthermore, when analyzing 
Th2-associated IL-5 and IL-13 production, we found that PMA/CD28 stimulation was 
superior to PMA/CD3 stimulation in enhancing production of these cytokines (figure 
7B). Of note, CCL1 production could not be detected in this assay system (data not 
shown). In aggregate, the data suggests that PMA/CD28 stimulation favours Th2 
responsiveness in this assay. Since PMA/CD28 signaling was shown to be 
independent of Lck, but mainly dependent on PKCθ, whereas PMA/CD3 signaling 
was both Lck and PKCθ dependent we evaluated the effect of both proximal kinases 
in this human whole blood assay and evaluated IFNγ and IL-13 production since 
these cytokines were most readily produced. Figure 7C shows that indeed PMA/
CD3-induced IFNγ production is depending on both Lck and PKCθ signaling, whereas 
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PMA/CD28-induced IL-13 production is Lck-independent and PKCθ dependent. 
These results clearly show that the differential stimulations identified in the Jurkat 
assay can be translated towards a primary human cellular assay and are depending 
on the same proximal signaling hubs. Furthermore, also in this setting it can be 
observed that PMA/CD3 stimulation diverges more towards a Th1-like phenotype, 
whereas PMA/CD28 stimulation skews more towards a Th2-like response.
PMA/CD3 stimulation of purified human CD4+ Tcells enhances Th1 activation, 
whereas PMA/CD28 potentiates Th2 activation
Using purified human CD4+ T cells we validated the effects observed on Jurkat T 
cells and in a primary human whole blood assay setting. Of all stimuli used PMA/CD3 
Figure 8: PMA/CD3 and PMA/CD28 stimulation on purified primary human CD4+ T cells. Purified 
CD4+ T cells were stimulated with anti-CD3/CD28, PMA/CD3 and PMA/CD28 and cultured for 24 hours 
in the presence or absence of pathway inhibitors for Lck (A420983; 1 μM) and PKC (AEB071; 1 μM). 
Culture supernatants were analyzed for IFNg, production (A), mRNA expression of the Th1 master 
transcription factor T-bet (B), the production of the Th2 cytokine IL-13 (C) and expression of the Th2 
master transcription factor GATA3 (D). Message RNA expression was normalized against ribosomal 
house hold gene RPL19. Data are presented of three independent experiments using purified human 
CD4+ T cells from three different healthy donors. Data are presented as mean + SD. Significance of 
differences are indicated by ** p < 0.01, * p < 0.05, using a mann-withney U-test.
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appeared to be the most powerful stimulus able to induce IFNγ production. Also in 
this setting inhibition of either Lck using A-420983, or PKC using AEB071 completely 
inhibited PMA/CD3 induced IFNγ production. CD3/CD28-mediated stimulation, 
which can be success-fully applied in this assay format induced IFNγ production, 
which was dependent on both Lck and PKC mediated signal transduction pathways. 
Of interest and comparable to the effects observed on CCL1 production by Jurkat T 
cells, Lck inhibition under PMA/CD28 stimulation did not inhibit IFNγ production and 
even appears to slightly enhance IFNγ production (Figure 8A). The observed effect 
on IFNγ production of the different stimuli is in line with the effects observed on the 
induction of the Th1 master transcription factor Tbet (Figure 8B). Both inhibition of 
Lck and PKC reduced CD3/28 and PMA/CD3 mediated induction of Tbet, whereas 
Lck inhibition did not affect PMA/CD28-induced expression of Tbet. PMA/CD28 was 
the most profound inducer of IL-13 in CD4+ cells (Figure 8B). Interestingly IL-13 
production under al stimulatory conditions used is dependent on PKC, whereas Lck 
inhibition does not affect IL-13 production under PMA/CD3 or PMA/CD28 culture 
conditions. Under all culture conditions inhibition of PKC reduced IL-13, which was 
paralleled with reduced GATA3 expression (Figure 8D), whereas inhibition of Lck 
appeared to promote Th2 dvelopment under all stimuli used, which was reflected by 
enhanced expression of GATA3.
Conclusions
In this study we systematically explored pathways involved in T cell activation by 
molecular profiling. We showed that TCR (both CD3/28 and PMA/CD3) driven 
stimulation profiles are truly distinct from co-stimulatory profiles mediated via PMA/
CD28. Secondly, using selective inhibitors and siRNA we found that the proximal 
kinase Lck is involved in CD3 and not PMA/CD28 activation, whereas PKCθ appears 
to be a crucial central signaling kinase in both TCR and PMA/CD28 (co)-stimulatory 
activation of T cells. Finally, stimulations involving TCR/CD3 appear to preferentially 
induce a Th1-like or Th17-like fingerprint, whereas lack of TCR/CD3 signaling in the 
presence of PMA/CD28 stimulation diverts T cells towards a Th2-like state. 
It has been suggested that the strength of TCR-signaling can regulate the fate 
determination of naive T cells; high-potency signals skew towards Th1 differentiation, 
whereas low potency signals promote Th2 differentiation [6, 22]. Although TCR 
and co-stimulatory pathways have been the focus of many studies in the previous 
decades, the direct contribution of TCR stimulation vs. co-stimulatory signals towards 
Th differentiation is not fully understood. By stimulating T cells with PMA/CD3 and 
PMA/CD28 we dissected signaling pathways and explored the activation profiles. 
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CD3-mediated signaling rapidly increased intracellular Ca2+, a second messenger 
to activate many enzymes including Calcineurin, which resulted in an increased 
nuclear translocation of NFATc1. Interestingly, PMA/CD28 stimulation did not result 
in a Ca2+-mediated response (and was therefore marked a calcium-independent 
stimulation) but enhanced many of the co-stimulatory mediators including MAPK/
AP1 and NFκB signal transduction. These results are in line with earlier studies 
that showed differential effects of cyclosporine A (CsA) and dexamethasone on 
CD3 vs CD28-mediated signaling, which revealed that PMA/CD28 stimulation was 
insensitive towards CsA-mediated Calcineurin inhibition in contrast to PMA/CD3 
stimulation [20, 23]. 
Gene expression induced by combinations of stimulatory signals revealed pathway-
specific biomarkers or fingerprints. PMA/CD3-induced gene profiles included IL-
2, IFNγ, XCL1, granzyme B, and FASL, which have been associated with a Th1 
type of response [24-25]. Also, sustained NFAT signaling, which is also induced 
via PMA/CD3 stimulation, has been shown to promote Th1-like gene transcripts, 
including IFNγ, FasL and P-selectin glycoprotein ligand 1 [26]. Our results are 
further substantiated by the finding that T-bet (TBX21), the Th1 master transcription 
factor [27], and RUNX3, which together with Tbet are crucial for inducing IFNγ and 
repressing IL-4 [28], were highly expressed under PMA/CD3-stimulatory conditions. 
PMA/CD28 stimulation does not induce a Ca2+ flux nor does it increase nuclear 
translocation of NFAT. However it provides the cell with a high level of co-stimulatory 
signaling, and induces a completely distinct genomic fingerprint compared to PMA/
CD3 stimulation. Following PMA/CD28 stimulation, Jurkat T cells highly expressed 
CCL1/I309, a chemokine which is highly expressed during a Th2-eosinophil 
response in allergic airway diseases [29-30]. Lymphotoxin (LT), a cytokine which 
is associated with a Th2-type of response controlling IgE production [31], was also 
highly expressed under PMA/CD28 stimulation. In conjunction with this finding, 
the master transcription factors for Th2, GATA3 [32] and the Retinoid X Receptor 
(RXR) [33], were induced under the PMA/CD28 stimulatory condition. Notably, Th2-
associated cytokines like IL-4, IL-5 and IL-13 were not induced in Jurkat T cells 
after PMA/CD28-stimulation, this in contrast with PMA/CD28 stimulation of human 
whole blood, which could be due to the developmental blockage of Jurkat T cells. 
Supplemental figure 2 shows a schematic overview summarizing the involvement of 
the signaling pathways and genes induced under differential stimulation as observed 
in this study and highlights their relation towards T helper 1 and -2 development.
Our results are in line with the notion that high calcium levels drive Th1 and CTL 
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responses and low calcium levels drive Th2 responses [7, 34-35], which was 
further substantiated by our results using inhibitors for Lck and Cn, which modulate 
Calcium signaling in T cells. These inhibitors repressed Th1-associated genes under 
PMA/CD3-stimulation, but induced Th2 transcription factors GATA3 and RXRA, 
revealing a skewing of Th1 towards Th2 profiles. In contrast, PMA/CD28 stimulation 
in the presence of Lck and Cn inhibition, Th2-associated genes, e.g. CCL1, were 
not affected or even induced. The crucial role of Calcium and Lck in driving Th1 
response is in line with the observation that knock down of Lck affects the virus-
specific Th1/CTL response in mice and Lck deficiency increases Th2 associated 
cytokine production [36-37]. Interestingly, lack of Calcium signaling can give rise to 
an anergic T cell phenotype (reviewed in [38]). Therefore it would be of interest to 
further explore the role of Lck in calcium-dependent activation via PMA/CD3 on Th1/
CTL responses and calcium-independent activation of T cells via PMA/CD28 on the 
induction of anergy in more detail. 
CD28 signaling has been functionally linked with PKCθ induced activation of NFκB 
[39], which was also validated using PMA/CD28 as stimulus [40]. Previously it 
has been reported that CD28-costimulation induces GATA3 expression and Th2 
differentiation via the activation of NFκB [41-42]. Additional studies in mice revealed 
that PKCθ is involved in mounting both Th2- and Th1-mediated lung inflammation, 
although Th2-mediated inflammation is more PKCθ-dependent [43]. Our studies 
show that inhibition of PKCθ can indeed inhibit a PMA/CD28 stimulation, which was 
reflected by the effect of PKCθ inhibition on the PMA/CD28-induced Th2-like gene 
expression profile. These observations are in line with the results from CD28 knock-
out mice and inhibition of CD28 signaling using CTLA4Ig, showing that the CD28 co-
stimulatory signaling is crucial for mounting a proper Th2 response. In contrast, Th1 
and CTL responses were found to be less dependent on CD28 signaling [44-45]. 
Of interest, PKCθ inhibition in our hands, also affected PMA/CD3-induced Th1-like 
expression profiles. These results underline the duality of PKCθ in the integration 
of TCR and CD28-mediated signaling events which is evident from PKCθ KO mice 
experiments. 
Finally, our results also show that this differential stimulation does not only occur in 
Jurkat T cells, but also plays a role in primary human T cells. These cells were found 
to secrete a Th1-like response (Tbet-IFNγ) via PMA/CD3 stimulation, whereas PMA/
CD28 stimulation led to a Th2 activation profile (GATA3-IL-5/IL-13). In these cells 
inhibition of the Lck/Cn/NFAT pathway was only effective after PMA/CD3 stimulation 
whereas inhibition of PKCθ inhibited both PMA/CD3-induced IFNγ production and 
PMA/CD28-induced IL-13 production. These results illustrate that the findings in 
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the Jurkat T cell line were successfully translated and relevant to a human primary 
cellular setting. Interestingly, PMA/CD3 stimulation also enhanced IL-17 production 
in the primary human whole blood assay and increased the expression of the IL-21 
receptor, which is crucial for Th17 induction [46-47], in Jurkat T cells. These results 
suggest that additional signals, like IL-21 in conjunction with TGFβ and IL-6, are 
necessary to differentiate from a Th1-like phenotype towards a Th17 phenotype, 
whereas the absence of TGFβ in the presence of high levels of IL-2 will favor Treg 
development or stabilization. Therefore further exploration of these differential 
stimulations in the presence of defined /different cytokine stimuli could further 
elucidate T helper cell differentiation and establish sub-set specific genome profiles. 
The findings described in this paper offer a robust platform for in vitro activation of 
T cells, in which observed responses can be easily translated form Jurkat T cells, 
towards purified CD4+ T cells and even human whole blood. This can be of interest 
for efficiency and selectivity profiling of kinase inhibitors or for pathway-specific 
biomarker identification for future drug development and clinical studies.
Materials and Methods
Compounds
Inhibitors selectively targeting defined pathways used in this study were A-420983 
(1 mM; Lck inhibitor) [48], AEB-071 (10 mM; PKCθ inhibitor) [49] and Cyclosporin A (1 
mM; Calcineurin inhibitor). Additionally, inhibitors of the MAPK pathway, SP600125 
(10 mM; pan JNK), PD98059 (10 mM; MEK1/2), Org 48762-0 (10 mM; P38) [50] were 
used. All compounds were dissolved in 100% DMSO. Maximal and final concentration 
of DMSO used in the culture assays was 0.1% v/v.
Cell culture
Jurkat E6.2.11 T cells were cultured in DMEM F12 medium (#041-94895M, Gibco) 
supplemented with 10% FBS (#10099-141, Invitrogen) and 80 U/ml penicillin/80 μg/
ml streptomycin (#15140-122 Gibco). Cells were cultured at concentrations between 
1-2x105 cells/ml at 37°C/5%CO2. Cells were stimulated for 15 minutes up to 24 
hours with anti-CD3 (1 mg/ml, OKT3), anti-CD28 (1 mg/ml, pericluster CD28 #M1456 
Sanquin, the Netherlands), PMA (10 ng/ml, Sigma, USA) and ionomycin (1 mg/ml, 
Sigma, USA), or combinations thereof. For gene expression profiling Jurkat T cells 
were seeded in T25 culture flasks at a concentration of 1x106 cells/ml (1x107 cells 
in total) and cultured overnight at 37°C/5%CO2, one day prior to stimulation. On the 
day of the experiment cells were preincubated with the compound of interest for 30 
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minutes, followed by a stimulation with either CD3/CD28, PMA/CD28 or PMA/CD3, 
at concentrations of 10 ng/ml PMA, 1 μg/ml CD3 and 1 μg/ml CD28. Jurkat T cells 
were cultured in the presence or absence of stimulation for one or eight hours in 
total, after which the cells were washed in ice cold PBS. Thereafter cell pellets were 
collected and snap frozen at -80°C. Cell pellets were stored until further processing. 
Isolation and quality check of mRNA
Total RNA was isolated from Jurkat T cells using the RNeasy mini extraction kit 
(Qiagen # 74106) according to the manufactures’ protocol. RNA was dissolved and 
diluted in RNAse free water and the RNA concentration was determined via Nanodrop 
analysis. The quality of total RNA was evaluated by capillary electrophoresis using 
an Agilent 2100 Bioanalyzer (Agilent Technologies, Palo Alto, Calif.). Double-
stranded cDNA was synthesized from 1.5 μg total RNA using the One-Cycle Target 
Labeling Kit (Affymetrix Santa Clara, CA), and used as a template for the preparation 
of biotin-labeled cRNA using the GeneChip IVT Labeling Kit (Affymetrix Santa Clara, 
CA). Biotin-labeled cRNA was fragmented at 1 μg/μl following the manufacturer’s 
protocol. After fragmentation, cRNA (10μg) was hybridized at 45°C for 16-17 hours 
to the Human Genome U133A 2.0 Array or the Human Genome U133 Plus 2.0 Array 
(Affymetrix, Santa Clara, CA). Following hybridization, the arrays were washed, 
stained with phycoerythrin-streptavidin conjugate (Molecular Probes, Eugene, OR), 
and the signals were amplified by staining the array with biotin-labeled anti-streptavidin 
antibody (Vector Laboratories, Burlingame, CA) followed by phycoerythrin-
streptavidin. The arrays were laser scanned with an GeneChip Scanner 3000 6G 
(Affymetrix, Santa Clara, CA) according to the manufacturer’s instructions. Data was 
saved as raw image file and quantified using GCOS (Affymetrix).
Statistical analysis
The .CEL files were analyzed with the R (www.r-project.org) and the BioConductor 
software package (www.bioconductor.org). Normalization was done using gcrma. 
Building of the experimental design and calculation of the ratios was done with the 
limma package. Regulated probe sets were selected on basis of the fold change and 
the adjusted p-value (Benjamini-Hochberg correction).  Multivariate data analysis 
and clustering was done with standard methods in the R software package (www.r-
project.org). For the principal component analysis and hierarchical clustering, ratio 
data were used. The ratio data were calculated for each treatment to its corresponding 
control. For the treatment with the stimuli, the untreated cells were taken as a control. 
For the treatment with stimulus + compound combinations, the treatment with the 
70
Chapter 2
2
stimulus alone was taken as a control. Results were expressed as mean ± SEM. 
Significance of differences was determined using a one-way ANOVA followed by 
post-hoc testing as indicated. Data sets can be found in GEO (http://www.ncbi.nlm.
nih.gov/gds/) under accession number GSE30678. 
FLIPR Calcium flux Assay
96-wells plates were coated with poly-L-lysine in PBS for 1 hour at 37 oC. Jurkat 
T cells were seeded at a concentration of 7x105 in culture medium and rested for 
1 hour at 37°C / 5%CO2. Thereafter cells were incubated for 1 hour in the dark 
with FLIPR calcium buffer, according to the manufacturers’ protocol. Stimuli were 
added via the Flexstation384 and calcium release was monitored in time (Molecular 
devices, Sunnyvale, USA).
Western Blotting and nuclear translocation assay
Cells were washed in ice-cold PBS and pellets were lysed on ice in lysis buffer 
(Biosource, cat nr FNN0011, supplemented with 1 x protease inhibitor cocktail 
Roche cat no 11873580051, 1 mM PMSF Fluka cat no 93482, phosphatase inhibitor 
cocktail I, Sigma cat no P2850, phosphatase inhibitor cocktail II, Sigma cat no P5726) 
followed by an incubation for 30 min on ice. The lysates were stored at -80°C until 
further analysis.
Phosphorylation of proteins from stimulated Jurkat cells were evaluated via western 
blot analysis. Briefly, samples were run on a 4-12% NuPage gels (#NP321BOX, 
Invitrogen) for 35 min on 200V in 1 x MES buffer (#NP0002, Invitrogen, USA) and 
subsequently transferred to a PVDF membrane (#162-0184, Biorad). The blots were 
blocked in PBS/0.05% Tween-20 with 1% skim milk (#232100, Difco) and 1 % BSA. 
Blots were incubated O/N at 4°C in a roller bottle with the primary antibody diluted 
1:1000 in block buffer, followed by incubation with a secondary detection antibody. 
Thereafter blots were incubated in ECL (#RPN2106V1 and RPN2106V2 Amersham 
Pharmacia) and hyperfilms (#RPN3103K, Amersham Pharmacia) were exposed and 
developed. For the detection the following antibodies were used: pLck/Src (Tyr416 
Cat No 2101L), Lck (Cat No 2752), pZAP70 (Tyr319 Cat No 2701), pPKCθ (Thr538, Cat 
No 9377), pMARCKS (Ser152/156 Cat No 4273) and ATF-2 (Thr71 Cat No 9221) (all cell 
signaling technology, Danvers, USA). pP38 (Thr180/Tyr182 Cat No 44-684G)), pERK 
(Thr185/Tyr187 Cat No 44-680G), pJNK1/2 (Thr183/Tyr185 Cat No 44-682G), JNK1 (Cat 
No 44-690G) were obtained from Invitrogen (Carlsbad, USA) and c-Jun (pSer73) was 
obtained from calbiochem (cat no 420114). For the analysis of nuclear translocation 
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of the transcription factors NFAT, NFkBp65 and c-JUN, nuclear fractions of activated 
Jurkat T cells were isolated via hypotonic shock and levels of activated transcription 
factors in the nuclear lysates was tested in a TransAM transcription factor ELISA 
according to the manufacturers’ protocol (Active Motif, Carlsbad, USA).
Knock down of PKCθ and Lck in Jurkat T cells
Jurkat T cells (2x10e7 cells/ml) were mock transfected or electroporated (250V/975μF) 
with siRNA targeting Lck (RefSeq accession-number NM-005356; sense 
5’-GCACGCUGCUCAUCCGAAAdTdT) and PKCθ (RefSeq accession-number NM-
006257; sense 5’-GCAGCAAUUUCGACAAAGAdTdT) in different concentrations of 
500, 100 and 20 nM or scrambled control siRNA (Thermo scientific, Dharmacon 
Inc, Lafayette, USA). Electroporated cells were cultured in M505 supplemented with 
10% FCS. Cells were stimulated 72 hours after electroporation and knock-down 
efficiency of the specified proteins was checked via western blot analysis. Culture 
supernatants of PMA/CD28 or PMA/CD3-stimulated cells were collected after 24 
hours and production of respectively CCL1 and IL-2 was determined.
Experiments with WBA
Peripheral whole blood was obtained by venipuncture from healthy adults (male/
female) and was collected into lithium heparinised tubes. Blood was obtained from 
healthy volunteers and the time between puncture and processing was less than 1 
hour. Blood was diluted 1:4 with RPMI 1640 (Life Technologies, cat no. 32404-014) 
supplemented with penicillin/streptomycin (GibcoBRL, cat 15140-122) and 2 mM 
L-glutamine (GibcoBRL, cat 25030-024) and distributed (200 μl/well) into 96-wells 
plates (Nunc, Cat 167008). Blood cultures were stimulated with soluble αCD3/PMA 
and soluble αCD28/PMA, or left unstimulated. Blood (200 μl/well) in RPMI 1640 
medium was incubated with 25 μl compound (maximum of 0.1% v/v DMSO).
Cytokine determination
Cytokines and chemokines IL-2, CCL1/I309 and XCL1, secreted into the supernatant 
of stimulated Jurkat T cells were determined via ELISA (R&D systems, USA). 
Cytokines IL-17, IFNγ, IL-13 and IL-5, produced by human CD4+ T-cells activated in 
whole blood, cultured in the presence or absence of compounds were determined in 
the culture supernatant, using a bead-based human cytokine multiplex kit (Bioplex-
system; Bio-Rad, Veenendaal, The Netherlands) according to the manufacturer’s 
instructions. Culture suppernatants were collected at day 1 of culture. Samples 
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were analyzed using a Luminex-100 analyzer (Luminex, Austin, USA) with Bio-
plex Manager Software 3.0 (Bio-Rad). Proteins were discriminated based on the 
fluorescent label of the bead and the PE levels were corrected for background levels 
of negative controls. The sensitivity of the cytokine assay was less than 5 pg/ml for 
all cytokines measured.
cDNA synthesis and q-PCR
Primary human CD4+ T cells were isolated from buffy coats from three healthy donors 
using MACS negative CD4+ purification technology (Miltenyi biotech, Germany), 
yielding a overall 96% pure CD4+ T cell population. RNA from stimulated CD4+ 
T cells was isolated using an RNeasy minikit (QIAGEN Gmbh, Germany). RNA 
content of samples was analyzed using Nanodrop (Agilent technologies, Ca, USA) 
and purity was analyzed using the Agilent RNA 6000 nanokit protocol on the RNA 
nano labchip using the Agilent 2100 bioanalyzer (Agilent technologies, Waldborn, 
Germany). Three microgram of RNA was used for cDNA synthesis using random 
hexamer primer mix (invitrogen), 10 mM dNTP, M-MLV RT buffer and M-MLV Reverse 
transcriptase (Promega). RT reaction was performed at 42 oC for 1 hour followed by 
a deactivation for 5 minutes at 90 oC. cDNA of the Th1 master transcription factor 
Tbx21 (Tbet), Th2 transcription factor GATA3 or the control household gene RPL19 
was applified using Power SYBR green mastermix (Applied Biosystems, Warrington, 
UK) and expression was monitored on the ABI prism 7900 HT sequence detection 
system (Applied Biosystems, Warrington, UK), Ct values were normalized for the 
expression of the RPL19 gene.
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Figure 4 
Supplement figure S1: PCA using the ratio data vs. the respective controls. Cells were treated 
for 8 hours with the single stimuli CD28, CD3 and PMA (black squares) and with the stimulatory 
combinations PMA/CD28 (blue circles) CD3/CD28 (green triangles) and CD3_PMA (red diamonds). 
The corresponding treatments with the stimulus+inhibitor combination are represented by the same 
symbols. Eg. the red diamond with the AEB071 label represents the samplein treated with CD3+PMA 
and AEB071. This graph shows that PMA/CD28 stimulation was mainly affected by AEB071, whereas 
PMA/CD3 stimulation was mainly modulated by CsA, A420983 and AEB071. The symbols around the 
origin represent the treatments with the MAPK inhibitors, which only had a marginal effect on the 
stimuli used (the labels have been omitted for clarity). The numbers denote the number of significantly 
regulated probe sets for these conditions compared to the respective controls. These numbers were 
very low for the conditions including MAPK inhibitors and CD28 stimulation alone and for A420983 
and CsA after PMA/CD28 stimulation (centered around the origin of the graph) and have therefore 
been omitted for clarity. For details of regulated probe sets for all conditions and the overlap between 
these sets, see supplementary Table 1. Repeating this analysis with different values for the fold change 
and p–value cut off yielded essentially the same results for the multivariate analysis. 
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Supplement figure S2: A schematic presentation of signaling pathways and induced gene profiles via 
differential stimulation of T cells. This figure highlights the findings of this study indicating that TCR/
CD3-induced Calcium signaling is necessary for efficient T helper 1 development, whereas absence of 
calcium signaling and sufficient activation of NFκB/AP1 lead to T helper 2 development (as indicated 
by green-red intensity plots). A selected list of genes is listed derived from the IL-2 and CCL1 gene 
profiles shown in figure 7.
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Abstract 
Mycophenolic acid is the active ingredient of the immunosuppressant mycophenolate 
mofetil which is widely used in transplantation medicine and autoimmunity. 
Mycophenolic acid inhibits inosine monophosphate dehydrogenase, an enzyme 
involved in biosynthesis of guanine nucleotides required for lymphocyte clonal 
expansion. Here, we present novel insights into the mechanisms underlying 
mycophenolic acid-mediated suppression of human CD4+ T-cells. Upon CD3/CD28 
stimulation, mycophenolic acid inhibited T-cell IL-17, IFN-γ and TNF-α production 
but not IL-2 production. Phenotypic analysis showed that drug treatment enhanced 
expression of negative co-stimulators PD-1, CTLA-4 and the transcription factor 
FoxP3 and decreased expression of positive co-stimulators CD27 and CD28, 
whereas CD25 was unaffected. Mycophenolic acid -treated cells were anergic, but not 
suppressive, and at the same time proved hyperblastoid with high metabolic activity. 
Moreover, a reduced Akt/mTOR and STAT5 signalling was observed. Interestingly, 
the co-stimulatory molecule CD70 was uniquely and dose-dependently upregulated 
on mycophenolic acid-treated T cells and found to be directly linked to target enzyme 
inhibition. CD70 on mycophenolic acid -treated cells proved functional: an anti-CD70 
agonist was found to restore both STAT5 and Akt/mTOR signaling and may thereby 
prevent apoptosis and promote survival. These novel insights may contribute to 
optimization of protocols for MPA-based immunosuppressive regimens. 
Running title: MPA-mediated suppression of human CD4+ T-cells
Key words: Mycophenolate mofetil, mycophenolic acid, immunosuppression, 
immune regulation, lymphocyte activation, PI-3 kinase/Akt pathway
Abbreviations: 4E-BP1, eukaryotic translation initiation factor 4E binding protein 1; 
5-Aza, 5-Aza-2’-oxylcytidine; Akt/PKB, protein kinase B; CFSE, carboxyfluorescein 
succinimidyl ester; dGTP, deoxyguanosine triphosphate; DNMTs, DNA 
methyltransferases; FSCs, forward angle light scatters; GEFs, guanine-nucleotide 
exchange factors; GTP, guanosine triphosphate; Gua, guanosine; IFN-γ, interferon-γ; 
IL, interleukin; IMPDH II, type II isoform of inosine monophosphate dehydrogenase; 
MFIs, mean fluorescence intensities; MMF, mycophenolate mofetil; MPA, 
mycophenolic acid; PBMCs, peripheral blood mononuclear cells; PBS, phosphate-
buffered saline; PI3K, phosphatidylinositol-3 kinase; RA, rheumatoid arthritis; Rh123, 
rhodamine 123; SLE, systemic lupus erythematosus; TNF, tumor necrosis factor. 
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Introduction
Mycophenolic acid (MPA) is the active ingredient of the immunosuppressant 
mycophenolate mofetil (MMF/Cellcept). MPA-based therapies are widely used 
in solid organ and stem cell transplantation and autoimmune disease (1;2). MPA 
selectively targets the type II isoform of inosine monophosphate dehydrogenase 
(IMPDHII), an enzyme involved in the biosynthesis of guanine nucleotides (GTP and 
dGTP). The depletion of GTP/dGTP pools is thought to be the mechanism of action 
by which MMF inhibits the proliferative response in vitro and in vivo. Recent studies, 
however, suggest that additional mechanisms must underlie MPA-mediated immune 
suppression. Sankatsing et al. (3) showed that MMF inhibits T-cell proliferation without 
lowering intracellular dGTP and GTP. Qiu et al. reported (4) that MPA also affects 
ATP and pyrimidine synthesis in primary human T-cells.  Moreover, Demirkiran et al. 
(5) found that MMF-based therapy as opposed to calcineurin inhibition, positively 
affects the frequency of circulating Treg cells in liver transplant recipients.
Resting naïve and memory T-cells and activated T-cells display different metabolic 
signatures (6). A growing body of evidence indicates that the ability of lymphocytes 
to proliferate, activate or die is controlled by their ability to take up nutrients and to 
regulate energy metabolism. Both T-cell receptor engagement and co-stimulation are 
required for productive T-cell responses and the absence of co-stimulation results 
in T-cell anergy (7). In a productive immune response, ligation of CD28 not only 
activates the phosphatidylinositol-3 kinase (PI3K)-Akt/PKB pathway but also induces 
the activation of mTOR (8), which promotes translation and protein synthesis via 
its downstream substrates S6K1 and 4E-BP1. Activation of the Akt/mTOR pathway 
thus metabolically fuels the needs of T-cell activation and expansion. 
In contrast to CD28, the co-stimulatory molecule CD27 is not required for entry into 
the cell cycle upon T-cell activation, but is important for formation of the effector T-cell 
pool by enhancing proliferation and survival of activated T-cells (9). Expression of the 
CD27 ligand, CD70, is highly restricted and activation dependent. CD70 agonistic 
ligation activates the PI3K-Akt/PKB and MAP kinase (MAPK) signaling pathways in 
primary B cells and in some human T-cell clones (10;11). The expression pattern of 
the CD27 and CD70 receptor-ligand pair is thus crucial for regulation of the immune 
response. The growth factor IL-2 is essential for T-cell proliferation and function. 
By binding to the IL-2 receptor (CD25), various signal molecules can be activated 
including Janus kinase (Jak), STAT3/5, Ras/Erk and PI3K (12;13). Recent evidence 
indicates that the IL-2/Jak/STAT5 pathway is closely linked to PI3K/Akt (14-16). 
84
Chapter 3
3
In this study, we assessed the effects of MPA treatment on highly purified helper 
T-cell populations. Our results show that there is more to MPA-mediated immune 
suppression than previously known. We found that MPA treatment led to a state of 
anergy and a concomitant metabolic reprogramming. Interestingly, the co-stimulatory 
molecule CD70 was uniquely and dose-dependently upregulated on MPA-treated 
T-cells and found to be directly linked to IMPDH inhibition. MPA-induced CD70 
expression and ensuing ligation may serve a mechanism to protect cells from 
apoptosis and to switch their metabolic program to fuel CD4+ T-cell survival.
Materials and Methods
Reagents 
MPA and guanosine (Sigma-Aldrich, St Louis, USA) and  A77 1726  (Alexis 
Biochemicals (Lausen, Switzerland) were dissolved in methanol (MPA) or DMSO 
(A77 1726 and guanosine) and stored according to the manufacturer’s instruction.
Cell isolation and culture of cells
Buffy coats were obtained from healthy blood donors (Sanquin Blood Bank, Region 
South East, The Netherlands) upon written informed consent for scientific use, 
according to the Declaration of Helsinki. Peripheral blood mononuclear cells (PBMCs) 
and CD4+ T-cells were purified from PBMCs as described previously (17). The 
resultant CD4+ T-cell fraction, was labeled with anti-CD45RO-FITC (UCHL1; DAKO, 
Glostrup, Denmark), anti-CD25-PE (M-A251; BD Biosciences), anti-CD45RA-ECD 
(2H4) and anti-CD4-PC5 (13B8.2) (Beckman Coulter, Mijdrecht, The Netherlands) 
conjugated monoclonal antibodies (mAbs); thereafter naïve (CD45RA+CD25-) and 
memory (CD45RO+CD25-) CD4+ T-cells were sorted by high-purity flowcytometry 
cell sorting using an Altra cell sorter (Beckman Coulter). The purity of sorted cells 
was > 98%. 
Sorted cells were cultured in RPMI-1640 medium as described previously (17) 
and stimulated with beads coated with anti-CD3 and anti-CD28 antibodies (T Cell 
Expanders, Dynal Biotech, Oslo, Norway), in a bead:cell ratio of 1:2 in the absence 
or presence of immunosuppressive reagents as indicated. Recombinant human 
cytokines IL-2 (rhIL-2, 12.5 U/ml, Proleukine, Chiron, Amsterdam, The Netherlands) 
and/or 5-Aza-2’-deoxycytidine (5-Aza, 1 μM, Sigma-Aldrich) were added to the cell 
cultures, where indicated. 
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Cell proliferation assay
Typically 5 x 104 per well FACS sorted T-cells were stimulated in the absence 
or presence of a grade dose of MPA. Cell proliferation was monitored by [3H]-
thymidine incorporation using a Gas Scintillation Counter (Canberra Packard, Matrix 
96 Beta-counter, Meriden, USA). One µCi [3H]-thymidine (Amersham Biosciences, 
Piscataway, NJ) was added to each well and cells were harvest after 6h of culture. 
Proliferation is expressed as mean counts per 5 minutes of triplicate measurements 
± SD. Relative inhibition was calculated using the following formula; %inhibition= 1- 
([3H]-thymidine incorporation with MPA/[3H]-thymidine incorporation without MPA) 
x 100%.
Flow cytometry, antibodies and  CFSE labeling
Cells were phenotypically analyzed by five-color flowcytometry FC500 (Coulter 
Cytomics FC500, Beckman Coulter) using Coulter Epics Expo 32 software as 
described previously (17). The following conjugated mAbs were used: Annexin-V-
FITC (eBioscience, Uithoorn, The Netherlands), anti-CD25-Biotin (4E3; Miltenyi, 
Bergisch Gladbach, Germany) or –PeCy7 (BC96; eBioscience), anti-CD70-PE 
(KI-24; BD Bioscience), anti-CD27-PE (M-T271; DAKO) or –Biotin (M-T271; 
Ancell, Bayport, USA), anti-CD28-PE (CD28.1; DAKO), anti-PD-1-FITC (MIH-4; 
BD Bioscience), anti-CD45RO-ECD (UCHL1), anti-CD4-PeCy5 (T4), anti-CD3-
PeCy5 (UCHT1), anti-CD8-ECD (SFCI21Thy2D3) (all from Beckman Coulter). The 
detection of biotinylated antibodies was performed with streptavidin conjugated to 
PeCy7 (Beckman Coulter). For intracellular staining, anti-FoxP3-FITC (PCH101) 
and anti-CTLA-4-PE (BNI3) (both from eBioscience) were performed after Fix-
Perm-treatment (eBioscience). Appropriate isotype control mAbs were used for gate 
settings. The data were analyzed using CXP software (Beckman Coulter).
FACS sorted cells (10 x 106) were labeled with 2 µM carboxyfluorescein succinimidyl 
ester (CFSE; Molecular Probes, Leiden, The Netherlands) to monitor cell division, as 
described previously (17).
Cytokine production
Human IL-1ra, IL-2, IL-10, IL-17, IFN-γ, TNF-α and GM-CSF were determined in the 
culture supernatant, using multiplex analysis (Bioplex-system; Bio-Rad, Veenendaal, 
The Netherlands), according to the manufacturer’s instructions. The sensitivity of the 
cytokine assay was less than 5 pg/ml for all cytokines measured.
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Re-stimulation and co-culture suppression assays
FACS sorted CD4+ T-cells (5 x 104 per well) were stimulated with anti-CD3/anti-
CD28 mAb-coated beads in the absence or presence of 1 µM MPA. After expansion, 
the cells were harvested at day 6, washed and rested for 2 days in culture medium 
containing 5% HPS, and re-stimulated with anti-CD3/anti-CD28 mAb-coated 
beads (bead:cell = 1:5) in the absence or presence of added IL-2 (12.5 U/ml). Cell 
proliferation was examined after 2 days of culture. For Western blot analysis, MPA-
pretreated and/or non-treated T-cell were re-stimulated with anti-CD3/anti-CD28 
mAb-coated beads. MPA (1 μM) and anti-CD70 mAb (1 μg/ml, Fitzgerald, Belgium) 
were included where indicated. Cells were harvested after 5h incubation at 37°C 
and lysed.
After T-cell priming, the recovered viable cells were added at different ratios to a newly 
set-up primary mixed lymphocyte culture (MLC; consisting of original responder and 
stimulator T-cells) to analyze the suppressive capacity. Proliferation was determined 
at day 4 of culture.
Mitochondrial staining
The mitochondrial mass and/or the mitochondrial membrane potential were stained 
using Rhodamine 123 (Rh123, Molecular Probes). FACS-sorted CD4+ T-cells (5 x 
104 per well) were stimulated with anti-CD3/anti-CD28 mAb-coated beads in the 
absence or presence of MPA for 6 days. Rh123 (2 μM) was added to the culture 
mixture for the last 30 minutes of culture. Cells were washed with PBS containing 
0.2% BSA twice before being analyzed by flowcytometry.
Western blot analysis 
The cells were lysed with whole cell lysis buffer containing phosphatase and protease 
inhibitors (Cat. FNN0011, Invitrogen, Breda, The Netherlands). Equal amounts of 
protein per sample were separated on SDS-PAGE and subsequently transferred to 
PDVF membranes. The membrane was then probed with indicated antibodies Akt 
(pThr308), mTOR (pSer2448), 4E-BP1 (pSer65) and STAT5 (pTry694) (all from Cell 
Signaling Technology, Danvers, USA) according to the manufacturer’s instructions. 
Statistics
A Mann-Whitney U test was used for the statistical analysis; P values below 0.05 
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were considered statistically significant and are indicated with asterisks (*, p<0.05; 
**, p<0.01).
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Figure 1: MPA inhibits T-cell 
proliferation without affecting 
early apoptosis. (A) MPA dose-
dependently prevents the 
proliferation of naïve and memory 
T-cells. FACS sorted human naïve 
(CD45RA+CD25-) and/or memory 
(CD45RO+CD25-) CD4+ T-cells were 
stimulated with anti-CD3/anti-CD28 
mAb-coated beads in the presence 
of a grade concentrations of MPA. 
Proliferation was measured by 
[3H]-thymidine incorporation 
during the last 6h of a 3-day culture. 
(B) MPA inhibits T-cell proliferation 
by depleting the pool of guanosine. 
FACS sorted naive T-cells were 
stimulated in the absence or 
presence of MPA (1 μM) as 
described under (A). Guanosine 
(Gua, 100 µM) was daily added into 
the culture mixture where 
indicated. The incorporation of [3H]-thymidine was determined at day 2, 3, 4, 5 and 6 of culture, 
respectively. (C) MPA does not induce early cell apoptosis. FACS sorted naïve T-cells were cultured in 
the absence (grey shade) or presence (black line) of MPA (1 μM). After 24h stimulation, cells were 
analyzed by flowcytometry for the surface staining of Annexin-V. The overlay histogram of Annexin-V 
is displayed. (D) Effect of MPA on cell viability. FACS sorted naïve T-cells were stimulated in the absence 
or presence of MPA (1 μM) and analysed at day 1 and 3 of culture by flowcytometry. The live gate was 
set based on the forward angle light scatter (FSCs), the side angle light scatter (SSCs), and Annexin-V/
PI staining. Data are from n = 6 different healthy donors (A, D), or shown representative experiments 
of 3 (B, C) separate experiments performed with cells obtained from different cell donors. Mean and 
SD of triplicate measurement are shown (B). Black bar in (D) indicates the median value of % viable cell 
count. W/O: without addition of MPA; NS: no stimulation; Gua: guanosine.
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Results
MPA dose-dependently inhibits human CD4+ T-cell proliferation without 
affecting cell apoptosis
MPA blocks cell cycle progression at the early mid-G1 phase by interrupting the 
de novo purine biosynthesis, thereby depleting the pool of dGTP (18). Also in our 
culture system, MPA was shown to dose-dependently inhibit proliferation of FACS-
sorted naïve (CD45RA+CD25-) as well as memory (CD45RO+CD25-) CD4+ T-cells, 
with a near maximum inhibition at 1 μM (Figure 1A). Exogenous addition of IL-2 
did not affect the MPA-induced proliferation inhibition (data not shown). Exogenous 
guanosine, at a dose of  100 μM (18), completely reversed MPA-induced proliferation 
inhibition without affecting proliferation kinetics. This confirms that depletion of 
intracellular guanine nucleotides underlies MPA-induced proliferation inhibition 
(Figure 1B). Similar results were obtained with memory (CD45RO+) T-cells (data 
not shown). 
We next investigated whether enhanced induction of apoptosis played a role in MPA-
induced proliferation inhibition. Cells were stimulated with anti-CD3/anti-CD28 mAb-
coated beads in the absence or presence of MPA for 24h and the number of apoptotic 
cells was determined using Annexin-V staining. There was no further induction of 
apoptosis following MPA treatment when compared to non-treated cells (Figure 1C). 
Also, the percentage of viable cells remained stable over the three-day culture 
period, regardless of the absence or presence of MPA (Figure 1D). These data were 
confirmed by Western blot showing that MPA treatment did not alter expression of 
active caspase 3 (data not shown). Similar results were found for both CD45RA+ 
and CD45RO+ subsets (data not shown). The results show that MPA inhibits 
proliferation of human CD4+ T-cell without affecting early cell apoptosis.
MPA treated CD4+ T-cells are hyperblastoid
Remarkably, although MPA, at 1 µM, completely inhibited CD4+ T-cell proliferation, 
highly enlarged cells were found upon microscopic inspection (data not shown). 
Flowcytometry confirmed that these cells were in a hyperblastoid state. MPA-
treated cells were noticeably larger than in the untreated condition as reflected by 
the increase of the forward angle light scatters (FSCs) of viable cells (Figure 2A). 
Conversely, A77 1726, the active metabolite of leflunomide, known to block the de 
novo pyrimidine biosynthetic pathway, failed to increase cell size. 
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Figure 2: MPA treatment results in hyperblastoid cells and blocks cell cycle progression. (A) MPA, 
but not A77 1726, enhances cell size. FACS sorted naive T-cells were stimulated for 6 days in the 
absence (grey shade) or presence (black line) of MPA (1 μM) or A77 1726 (300 μM), respectively. The 
overlay histogram of FSCs of viable cells is displayed. (B) MPA treatment blocks cell cycle progression. 
FACS sorted naive T-cells were labeled with the fluorescence dye CFSE and stimulated in the absence 
(W/O) or presence of MPA (0.3 μM and 1 µM, respectively). Loss of CFSE fluorescence of viable cells, 
indicating cell division progression, was measured by flowcytometry at day 5. CFSE vs FSCs dot plots are 
displayed. Data are shown representative experiments of three independent experiments performed 
with cells obtained from different blood donors. W/O: without the addition of MPA or A77 1726.
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Results
MPA dose-dependently inhibits human CD4+ T-cell proliferation without 
affecting cell apoptosis
MPA blocks cell cycle progression at the early mid-G1 phase by interrupting the 
de novo purine biosynthesis, thereby depleting the pool of dGTP (18). Also in our 
culture system, MPA was shown to dose-dependently inhibit proliferation of FACS-
sorted naïve (CD45RA+CD25-) as well as memory (CD45RO+CD25-) CD4+ T-cells, 
with a near maximum inhibition at 1 μM (Figure 1A). Exogenous addition of IL-2 
did not affect the MPA-induced proliferation inhibition (data not shown). Exogenous 
guanosine, at a dose of  100 μM (18), completely reversed MPA-induced proliferation 
inhibition without affecting proliferation kinetics. This confirms that depletion of 
intracellular guanine nucleotides underlies MPA-induced proliferation inhibition 
(Figure 1B). Similar results were obtained with memory (CD45RO+) T-cells (data 
not shown). 
We next investigated whether enhanced induction of apoptosis played a role in MPA-
induced proliferation inhibition. Cells were stimulated with anti-CD3/anti-CD28 mAb-
coated beads in the absence or presence of MPA for 24h and the number of apoptotic 
cells was determined using Annexin-V staining. There was no further induction of 
apoptosis following MPA treatment when compared to non-treated cells (Figure 1C). 
Also, the percentage of viable cells remained stable over the three-day culture 
period, regardless of the absence or presence of MPA (Figure 1D). These data were 
confirmed by Western blot showing that MPA treatment did not alter expression of 
active caspase 3 (data not shown). Similar results were found for both CD45RA+ 
and CD45RO+ subsets (data not shown). The results show that MPA inhibits 
proliferation of human CD4+ T-cell without affecting early cell apoptosis.
MPA treated CD4+ T-cells are hyperblastoid
Remarkably, although MPA, at 1 µM, completely inhibited CD4+ T-cell proliferation, 
highly enlarged cells were found upon microscopic inspection (data not shown). 
Flowcytometry confirmed that these cells were in a hyperblastoid state. MPA-
treated cells were noticeably larger than in the untreated condition as reflected by 
the increase of the forward angle light scatters (FSCs) of viable cells (Figure 2A). 
Conversely, A77 1726, the active metabolite of leflunomide, known to block the de 
novo pyrimidine biosynthetic pathway, failed to increase cell size. 
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Figure 2: MPA treatment results in hyperblastoid cells and blocks cell cycle progression. (A) MPA, 
but not A77 1726, enhances cell size. FACS sorted naive T-cells were stimulated for 6 days in the 
absence (grey shade) or presence (black line) of MPA (1 μM) or A77 1726 (300 μM), respectively. The 
overlay histogram of FSCs of viable cells is displayed. (B) MPA treatment blocks cell cycle progression. 
FACS sorted naive T-cells were labeled with the fluorescence dye CFSE and stimulated in the absence 
(W/O) or presence of MPA (0.3 μM and 1 µM, respectively). Loss of CFSE fluorescence of viable cells, 
indicating cell division progression, was measured by flowcytometry at day 5. CFSE vs FSCs dot plots are 
displayed. Data are shown representative experiments of three independent experiments performed 
with cells obtained from different blood donors. W/O: without the addition of MPA or A77 1726.
Next, a CFSE-based cell cycle assay was performed to study cell division by 
flowcytometry. MPA blocked cell cycle progression in a dose-dependent manner, 
which was in accordance with reduced [3H]-thymidine incorporation (Figure 2B). 
Notably, although 1uM MPA halted cell cycle progression after one division, a 
hyperblastoid phenotype was observed. Previously, MPA was reported to increase 
cell volumes in human monocytic precursor cell lines (19). Here we show that MPA 
is capable to enhance the cell size of primary human CD4+ T-cells.
MPA inhibits the production of IL-10, IL-17, IFN-γ, and TNF-α, whereas IL-2 
production is unaffected 
The non-proliferative, but hyperblastoid, phenotype of MPA-treated cells suggested 
90
Chapter 3
3
transformation into an active metabolic state. Intrigued by this, we investigated the 
functionality (cytokine production) of these cells. Within the naïve T-cell subset, MPA 
treatment down-regulated the production of IFN-γ, TNF-α and GM-CSF significantly 
(p<0.05, Figure 3A). IL-17 appeared decreased following MPA treatment, albeit not 
statistically significant. Interestingly, the production level of IL-2 was unaffected, 
suggesting that IL-2 synthesis and secretion was not inhibited by MPA. Similarly, 
within the memory cell subset, the production of IL-17, IFN-γ, TNF-α and GM-CSF 
were significantly inhibited (p<0.05) whereas IL-2 was unaffected (Figure S1A). IL-
10 was produced by memory T-cells and its production was significantly decreased 
following MPA-treatment (Figure S1A).
MPA enhances the expression of CD70, FoxP3, PD-1, and CTLA-4
Next the phenotype of MPA-treated T-cells following CD3/CD28 stimulation was 
evaluated. Neither the expression pattern of CD25, nor that of CD45RO was affected 
following MPA treatment (Figure 3B). After a six-day incubation with MPA, the 
percentage of both CD27+ and CD28+ cells was slightly decreased (p<0.05), 
whereas the percentage of cells expressing negative co-stimulators (PD-1+ and 
CTLA-4+) and transcription factor FoxP3 (FoxP3+) were significantly increased 
(p<0.05). A similar pattern was found when analyzing expression levels (mean 
fluorescence intensities, MFIs; data not shown). Surprisingly, MPA treatment led to a 
substantial increase in CD70 expression, reflected in both the percentage of positive 
cells numbers and the MFIs. This proved to be a unique feature among other 
immunosuppressants tested like A77 1726, rapamycin, cyclosporine A and 
dexamethasone (data not shown). In the memory T-cell subset, similar phenotypic 
changes were observed following MPA treatment (Figure S1B); CD27 and CD28 
were downregulated while PD-1, FoxP3 and CD70 were upregulated by MPA. The 
expression level per cell for CD25 (MFIs) was increased by MPA, although there was 
a slight decrease in the percentage of CD25+ cells within the memory T-cell subset. 
While the % of CTLA-4-expressing cells was decreased, the MFI of CTLA-4 was 
enhanced following MPA treatment. 
MPA treatment of T-cells results in a state of anergy
Since several negative regulators like PD-1, CTLA-4 and the transcription factor 
FoxP3 were enhanced following MPA treatment, we assessed whether the cells had 
become anergic in a re-stimulation assay. Cells pretreated with MPA showed a 
significantly reduced proliferative capacity during the secondary stimulation and this 
hypo-responsive state was partially reversed by addition of IL-2 (Figure 4A). The 
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Figure 3: Cytokine fingerprint and phenotype of activated naïve T-cells following MPA treatment. (A) 
MPA inhibits the production of IFN-γ, IL-17, TNF-α, and GM-CSF leaving IL-2 and IL-1ra unaffected. FACS 
sorted naive T-cells were stimulated in the absence (W/O) or presence of MPA (1 µM). Human IL-1ra, 
IL-2, IL-17, IFN-γ, TNF-α, and GM-CSF was determined in culture supernatants at day 3 of culture. *, p 
< 0.05; **, p < 0.01. (B) Effect of MPA on the phenotype of activated T-cells. Following six-day culture in 
the absence (W/O) or presence of MPA (1 µM), activated naïve T-cells were analyzed by flowcytometry 
for the surface staining of CD45RO, CD25, CD27, CD70, CD28, and PD-1, and/or for the intracellular 
staining of CTLA-4 and FoxP3. The percentage of positive cells for each marker as well as the median 
value (black bar) is displayed. The baseline expression level was acquired at the start of culture before 
the addition of stimulators and the compound. Data are from 6 independent experiments performed 
with cells obtained from different blood donors. W/O: without addition of MPA.
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transformation into an active metabolic state. Intrigued by this, we investigated the 
functionality (cytokine production) of these cells. Within the naïve T-cell subset, MPA 
treatment down-regulated the production of IFN-γ, TNF-α and GM-CSF significantly 
(p<0.05, Figure 3A). IL-17 appeared decreased following MPA treatment, albeit not 
statistically significant. Interestingly, the production level of IL-2 was unaffected, 
suggesting that IL-2 synthesis and secretion was not inhibited by MPA. Similarly, 
within the memory cell subset, the production of IL-17, IFN-γ, TNF-α and GM-CSF 
were significantly inhibited (p<0.05) whereas IL-2 was unaffected (Figure S1A). IL-
10 was produced by memory T-cells and its production was significantly decreased 
following MPA-treatment (Figure S1A).
MPA enhances the expression of CD70, FoxP3, PD-1, and CTLA-4
Next the phenotype of MPA-treated T-cells following CD3/CD28 stimulation was 
evaluated. Neither the expression pattern of CD25, nor that of CD45RO was affected 
following MPA treatment (Figure 3B). After a six-day incubation with MPA, the 
percentage of both CD27+ and CD28+ cells was slightly decreased (p<0.05), 
whereas the percentage of cells expressing negative co-stimulators (PD-1+ and 
CTLA-4+) and transcription factor FoxP3 (FoxP3+) were significantly increased 
(p<0.05). A similar pattern was found when analyzing expression levels (mean 
fluorescence intensities, MFIs; data not shown). Surprisingly, MPA treatment led to a 
substantial increase in CD70 expression, reflected in both the percentage of positive 
cells numbers and the MFIs. This proved to be a unique feature among other 
immunosuppressants tested like A77 1726, rapamycin, cyclosporine A and 
dexamethasone (data not shown). In the memory T-cell subset, similar phenotypic 
changes were observed following MPA treatment (Figure S1B); CD27 and CD28 
were downregulated while PD-1, FoxP3 and CD70 were upregulated by MPA. The 
expression level per cell for CD25 (MFIs) was increased by MPA, although there was 
a slight decrease in the percentage of CD25+ cells within the memory T-cell subset. 
While the % of CTLA-4-expressing cells was decreased, the MFI of CTLA-4 was 
enhanced following MPA treatment. 
MPA treatment of T-cells results in a state of anergy
Since several negative regulators like PD-1, CTLA-4 and the transcription factor 
FoxP3 were enhanced following MPA treatment, we assessed whether the cells had 
become anergic in a re-stimulation assay. Cells pretreated with MPA showed a 
significantly reduced proliferative capacity during the secondary stimulation and this 
hypo-responsive state was partially reversed by addition of IL-2 (Figure 4A). The 
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Figure 3: Cytokine fingerprint and phenotype of activated naïve T-cells following MPA treatment. (A) 
MPA inhibits the production of IFN-γ, IL-17, TNF-α, and GM-CSF leaving IL-2 and IL-1ra unaffected. FACS 
sorted naive T-cells were stimulated in the absence (W/O) or presence of MPA (1 µM). Human IL-1ra, 
IL-2, IL-17, IFN-γ, TNF-α, and GM-CSF was determined in culture supernatants at day 3 of culture. *, p 
< 0.05; **, p < 0.01. (B) Effect of MPA on the phenotype of activated T-cells. Following six-day culture in 
the absence (W/O) or presence of MPA (1 µM), activated naïve T-cells were analyzed by flowcytometry 
for the surface staining of CD45RO, CD25, CD27, CD70, CD28, and PD-1, and/or for the intracellular 
staining of CTLA-4 and FoxP3. The percentage of positive cells for each marker as well as the median 
value (black bar) is displayed. The baseline expression level was acquired at the start of culture before 
the addition of stimulators and the compound. Data are from 6 independent experiments performed 
with cells obtained from different blood donors. W/O: without addition of MPA.
expression of human KI67 protein is associated with cell proliferation (20). We found 
cells primed in the presence of MPA had both a lower KI-67 index (percentage of 
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cells staining positive for the KI-67 antigen) and a lower expression level per cell 
(MFI). Addition of IL-2 restored the expression of KI-67 (Figure 4B). Since the anergic 
phenotype is reminiscent of a regulatory phenotype, the suppressive capacity of 
these cells was assessed in co-culture experiments. Addition of MPA-treated cells at 
different ratios to a newly set-up mixed lymphocyte culture revealed no difference 
between MPA-treated and non-treated cells. In contrast, purified regulatory T-cells 
(CD4+CD25+) showed a dose-dependent suppression (Figure 4C). 
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Figure 4: Re-stimulation assay of MPA-treated T-cells in the absence or presence of exogenous 
addition of IL-2. FACS sorted naive T-cells were pretreated without or with MPA (1 µM) for six days. 
Thereafter cells were rest and re-stimulated with anti-CD3/anti-CD28 mAb-coated beads in a ratio of 
1:5 (bead: cell) for another two days. (A) Proliferation was measured by [3H]-thymidine incorporation. 
(B) The expression of KI-67 was analysed using flowcytometry at day 2 and the histogram of KI-67 is 
shown. (C) The suppressive potential of MPA-treated cells was investigated in a co-culture suppression. 
FACS sorted naive T-cells were expanded in the absence or presence of MPA for six days. Thereafter, 
various recovered viable cells were used to co-culture with conventional T-cells (Tconv, CD4+CD25+, 
5x104) under the stimulation of anti-CD3/anti-CD28 mAb-coated beads (1x104). Proliferation of Tconv 
was determined by [3H]-thymidine incorporation. IL-2 (12.5 U/ml) was included where indicated. Mean 
and SD of triplicate measurement are shown (A, C). Data are shown representative experiments of 3 
separate experiments performed with cells obtained from different cell donors. Non-treated T-cells 
(W/O, square); MPA-pretreated T-cells (MPA, triangle); purified regulatory T-cells (Treg,diamond).
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Figure 5: MPA-treated hyperblastoid T-cells have higher metabolic capacity and display high CD70 
expression. (A) Higher mitochondrial uptake of Rh123 for MPA-treated cells. FACS sorted naive T-cells 
were stimulated in the absence (grey shade and black thin line) or presence (black dotted line and 
black bold line) of MPA for six days. Rh123 (2 µM) was added into the 6-day culture for 30min and the 
uptake of Rh123 was determined by flowcytometry. The overlay histogram of Rh123 is displayed. (B) 
MPA dose dependently induces the expression of CD70. Sorted naïve T-cells were stimulated for six 
days in the presence of a grade concentration of MPA where indicated. The percentage of CD70+ cells 
out of the total viable cells is displayed. (C) Strong inhibition of proliferation while higher expression 
of CD70 following 1 µM MPA treatment. Sorted naïve T-cells were labeled with CFSE and stimulated 
in the absence or presence of MPA (0.3 μM and 1 µM, respectively). Loss of CFSE fluorescence of 
viable cells was measured at day 5. CFSE vs CD70 dot plots are displayed. (D) CD70 expression is 
linked to enhanced cell size.  Sorted naïve T-cells were stimulated as described under (A) and analysed 
by flowcytometry. Cells are gated based on the expression of CD70 within CD4+ population and the 
histogram of FSCs is displayed. Results are representative experiments performed with cells obtained 
from at least 3 different blood donors.
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MPA-treated hyperblastoid T-cells have high metabolic capacity and are CD70 
positive
During lymphocyte blastogenesis, an increase in mitochondrial mass and/or 
mitochondrial membrane potential per cell is observed. The mitochondrial uptake 
of Rh123 was used to assess the cellular metabolic state of MPA-treated cells. 
Following six-day of treatment, cells showed a higher uptake of Rh123, revealing a 
higher metabolic capacity (Figure 5A). 
Enhanced expression of CD70 appears one of the hallmarks of MPA treatment. Using 
a graded concentration of MPA, we observed a concomitant, enhanced expression 
of CD70 (Figure 5B). CFSE-based analysis indicated that MPA at 1 μM allowed for 
only a single cycle of cell division, but resulted in more than 50% of CD70+ cells 
(Figure 5C). Thus, the increasing doses of MPA led to higher inhibition rates and 
more CD70+ cells. We then assessed whether increased cell size was associated 
with enhanced CD70 expression. Following MPA treatment, both the CD70+ and 
CD70- cells became hyperblastoid, but interestingly, MPA-treated CD70+ cells 
displayed even larger cell sizes than CD70- cells (Figure 5D).
MPA and 5-Aza synergistically increase CD70 expression
CD70 has been reported to be a DNA-methylation sensitive T-cell gene (21). To 
test whether MPA-induced CD70 expression is through the regulation of the DNA 
methylation status, we treated cells with the DNA methyltransferases (DNMTs) 
inhibitor 5-Aza in the absence or presence of MPA. Interestingly, MPA alone and 
5-Aza alone both induced the expression of CD70 at a similar level (Figure 6A). 
However, when MPA and 5-Aza were used in combination, CD70 expression was 
synergistically upregulated (10-14% vs 51%). The data suggest that MPA via GTP 
depletion, directly or indirectly affects DNMTs activity thereby enhancing CD70 
expression. Indeed, when cells were treated with MPA in the presence of guanosine 
(exogenous suppletion ), the enhanced expression of CD70 was completely reversed 
(Figure 6B). 
MPA affects metabolic pathways 
 Under productive, stimulatory conditions, CD3/CD28-mediated activation of naive 
and memory T-cells results in an increased phosphorylation of the Akt/mTOR 
pathway to metabolically fuel the needs of activated and expanding T-cells. 
Interestingly, CD3/CD28-activated T-cells cultured in the presence of MPA, displayed 
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a reduced phosphorylation status of the Akt/mTOR pathway (mainly affecting pAkt 
Thr308/Ser473, and the mTOR substrate p4E-BP1 Ser65, with a marginal effect on 
pmTOR Ser2448; Figure 7A). Furthermore, even in the presence of IL-2 and CD25 
(Figure 3A/B), MPA-treatment led to reduced activation of the growth and survival 
factor STAT5 (pSTAT5 Tyr694, Figure 7A). However, this reduced metabolic status 
did not increase the apoptotic sensitivity of MPA-treated cells determined by active 
caspase 3 staining on Western blot (caspase 3 Asp175, data not shown). Reactivation 
of MPA-induced anergic T cells with CD3/CD28 in the absence of MPA revealed that 
also MPA-pretreated T-cells show reduced activation of the Akt/mTOR pathway, with 
a reduction of STAT5 phosphorylation being most prominent (Figure 7B). 
Thereafter, we investigated whether these metabolic pathways are functionally linked 
to MPA-induced expression of CD70. It has been reported that CD70 engagement 
on B cells functionally activates the PI3K/Akt pathway controlling growth, expansion 
and differentiation (10). Here, CD70 ligation by an agonistic mAb in the presence 
of MPA and CD3/CD28 stimulation of MPA-induced anergic T-cells resulted in a re-
activation of the Akt/mTOR pathway (Figure 7C). Notably, CD70 ligation in these 
conditions also led to a profound restoration of STAT5 activity. Consistent with these 
results, CD70 ligation under the same condition protected MPA-induced anergic 
T-cells from cell apoptosis (Figure 7D).
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Figure 6: MPA and 5-Aza synergistically increase 
the expression of CD70. FACS sorted memory T-cells 
were stimulated with anti-CD3/anti-CD28 mAb-coated 
beads in the absence (W/O) or presence of MPA for 6 
days. (A) The DNMTs inhibitor 5-Aza was added at the 
start of culture where indicated. CD70 vs CD27 dot-
plots are displayed. (B) Guanosine was added daily 
into the culture mixture where indicated. The overlay 
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are displayed. Flowcytometry analysis was performed at 
day 6 of culture. Results are representative experiments 
performed with cells obtained from 2 different blood 
donors. Gua: guanosine. W/O: without addition of MPA.
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Figure 7: MPA treatment modulates the Akt/mTOR pathway and affects STAT5 phosphorylation, 
which is functionally linked to CD70 signaling. FACS sorted memory T-cells were stimulated with 
anti-CD3/anti-CD28 in the absence (W/O) or presence of MPA (1μM) for 6 days. (A) Cell lysates were 
made at day 3/6 and the effect of MPA treatment on the AKT/mTOR pathway and STAT5 in CD3/CD28-
stimulated T-cells was evaluated via Western blot analysis. (B) As MPA treatment renders cells anergic, 
MPA pretreated and non-pretreated (W/O) viable cells were recovered at day 6 and re-stimulated 
for another 5h using anti-CD3/anti-CD28. Thereafter, the effect of MPA pretreatment on the Akt/
mTOR pathway and STAT5 was evaluated using Western blot analysis. (C) The effect of CD70 ligation 
on the Akt/mTOR pathway and STAT5 in MPA treated CD3/CD28-stimulated T-cells. MPA pretreated 
viable cells (6 days) were re-stimulated for 5h with anti-CD3/anti-CD28 plus MPA in the absence (Ctrl) 
or presence of anti-CD70 mAb. The phosphorylation status of the Akt/mTOR pathway and STAT5 on 
Western blot is displayed. β-Actin served as a loading control. (D) MPA pretreated viable cells (6 days) 
were re-stimulated for 48 h with anti-CD3/anti-CD28 plus MPA in the absence (medium) or presence 
of non-coated beads (control) or presence of anti-CD70 mAb-coated beads (aCD70). The apoptotic 
cells were determined using Annexin-V surface staining. The percentage of Annexin-V positive cells 
is indicated and the values of the mean fluorescence intensities (MFIs) are shown in the brackets. 
Results are representative experiments performed with cells obtained from 2 different blood donors. 
Ctrl: control.
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Discussion
Our key finding is that MPA does not merely inhibit cell proliferation via depletion of 
intracellular guanosine nucleotide pools, but that MPA-treatment of human CD4+ 
T-cells leads to a state of anergy and to metabolic cellular reprogramming, which 
proved reversible. Moreover, the unique feature of MPA-induced CD70 expression 
on T-cells may qualify as a pharmacodynamic biomarker. 
MPA, the active ingredient of MMF/Cellcept, is widely used in transplantation and 
autoimmunity. MPA is well-known to deplete the intracellular pool of guanosine 
nucleotides. A recent study, however, reported that MMF inhibits T-cell proliferation 
in kidney transplant recipients without lowering intracellular dGTP and GTP (3). In 
the present study, we therefore assessed the direct effects of MPA treatment on 
purified CD4+ T-cells and found that MPA treatment led to a state of anergy and 
cellular metabolic reprogramming. It has been reported that MPA treatment of human 
peripheral blood lymphocytes stimulated with PHA neither reduced early TCR-
mediated activation events such as CD25 expression and IL-2 synthesis, nor induced 
T-cell apoptosis (22). The inhibition of IMPDH activity during MMF therapy of stable 
heart transplant recipients was associated with up-regulation of CD69 expression on 
B cells and CD25 expression on CD4+ T-cells (23). Here, by using highly purified 
human CD4+ T-cells in an antigen presenting cell free culture system, we showed 
that MPA did not affect the expression of CD25 and IL-2 production, nor did it affect 
early T-cell apoptosis. Although MPA was reported to induce cell apoptosis in several 
cell lines (19;24) and in an in vivo mouse model (25), it would infer from our findings 
that the induction of apoptosis by MPA is limited to specific cell types. Signaling via 
IL-2 (or IL-2 family members) in general increases STAT5 phosphorylation, which 
is an important step in controlling proliferation and cell survival (26). Interestingly, 
MPA treatment dramatically reduced STAT5 phosphorylation, without affecting the 
expression of CD25 and the levels of IL-2. Thus, in the presence of MPA cells are 
unresponsive to IL-2. When MPA is washed-out, however, the IL-2 unresponsive, 
anergic state is (partly) reversed as evidenced by the addition of IL-2. 
Strikingly, we find MPA has a unique property for increasing the expression of 
CD70, which is not shared by other immunosuppressants tested here. That MPA 
and 5-Aza synergistically increase CD70 expression suggests a relation between 
MPA and methyltransferases. Reduction of GTP levels within T-cells through IMPDH 
inhibition by MPA may thus affect the DNMTs enzyme activity thereby enhancing the 
expression of CD70. Indeed, the addition of guanosine completely reversed MPA-
enhanced CD70 expression. Few other data are available on the effect of MPA on 
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expression of TNF- and TNF-receptor molecules. In contrast to our findings, Van 
Rijen et al. (27) showed that MPA was a potent inhibitor of the expression of CD70. 
The difference between these observations may be explained by their use of human 
PBMCs and an indirectly fluorescent labeled CD70 mAb. Overexpression of CD70 
is seen in both rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) 
patients (21;28). Interestingly, in the study of Oelke et al. (21) 5 out of 14 patients 
received MMF in their treatment protocol. Previously, CD70 engagement on B cells 
was shown to functionally activate the PI3K/Akt pathway thus controlling cell growth, 
expansion and differentiation (10). We found that MPA-induced CD70 expression 
on T-cells is indeed functional. First, we observed that MPA-treated hyperblastoid 
cells had higher metabolic capacity and the expression of CD70 was correlated 
to hyperblasticity. Second, ligation of CD70 was capable to restore the Akt/mTOR 
pathway and the phosphorylation of STAT5, particularly in the memory CD4+ T-cell 
subset. Third, ligation of CD70 protected MPA-treated T-cells from cell apoptosis. 
CD27 is typically expressed on all naïve T-cells, while it is variable and generally 
low on memory T-cells (29). Following MPA treatment, we also observed that naïve 
T-cells expressed higher amounts of CD27 in comparison to memory T-cells. The 
presence of CD70 ligation via endogenous CD27, provided by MPA-treated naïve 
T-cells, may explain the different observations with naïve and memory T-cells. 
Moreover, it may explain the opposing findings by Quemeneur et al. (22) showing 
that STAT5 phosphorylation was not impaired by MPA treatment using a human PBL 
assay (not purified subsets). It is likely that, in this multicellular culture system with 
naïve (CD27 high) and, memory T-cells (CD70 high), B cells, and dendritic cells, the 
ligation of CD27-CD70, provided by cellular interplay, is responsible for increase of 
STAT5 signaling (22).
It should be appreciated that the mechanism of action of the majority of drugs used 
in medicine is largely unknown. This notion is true even in cases where the direct 
target of the drug has been identified (e.g. IMPDH for MPA). The lack of knowledge 
in our understanding will be aided in the future by the identification of target 
engagement, surrogate efficacy and clinical efficacy biomarkers in combination with 
pharmacokinetics. In that context, our studies reveal that the mechanism of action 
underlying MPA-mediated immune suppression of CD4+ T cells is multifaceted. 
Besides depletion of intracellular guanine nucleotides, MPA treatment downregulates 
the production of pro-inflammatory cytokines, induces the expression of negative co-
stimulators and intrinsically modifies intracellular signaling events, suppressing Akt/
mTOR and STAT5 pathways. MPA thus modulates transcriptional activities relevant 
to metabolism and survival, leading to the T-cell anergic state. Importantly, the data 
suggest that MPA treatment does not lead to irreversible effects on immune function 
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and that optimal dosing of MPA may minimally impact homeostatic mechanisms and 
thereby maintain immunological balance (5). Moreover, the unique feature of MPA-
induced, dose-dependent CD70 expression may qualify as a pharmacodynamic 
biomarker. A better understanding of mechanisms underlying MPA-mediated 
immune suppression will contribute to optimization of protocols for MPA-based forms 
of therapy in transplantation and autoimmunity. 
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Figure S1: Cytokine fingerprint and phenotype of activated memory T-cells following MPA 
treatment. (A) MPA inhibits the production of IFN-γ, IL-10, IL-17, TNF-α, and GM-CSF leaving IL-2 and 
IL-1ra unaffected. FACS sorted memory T-cells were stimulated in the absence (W/O) or presence of 
MPA (1 µM). Human IL-1ra, IL-2, IL-10, IL-17, IFN-γ, TNF-α, and GM-CSF was determined in culture 
supernatants at day 3 of culture. *, p < 0.05; **, p < 0.01. (B) Effect of MPA on the phenotype of 
activated T-cells. Following six-day culture in the absence (W/O) or presence of MPA (1 µM), activated 
memory T-cells were analyzed by flowcytometry for the surface staining of CD25, CD27, CD70, CD28, 
and PD-1, and/or for the intracellular staining of CTLA-4 and FoxP3. The percentage of positive cells 
for each marker as well as the median value (black bar) is displayed. The baseline expression level was 
acquired at the start of culture before the addition of stimulators and the compound. Data are from 6 
independent experiments performed with cells obtained from different blood donors. W/O: without 
addition of MPA.
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Abstract 
Thymus derived regulatory T cells (Treg) expressing the transcription factor FOXP3 
are essential for immune homeostasis. Phase-1 clinical trials of Treg-based 
immunotherapy in stem cell transplantation and type-1 diabetes reported safety 
and potential therapeutic efficacy. However, efficient expansion of a stable Treg 
population ex vivo remains a challenge. Therefore exploring novel ways for Treg 
expansion is a pre-requisite for successful immunotherapy. Based on the novel 
finding that CD28 signaling in murine Treg is crucial for peripheral Treg survival 
and proliferation, we here studied single-CD28 stimulation of human Treg, in the 
absence of T cell receptor stimulation. Single-CD28 stimulation of human Treg in 
the presence of recombinant human IL-2 (rhIL-2), as compared to combined anti-
CD3 plus CD28 and rhIL-2 stimulation, led to higher expression levels of FOXP3. 
Although Treg suppressor function of the resultant population was similar, pro-
inflammatory cytokine (IL-17A, IFNγ) production was strongly inhibited. This 
indicates that single-CD28 stimulation promotes stability of human Treg. Compared 
to combined CD3 and CD28 stimulation, single-CD28 antibody stimulation led to 
limited proliferation. Therefore we examined a CD28-superagonist antibody and 
found that Treg expansion was significantly increased as compared to the classical 
combined CD3 and CD28 stimulation. CD28-superagonist stimulation drove both 
naïve and memory Treg proliferation. Induction of the stable Treg phenotype induced 
by CD28 signaling in human Treg appeared PI3K-dependent. In conclusion, ex 
vivo single-CD28 stimulation of Treg by a superagonist antibody is of great interest 
for efficient and stable ex vivo expansion of human Treg intended for Treg-based 
immunotherapy.
Running head: 
Stable human Treg expansion by CD28 superagonist activation
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Introduction 
Regulatory T cells are crucial for immune homeostasis and tolerance. These cells 
are typically characterized by expression of the transcription factor FOXP3, and have 
been shown to play an important role in the prevention of graft-versus-host-disease 
(GVHD), transplantation rejection and autoimmunity1. Treg-based immunotherapy 
applying ex vivo expanded naturally occurring Treg (nTreg) prevented pathology in 
a wide variety of mouse models2-7. The prospects of these studies supported Treg-
based immunotherapy phase-I clinical trials in stem cell transplantation (SCT) and 
type-I diabetes, which reported safety and potential therapeutic efficacy8-12. This 
success promoted the recent initiation of Treg-based immunotherapy in solid organ 
transplantation (The One Study, ThRIL). Notwithstanding the first successes in the 
translation of Treg therapy to the clinic, successful ex vivo expansion of a stable Treg 
population in sufficient numbers still remains one of the key challenges in clinical 
practice in order to achieve full clinical efficacy. Combined T cell receptor (TCR)/
CD3 stimulation and CD28 in the presence of exogenously added recombinant 
human IL-2 (rhIL-2) is commonly used to expand human Treg13, 14. This procedure 
can lead to high cell yields, but also revealed Treg plasticity, characterized by loss 
of FOXP3 and the ability of the Treg to convert into (pathogenic) pro-inflammatory 
cytokine (IL-17A and IFNγ) secreting cells15-17. This prompted the search for agents 
that promote stability. High level expression of FOXP3 is important for optimal Treg 
function. This is maintained by hyper-demethylation of a non coding CpG motif, 
within the FOXP3 gene upstream of exon-1 that is referred to as the Treg-specific 
demethylated region (TSDR)18. The mTOR inhibitor rapamycin is often supplemented 
to enhance FOXP3 expression and prevent outgrowth of contaminating conventional 
T cells19-21. However, although rapamycin works favorable on Treg function, addition 
of rapamycin generally leads to lower overall cell yields21. Therefore, there is a need 
for novel approaches that yield high numbers as well as highly suppressive and 
stable Treg. 
It is well appreciated that CD28 stimulation plays an important role in the development 
of FOXP3+ cells in the thymus22, 23. Notably, recent data obtained in Treg-specific 
CD28 conditional knockout mice, indicates that CD28 signaling of thymus derived 
Treg is also crucial for peripheral Treg survival, proliferation and Treg suppressor 
function24. The intrinsic CD28 deficiency in peripheral Treg resulted in autoimmunity 
that could be prevented by supplementation with CD28-sufficient Treg24. Also, in 
rodent models it was demonstrated that CD28 stimulation promotes expansion of 
CD4+CD25+ Treg25, 26 but to date evidence in humans is lacking. We hypothesize 
that CD28 signaling in the absence of CD3 stimulation might play an important role 
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in human Treg homeostasis and that single-CD28 stimulation might drive stable 
expansion of human Treg, to be used for Treg-based immunotherapy.
Here, we demonstrate that single-CD28 stimulation in the absence of TcR (CD3) 
stimulation but in the presence of exogenously added rhIL-2 promotes superior 
FOXP3 expression and prevents the production of pro-inflammatory cytokines IL-
17A and IFNγ. The use of CD28-superagonistic mAbs further promotes polyclonal 
Treg expansion, to even higher levels as observed in case of classical CD3/CD28 
stimulation. The mechanism resulting in CD28 mediated Treg stability depends on 
PI3K signaling, since selective PI3K-inhibition by wortmannin prevented the stable 
phenotype. 
Marerials and Methods
Cell isolation
Peripheral blood mononuclear cells (PBMC) were isolated from buffy coats of 
healthy blood donors purchased from Sanquin Blood Supply Foundation, region 
South-East, Nijmegen, the Netherlands; buffy coats were obtained upon written 
consent from the donor for scientific use, and according to Dutch law. PBMCs and 
CD4+ were isolated and cultured as described previously15. Briefly, the CD4+ cells 
were labeled with anti-CD25-PeCy7 (M-A251; BD Biosciences, Breda, Netherlands) 
conjugated monoclonal antibody (mAb); Thereafter, CD4+CD25high Treg were sorted 
using FACSAria cell-sorter (BD Bioscience). In case of naïve and memory Treg 
sorting required, CD4+ cells were labeled with anti-CD25-PeCy7(M-A251) and anti-
CD45RA-pacific blue (HI100, Biolegend, San Diego, CA, USA) mAbs; thereafter 
CD4+CD45RA+CD25+ naïve Treg and CD4+CD45RA-CD25high memory Treg were 
sorted using FACSAria cell-sorter. Cell purity was typically over 98%.
Cell culture
Treg were stimulated with rhIL-2 cytokines (25 U/mL) alone, as control, or together 
with either soluble CD28 mAb (1 µg/mL, Clone CD28.2, BD), or plate-bound 
CD3 (5 µg/mL, Clone UCHT1, BD), or plate-bound CD3 (5 µg/mL) plus soluble 
CD28(1µg/mL), or CD28-superagonist ANC28.1 (1 µg/mL, Clone ANC28.1/5D10, 
Ancell, Bayport, MN, USA). Titration of sCD28 and CD28-superagonist antibodies 
at concentration range of 1-10 µg/mL led to similar results. Anti-CD3/anti-CD28 
mAb-coated microbeads (Invitrogen by Lifetechnologies, Bleiswijk, Netherlands) 
were used in a 1:2 bead-to-cell ratio to stimulate Treg. Cells were cultured in 96-
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well round bottom plates in RPMI 1640 (Invitrogen) as described previously27. In 
some experiments immunomodulating agents were analyzed, to this end Treg were 
pretreated with wortmannin (5 µM) or rapamycin (200 nM) (Sigma-Aldrich, St. Louis, 
Mo, USA) 19 or vehicle control for 30 min at 37°C. Thereafter, stimulators as indicated 
were added to the culture mixture
Flow cytometry, antibodies and CFSE labelling
Cells were phenotypically analyzed by multi-color flow cytometry (Beckman-Coulter, 
Brea, CA, USA). Antibodies and methodology can be found under Supplemental 
materials. To monitor cell division by flow cytometry, cells were labeled with 0.5 µM 
CFSE (Invitrogen)  and analyzed by flow cytometry as described previously28.
Cytokine detection assay
IL-17A and IFNγ were determined in the culture supernatants using Luminex cytokine 
assays (Invitrogen), according to the manufacturer’s instructions. The lower level of 
detection of IFNγ <5 pg/ml was and that of IL-17A was <10 pg/ml.
Co-culture suppression assays
The suppressor capacity of expanded-Treg was studied in co-culture assays. Treg 
were cultured for 7 days under the conditions described above. Thereafter, viable Treg 
were collected, washed and added at different ratio’s to CFSE-labeled CD4+CD25- 
responder T-cells (Tresp) together with anti-CD3/anti-CD28 mAb-coated beads in a 
1:5 bead-to-cell ratio for 3 days. Proliferation of Tresp was determined by analyzing 
CFSE dilution as described previously28.  
fOXP3 gene methylation
The FOXP3 methylation status was analyzed by bisulphate sequencing as described 
previously29.  A brief description can be found under supplemental materials. 
Statistics
Results are presented as mean+/-SD. P-values were determined using paired t test 
or One-way ANOVA, using the GraphPad Prism5.0 software. P-values less than 
0.05 were considered statistically significant. 
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Results
Single-CD28 stimulation of FACS-sorted CD4+CD25high Treg induces 
proliferation and  high level expression of FOXP3 
To assess the ability of single-CD28 stimulation to stimulate human Treg proliferation, 
highly purified FACS-sorted human CD4+CD25high Treg were labeled with CFSE and 
stimulated with soluble CD28 monoclonal antibodies (mAb), plate-bound CD3 mAb 
or both in the presence of rhIL-2 (25 U/mL) for 7-days. Thereafter, the cell division 
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Figure 1: Single-CD28 stimulation induces Treg proliferation and promotes high level FOXP3 
expression. Flow cytometry of FACS-sorted human Treg (CD4+CD25high) that were labeled with 
CFSE and stimulated with soluble CD28 mAb, plate bound CD3 mAb or both (Anti-CD3+CD28) in the 
presence of rhIL-2 (25 U/mL). As a control Treg cultured in the presence of rhIL-2 were included. Cell 
division indicated by the dilution of CFSE (A), intracellular expression of FOXP3 and active caspase 3 
(B, C) were determined at day 7 of the cultures. Numbers within the quadrant show the percentage 
of positive cells. Cumulative data of Treg proliferation (A), the mean fluorescence intensity (MFI) of 
FOXP3 (B), and the percentage of apoptotic cells (C) are shown in the right panels, respectively. N = 
3-4. Asterisks indicate significant differences.
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of Treg as indicated by the dilution of CFSE was determined using flow cytometry. 
Single-CD28 stimulation in the absence of T cell receptor ligation was indeed 
capable to drive Treg proliferation (44% ± 19, mean ± SD) (Figure 1A). Combined 
plate-bound CD3 plus soluble CD28 mAb (anti-CD3+CD28) stimulation resulted in 
the highest level of proliferation. Intriguingly, the dividing Treg that were observed 
following CD28 stimulation showed higher FOXP3 expression levels at day 7 of 
culture (MFI, 66 ± 24) than the dividing Treg that were observed following anti-CD3 
(MFI, 20 ± 4) or anti-CD3+CD28 (MFI, 21 ± 12) stimulation (Figure 1B). As it has 
recently been shown that CD28 signaling is required for post thymic survival and 
proliferation of mouse Treg24, we analyzed if single-CD28 stimulation in the absence 
of TcR stimulation influenced Treg survival by measuring the intracellular expression 
of active caspase-3 as an indicator of Treg cell apoptosis. Indeed, single-CD28 
stimulation in the presence of exogenously added rhIL-2 resulted in a slightly lower 
percentage of apoptotic cells as compared to anti-CD3+CD28 stimulated Treg (Figure 
1C). Irrespective of anti-CD28 or anti-CD3+CD28 stimulation the supplementation of 
rhIL-2 was required to induce proliferation of Treg (data not shown).
Single-CD28 stimulated Treg maintain suppressive capacity  and  reveal a 
highly demethylated TSDR
Thymus derived Treg contain a highly conserved non-coding sequence within 
the FOXP3 locus that is highly demethylated and is therefore known as the Treg-
specific demethylated region (TSDR). Hyper-demethylation of the TSDR is crucial 
for maintaining a high level of FOXP3 expression and suppressor capacity18. To 
explore if single-CD28 stimulation modifies the methylation status of the TSDR, 
bisulphite sequencing was applied. As compared to CD3 +CD28 or CD3-stimulated 
Treg, CD28-stimulated Treg revealed a tendency towards higher levels of TSDR 
hyper-demethylation (82% ± 19, mean ± SD) (Figure 2A). To assess if these CD28-
stimulated Treg maintained their suppressive capacity, CFSE-labeled FACS-sorted 
Treg were stimulated using CD28 or CD3 (for comparison) in the presence of rhIL-
2, and at day 7 the dividing Treg population, as indicated by CFSE-dilution, was 
FACS-sorted and analyzed for their suppressor capacity using a CFSE-based co-
culture suppression assays. CD28-expanded Treg, similar to CD3-expanded Treg, 
preserved their capacity to suppress the proliferation of T cells (Figure 2B). 
Single-CD28 stimulated Treg have a reduced pro-inflammatory cytokine 
producing potential. 
In recent years, it has become clear that FOXP3+ Treg may show functional plasticity 
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as indicated by their capacity to produce pro-inflammatory cytokines such as IL-17A 
and IFNγ under specific microenvironmental stimuli15, 16, 30. Thus, we analyzed the 
IL-17A and IFNγ producing potential of human FACS-sorted Treg that were stimulated 
with either single-CD28 or anti-CD3+CD28 mAb. Single-CD28 stimulated Treg, as 
compared to anti-CD3+CD28, revealed lower percentages of  IL-17A producing cells 
(4.9% ± 7, versus 11.2% ± 9.7 for CD3+CD28, mean ± SD) and these cells hardly 
produced IFNγ (1.7% ± 1.8, mean ± SD) (Figure 3). This indicates that single-CD28 
stimulation mediated expansion of human Treg results in a Treg population with 
increased stability as compared to anti-CD3+CD28 expanded Treg.
CD28-superagonist stimulation promotes a stable Treg phenotype and leads 
to profound polyclonal Treg expansion
Using a CD28-agonistic mAb and exogenously added rhIL-2, we showed that 
stimulation of Treg with this CD28-agonist led to a Treg population with increased 
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Figure 2: Single-CD28 stimulated Treg reveal a highly demethylated FOXP3 gene and profound 
suppressor function. (A) FACS-sorted human Treg were stimulated with soluble CD28 mAb, plate 
bound CD3 mAb or both (anti-CD3+CD28) in the presence of rhIL-2 (25 U/mL) for 7-days. Thereafter, 
cells were harvested and the demethylation status of FOXP3 gene was analyzed using bisulfate 
sequencing. Cumulative data derived from five to six different donors are shown. (B) CFSE-labeled 
FACS-sorted Treg were stimulated as described above. The divided cells (CFSE low population) were re-
sorted (left panel) at day 7 of the cultures, and subsequently their suppressive function was analyzed 
in a co-culture suppression assay. Overlay histograms show the inhibition of responder T cells (Tresp) 
proliferation following the addition of graded doses of Treg. Grey line: Tresp with stimulation, Black 
line: Tresp plus Treg of interest. The ratio of Treg:Tresp are indicated on the top. Representative 
experiment of N = 3 individual experiments conducted with cells obtained from different donors are 
shown.
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stability and good suppressor function, but lacked in full induction of proliferation. 
To improve this latter aspect, we stimulated Treg with the CD28-superagonist mAb 
ANC28.1, a strong inducer of  human conventional T cell proliferation31. 
Indeed, as compared to CD28-agonist stimulation, CD28-superagonist stimulation 
led to increased expansion of Treg, to a level comparable to that observed upon 
stimulation with anti-CD3/CD28 mAb coated microbeads (Anti-CD3/CD28 beads) 
(Figure 4A). Flow cytometry based TcR-Vβ analysis indicated a polyclonal expansion 
pattern in both the CD28-superagonist and anti-CD3/CD28 beads stimulated Treg 
(Figure 4B). CD28-superagonist stimulation, as compared to anti-CD3/CD28 beads 
stimulation, led to increased expression levels of FOXP3 and CTLA-4 and similar 
expression of Helios (Figure 4C). Furthermore, like single-CD28 stimulation (Figure 
1B), CD28-superagonist stimulation led to increased FOXP3 expression (Figure 4C). 
The suppressor capacity (Figure 4D) and methylation status (4E) of Treg expanded 
by CD28-superagonist or anti-CD3/CD28 beads stimulation was similar. Notably, in 
line with CD28 agonist stimulation (Figure 3) and in contrast to anti-CD3/CD28 beads 
stimulated Treg, CD28-superagonist stimulated Treg showed a stable phenotype as 
evidenced by their low capacity to produce IFNγ (Figure 4F). Although the percentage 
of IL-17A positive cells was not significantly reduced, IL-17A and IFNγ concentrations 
in cell culture supernatants were significantly reduced (Figure 4G). Taken together, 
this indicates that CD28-superagonist stimulation promotes proliferation of Treg, 
while maintaining a stable Treg phenotype.
Anti-CD28Anti-CD3+CD28
Figure 3
An
ti-C
D3
+C
D2
8
An
ti-C
D2
8
IL-
2
0
5
10
15
20
25
30
ns
**
*
%
IL
-1
7+
 c
el
ls
An
ti-C
D3
+C
D2
8
An
ti-C
D2
8
IL-
2
0
5
10
15
20
25
30
ns
**
**
%
IF
N γ
+ 
ce
lls
1.72                        0.27
                               5.30
0.16                        0.03
                               0.08
0.21                        0.00
                               0.02
IFNγ
IL
-1
7
IL-2
Figure 3: Single-CD28 stimulated Treg demonstrate fail to produce IFNγ. Flow cytometry of IL-17A 
and IFNγ of FACS-sorted human Treg that were stimulated with soluble CD28 mAb, plate bound CD3 
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Figure 4: CD28-superagonist 
drives polyclonal Treg 
proliferation and enhances 
expression of FOXP3, Helios 
and CTLA-4. Flow cytometry 
of FACS-sorted human Treg 
that were stimulated with 
soluble CD28-superagonist 
(CD28SA), and anti-CD3/
CD28 mAb coated microbeads 
(anti-CD3/CD28 beads) in the 
presence of rhIL-2 (25 U/mL). 
As a control Treg cultured in 
the presence of rhIL-2 only 
were included. (A) Fold Treg 
expansion during 7 days of 
the cultures (N=6). Asterisks 
indicate significant 
differences. (B) TcR Vβ 
repertoire analysis following 
the indicated stimuli (see 
legend) (N=2). (C) Intracellular 
expression of FOXP3, Helios 
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CD28-superagonist stimulation drives both naïve and memory Treg proliferation
It is debated whether naïve (CD4+CD45RA+CD25+) or rather memory 
(CD4+CD45RA-CD25high) Treg are the ideal candidate cell population to be used for 
Treg-based cell therapy32-34. Therefore we separated human Treg into naïve and 
memory subsets based on the expression of CD45RA using FACS sorting 
(Supplemental Figure S1) and stimulated the cells with CD28-superagonist or anti-
CD3/CD28 beads in the presence of rhIL-2 as described above. Comparable to anti-
CD3/CD28 beads stimulation, CD28-superagonist stimulation led to proliferation of 
both naïve and memory Treg as indicated by the expression of cell division marker 
KI67 (Figure 5A). Phenotypic analysis showed that CD28-superagonist like anti-
CD3/CD28 beads stimulation induced an almost complete isoform switching from 
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Figure 5: CD28-superagonist 
stimulation drives both naïve and 
memory Treg proliferation. Flow 
cytometry of FACS-sorted human 
naïve and memory Treg that were 
stimulated with CD28-superagonist 
(CD28 SA) or anti-CD3/CD28 mAb 
coated-microbeads in the presence 
of rhIL-2 (25 U/mL). As a control 
Treg cultured in the presence of 
rhIL-2 only were included. Dot plots 
shown intracellular expression of 
KI67 (A), isoform switch of CD45RA 
and CD45RO (B), and intracellular 
expression of FOXP3 and Helios (C). 
Numbers within (A) and (B) show 
the percentage of positive cells, 
and numbers within the histogram 
(C) show MFI.  A representative 
experiment of two individual 
experiments conducted with cells 
obtained from different donors is 
shown.
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CD45RA to CD45RO in the naive Treg  population (Figure 5B). CD28-superagonist 
stimulation, as compared to anti-CD3/CD28 beads stimulation led to enhanced 
expression of FOXP3 and Helios in both naïve and memory Treg (Figure 5C). 
Together this implies that CD28-superagonist is of interest for the ex vivo expansion 
of both naive and memory Treg.
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Figure 6: PI3Kinase is involved in 
CD28 SA induced Treg stability. Flow 
cytometry of FACS-sorted human 
CD4+CD25high Treg that were 
stimulated with CD28-superagonist 
(CD28 SA) or anti-CD3/CD28 mAb 
coated-microbeads and exogenously 
added rhIL-2 in the absence or presence 
of PI3K inhibitor wortmannin (5 µM), 
or mTOR inhibitor rapamycin (200 nM) 
for 30 min. (A) Intracellular FOXP3 
expression and (B) intracellular IL-
17A and IFNγ staining at day 7 of the 
culturesfollowing additional stimulation 
with PMA + Ionomycin plus Brefeldin-A 
for 4 hours. (C) Combined expression 
FOXP3 and IL-17A (left) or IFNγ (right). 
Numbers within the histogram (A) show 
the MFI of FOXP3, and numbers within 
the quadrants (B) show the percentage 
of positive cells. A representative 
experiment of 3individual experiments 
conducted with cells obtained from 
different donors is shown. 
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The phosphoinositide-3 kinase (PI3K) pathway regulates CD28-superagonist 
mediated Treg stability
CD28 stimulation is well known for its ability to activate the PI3K pathway and its 
downstream targets such as mTOR35. To test the signal pathways involved in CD28-
superagonist mediated preservation of human Treg, the cells were stimulated with 
the CD28-superagonist and exogenously added rhIL-2 in the absence or presence 
of a PI3K-inhibitor (wortmannin) or mTOR-inhibitor (rapamycin). Interestingly, when 
Treg were stimulated with CD28-superagonist, in the presence of wortmannin we 
observed both loss of FOXP3 expression (Figure 6A) and a concomitant increased 
potential for both IFNγ and IL-17A production (Figure 6B). These cytokines were 
primarily produced by cells that expressed lower FOXP3 levels (Figure 6C). 
Downstream inhibition of mTOR did not interfere in the stable phenotype induced by 
CD28-superagonist stimulation and might even further promote FOXP3 expression 
levels (Figure 6A). Together these data indicate that PI3K signalling is important in 
CD28-superagonist induced Treg stability.
Discussion
For safe and effective clinical Treg-based immunotherapy, the ability to select and 
expand stable and highly suppressive Treg from the peripheral derived Treg pool 
is a prerequisite. In the present study, we show that single CD28-stimulation of 
human peripheral Treg results in polyclonal expansion and preservation of a stable 
Treg phenotype and function as indicated by high level FOXP3 expression, hyper-
demethylation of the FOXP3 gene and profound suppressor function. Moreover, 
single CD28-mediated stimulation of Treg, in contrast to anti-CD3+CD28 stimulation, 
results in reduced plasticity as indicated by the reduced potential to produce IL-17A 
and the inability to produce IFNγ. CD28-superagonist stimulation drives polyclonal 
expansion of peripheral Treg to a significantly higher level as compared to anti-CD3/
CD28 beads expanded Treg. CD28-superagonist stimulation promotes expansion of 
both naïve and memory Treg. Finally, using a selective PI3K-inhibitor we found that 
PI3K signaling pathway plays a crucial function in the mechanisms that stabilizes 
CD28-superagonist expanded Treg. Together, our results demonstrate that CD28-
superagonist stimulation could serve to improve Treg ex vivo expansion protocols to 
obtain sufficient numbers of stable committed Treg.
CD28 is the best-characterized costimulatory molecule on T cells. CD28 stimulation 
is crucial for optimal naive T cell activation, cytokine production, proliferation, and 
survival36. With regard to Treg, CD28 stimulation plays an important role in the 
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development of FOXP3+ cells in the thymus as CD28 or CD28-ligand deficient mice 
reveal severely reduced naturally occurring Treg numbers and hence develop severe 
autoimmunity22, 23. Recent new insights obtained in CD28-conditional knockout mice, 
which post thymically affect CD28 expression in FOXP3+ Treg, supports the notion 
that CD28 stimulation also plays an important role in the proliferation and survival 
of Treg after thymic generation24. This specific CD28 deficiency in Treg results in 
autoimmune disease was prevented by supplementation with wild type CD28 
expressingTreg 24. This made us realize that CD28 signaling might also play an 
important role in Treg homeostasis of human Treg, and therefore we here addressed 
the question as to whether single-CD28 stimulation might drive stable expansion 
of human Treg. In fact, here we demonstrate that single-CD28 stimulation in the 
absence of TcR (CD3) stimulation, as compared to CD3 or CD3+CD28 stimulated 
Treg promotes superior Treg stability as indicated by increased FOXP3 expression 
and reduced expression of proinflammatory cytokines. 
Superagonistic CD28–specific mAbs are potent inducers of T cell proliferation both 
in vitro and in vivo in the absence of TCR engagement 37. Agonistic anti-rat CD28 
mAb JJ316, supports large-scale expansion of rat CD4+ CD25+ Treg cells in the 
absence of T-cell receptor stimulation25, 26  in vitro and prevents EAE and adjuvant 
arthritis in rats38, 39. These studies rationalized a phase I in vivo trial of a humanized 
anti-human CD28-superagonist mAb, TGN1412, that lacked toxicity in non-human 
primates40.  The trial was stopped due to rapid induction of multi-organ failure in six 
volunteers receiving the mAb41 that was likely caused by a cytokine storm42, 43. In 
our current work we have been studying mAb ANC28.1, a commercially available 
CD28-superagonist that possesses similar signaling signatures and functional 
properties as TGN141244. In contrast to our findings, it has been postulated that 
high purity FACS sorted human Treg did not respond to ANC28.1 stimulation after 
3 days31. However, it is generally known that high purity sorted Treg require more 
time and supplementation with exogenous rhIL-2 to enter cell division. In fact, we 
here demonstrate that prolonged (7 days) stimulation of high purity sorted Treg by a 
CD28-superagonist in the presence of exogenously added rhIL-2 results in vigorous 
proliferation of both highly pure FOXP3+ naïve and memory Treg. Moreover, we 
found that all of the Treg input participated after CD28-superagonist stimulation 
in the presence of rhIL-2. This stimulation led to polyclonal expansion of the Treg 
population and the expanded Treg revealed high and stable FOXP3 expression, 
limited pro-inflammatory cytokine producing potential and profound suppressor 
capacity. Although CD28-superagonist stimulation is not specific for Treg, we clearly 
demonstrate the great potential of CD28-superagonist in stable ex vivo expansion 
of human Treg.
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In the human peripheral blood both naïve (CD4+CD45RA+CD25+) and memory 
(CD4+CD45RA-CD25high) Treg populations have been characterized45 and it 
was suggested that naïve Treg would be the preferred starting population for the 
homogenous expansion of stable Treg32. Here we show that CD28-superagonist 
activation drives both proliferation of naïve as well as memory Treg and results in 
increased expression levels of FOXP3 in both Treg subsets. These data indicate that 
CD28-superagonist stimulation is of interest for the ex vivo expansion of both naive 
and memory Treg.
CD28 activation is known to enhance phosphoinositide3-kinase(PI3K) activity35 and 
its downstream targets Akt and mTOR46. The PI3K-Akt-mTOR signaling network 
regulates FOXP3 expression47. PI3K  signaling appears a crucial step in CD28 
mediated Treg stability as we here demonstrate that PI3K-inhibition destabilizes 
CD28-superagonist expanded Treg as indicated by the loss of FOXP3 expression 
and the increased potential to produce IFNγ and IL-17A. This was not observed 
in case of anti-CD3/CD28 stimulation, indicating that combined CD3 and CD28 
stimulation as compared to single-CD28 stimulation, next to PI3K, drives additional 
signaling pathways to regulate human Treg stability. In mice  PI3K signaling plays 
a dualistic role on Treg induction  and Treg maintenance46, 48, 49.  Future studies are 
needed to further explore the function of PI3K signaling in human Treg. Previously, 
we and others have shown that mTOR inhibition by rapamycin of in vitro stimulated 
human FACS isolated naturally occurring CD4+ CD25high Treg promotes selective 
outgrowth of FOXP3+ cells19, 50. Interestingly, here we demonstrate that the addition 
of rapamycin to CD28-superagonist stimulated Treg further augments the already 
increased expression of FOXP3, suggesting  that mTOR inhibition further boost 
CD28-superagonist driven Treg stability. Together this indicates that PI3K and mTOR 
have opposing roles in CD28-expanded human peripheral Treg. PI3K is needed for 
stable FOXP3 expression of CD28-expanded human peripheral Treg, while mTOR, 
as has been shown in anti-CD3/CD28 stimulated Treg, may negatively regulate 
FOXP3 expression19, 50. 
Summarizing, here we demonstrate that CD28-superagonist mediated ex vivo 
expansion of human Treg, which mechanistically depends on PI3K-signalling, might 
be a promising new avenue for the expansion of stable polyclonal Treg intended for 
Treg-based immunotherapy in transplantation and autoimmunity.
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Supplemental material: Methods (Supplemental)
Flow cytometry, antibodies
Antibodies used for flow cytometry : anti-CD3-PeCy5(UCHT1), anti-CD4-
PC5.5(13B8.2), anti-CD27-PC5.5(1A4CD27) (all from Beckman-Coulter), anti-
CD25-PeCy7(M-A251), anti-CCR6-PE(11A9), (both from BD Bioscience). Anti-
FOXP3-eFluo660(PCH101) or -eFluo450(PCH101), Anti-IL-17A-AlexFluo88 
(eBio64DEC17) and anti-IFNγ(4S.B3) (all from eBioscience, San Diego, CA, USA), 
anti-Helios-AlexFluo647(22F6, Biolegend), anti-CTLA4-PE(BNI3) and anti-active 
caspase 3-PE(C92-605) (both from BD Biosciences) were used after Fix-Perm-
treatment (eBiosciences). Appropriate isotype mAbs were used to define marker 
settings. Fixable viability dye (eBioscience) was used in some experiments. 
Data were analyzed using Kaluza software (Beckman-Coulter). To measure the 
intracellular cytokine producing potential the cells were stimulated with PMA plus 
Ionomycin in the presence of Brefeldin-A before analysis. To analyze the TCR-Vβ 
repertoire by flow cytometry we used a TCR-Vβ kit (Betamark, Beckman-Coulter) 
according to the manufacturer’s instructions.
FOXP3 gene methylation
In brief, geneGenomic DNA was isolated from FACS-sorted CD4+CD25high 
Treg using the QIAamp DNABloodMini kit (Qiagen, Venlo, Netherlands), Bisulfite 
converted  and amplified using bisulfite-specific polymerase chain reaction 
(PCR) (forward 59 TGGATATTTGGTTAGAGTTAAGAAT 39 and reverse 59 
ACCTAACACTCTCAAAACTTCAAAC 39). The purified PCR product was sequenced 
on an ABI 3130 Genetic Analyzer (Applied Biosystems by Lifetechnologies), and 
analyzed using Sequencing Analysis version 5.4 software. Cumulative methylation 
status data is presented as demethylation index; calculated by percentage 
demethylation after Treg culture : percentage demethylation of the input Treg 
population. Percentage demethylation of FACS-sorted input Treg is typically > 95%.
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Supplement Figure S1
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Supplemental Figure S1: Flow cytometry of FACS-sorted human naïve and memory Treg based on 
the expression of CD45RA and CD25. Purified human CD4+ T cells were stained with CD45-RA and 
CD25. Thereafter, CD45-RA+CD25+ naïve Treg and CD45-RA-CD25high memory Treg were FACS sorted. 
Subsequently, intracellular expression of FOXP3 was analysed in the sorted naïve and memory Treg by 
flow cytometry. Dotplots show a representative experiments of two individual experiments conducted 
with cells obtained from different donors.
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Abstract
Regulatory T cells (Treg) are important for immune homeostasis and are considered 
of great interest for immunotherapy. The paucity of Treg numbers requires the need 
for ex vivo expansion. Although therapeutic Treg flow-sorting is feasible, most centers 
aiming at Treg-based therapy focus on magnetic bead isolation of CD4+CD25+ Treg 
using a good manufacturing practice compliant closed system that achieves lower 
levels of cell purity. Polyclonal Treg expansion protocols commonly use anti-CD3 
plus anti-CD28 monoclonal antibody (mAb) stimulation in the presence of rhIL-2, with 
or without rapamycin. However, the resultant Treg population is often heterogeneous 
and pro-inflammatory cytokines like IFNγ and IL-17A can be produced. Hence, it 
is crucial to search for expansion protocols that not only maximize ex vivo Treg 
proliferative rates, but also maintain Treg stability and preserve their suppressive 
function. Here, we show that ex vivo expansion of low purity magnetic bead 
isolated Treg in the presence of a TNFR2 agonist mAb (TNFR2-agonist) together 
with rapamycin, results in a homogenous stable suppressive Treg population 
that expresses FOXP3 and Helios, shows low expression of CD127 and hypo-
methylation of the FOXP3 gene. These cells reveal a low IL-17A and IFNγ producing 
potential and hardly express the chemokine receptors CCR6, CCR7 and CXCR3. 
Restimulation of cells in a pro-inflammatory environment did not break the stability 
of this Treg population. In a preclinical humanized mouse model, the TNFR2-agonist 
plus rapamycin expanded Treg suppressed inflammation in vivo. Importantly, this 
Treg expansion protocol enables the use of  less pure, but more easily obtainable cell 
fractions, as similar outcomes were observed using either FACS-sorted or MACS-
isolated Treg. Therefore, this protocol is of great interest for the ex vivo expansion of 
Treg for clinical immunotherapy.
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Introduction
Following identification of Treg, the immunomodulating role of Treg was demonstrated 
in a variety of preclinical autoimmunity and transplantation models (1). Their clinical 
relevance was highlighted by demonstrating that the immunosuppressive function 
of Treg was hampered in autoimmunity and allergy (2). Clinical application of Treg 
has been hampered by the paucity of Treg cell numbers and the fact that standard 
methods of ex vivo Treg expansion produce heterogeneous cell populations (3). 
For clinical application of Treg-based immunotherapy isolation of Treg using a good 
manufacturing practice (GMP) system is required. Clinical grade flow-sorting which 
retrieves highly pure Treg is restricted to a few clinic centers worldwide. In contrast, 
magnetic bead isolation of CD4+CD25+ Treg using a GMP compliant closed system 
such as CliniMACS that result in lower Treg purity (4) are more generally used (5). 
For Treg expansion most centers apply polyclonal expansion protocols making use 
of anti-CD3 plus anti-CD28 mAb stimulation in the presence of rhIL-2 together with or 
without rapamycin (4, 6-11). This results in a heterogeneous Treg population revealing 
inadvertent pro-inflammatory (IL-17A, IFNγ) cytokine producing potential (12). The 
fact that human Treg could lose FOXP3 expression and suppressive functions and 
acquire the capacity to produce pro-inflammatory cytokines under pro-inflammatory 
micro-environmental conditions (13, 14) might have important implication for 
Treg-based clinical therapy. Therefore it is essential to develop highly efficacious 
expansion protocols that promote strong Treg proliferation whilst maintaining or 
promoting Treg stability and suppressor function. We and others have evidence that 
pharmaceutical agents influence Treg phenotype and functional capacity (15-18), 
indicating that by delicate selection of pharmaceutical agents it is possible to further 
support the stability of human Treg. In this respect the mTOR inhibition by rapamycin 
is an interesting example, since it has been shown to promote preferential outgrowth 
of highly suppressive Treg (7, 18, 19). In contrast to effector T cells (Teff), Treg are 
less sensitive to mTOR inhibition by rapamycin, since Treg proliferation and survival 
preferentially depends more on the STAT5 (20, 21) and Pim kinase pathways (22). 
Tumour necrosis factor receptor 2 (TNFR2) expression, in contrast to TNFR1, is 
restricted to lymphocytes and mainly binds membrane bound TNF instead of soluble 
TNF (23). The binding of TNFα to TNFR2 provides costimulatory signals to T cells 
that enhance T cell proliferation (24, 25) and cell survival (26). TNFR2 signalling 
is important for Treg, as TNFR2 deficient mice had reduced numbers of thymic 
and peripheral Treg (27), and TNFR2 -/- Treg were not able to control inflammatory 
responses in vivo (28). Human Treg also express a  higher level of TNFR2 than Teff 
(29, 30), and TNFR2+ Treg exhibited the most potent suppressive capacity (31). The 
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interaction of TNF-TNFR2 promotes Treg proliferation and survival via the activation 
of the NFkB pathway  (32). The fact that a TNFR2-agonist drives human Treg into a 
homogeneous population with potent suppressive capacity (29) indicates that TNFR2 
is a valuable target for facilitating ex vivo expansion of human Treg. In this study, 
we show that expansion of low purity MACS-isolated human Treg in the presence of 
TNFR2-agonist and rapamycin results in a stable homogenous FOXP3+, Helios+, 
CD127low Treg population that shows profound suppressor potential both in vitro, and 
in vivo in a preclinical humanized mouse model. Irrespective of the purity of Treg at 
the start of cell cultures, i.e. either low purity MACS-isolated or high purity FACS-
sorted Treg were expanded in the presence of TNFR2-agonist plus rapamycin, the 
resultant Treg population showed a stable Treg phenotype and potent suppressive 
capacity. Restimulation of cells in a pro-inflammatory environment did not break the 
stability of this Treg population. Thus, a TNFR2-agonist based expansion protocol 
shows great potential for ex vivo Treg expansion  for clinical purposes.
Materials and Methods 
Isolation of Treg
Peripheral blood mononuclear cells (PBMCs) were isolated by density gradient 
centrifugation (Lymphoprep, Nycomed Pharma AS, Oslo, Norway) of buffy coats 
obtained from healthy blood donors (Sanquin Blood Bank, Region South-East, 
Netherlands) upon written informed consent, according to the Declaration of 
Helsinki. CD4+ T cells were enriched using the RosetteSepTM human CD4+ T cell 
enrichment cocktail and processed according to manufacturer’s recommendations 
(StemCell Technologies, Vancouver, Canada). This resulted in a >95% purified CD4+ 
T cells and the absence of CD8+ cells. To obtain high purity Treg, FACS sorting of 
CD4+CD25high Treg was performed using a BD FACSAria cell sorter (BD Biosciences, 
Erembodegem, Belgium) after labeling CD4+ cells with CD25/Pe-Cy7(M-A251; BD 
Biosciences), termed as FACS-sorted Treg. More than 97% of Treg were FOXP3+ 
after the cell sorting. Less pure MACS-isolated CD4+CD25+ Treg were prepared 
using of human CD25 microbeads (Miltenyi Biotech, Bergisch Gladbach, Germany) 
according to manufacturer’s description. To mimic the purity of clinic grade isolation, 
15-20 mL of CD25 microbeads for every ten million CD4+ cells were used, thus the 
resultant Treg were 60-80% positive for FOXP3.
flow cytometry 
Cells were phenotypically analyzed using multicolor flowcytometry Navios 
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(Beckman-Coulter, Mijdrecht, Netherlands). The following conjugated mAb were 
used: CD127(R34.34)/APC-AF700, CD25(M-251)/APC or /Pe-Cy7 (BD), CD27(1A4-
CD27)/PE-Cy5.5, CD3(UCHT1)/ECD, CD4(1388.2)/PE-Cy5.5, CD62L(DREG56)/
ECD, HLA-DR(Immun-357)/FITC, CD8(B9.11)/APC-AF700 (all from Beckman-
Coulter), CCR6(11A9)/Biotin (BD Bioscience), CCR7(150503)/PE (R&D, Minneapolis, 
US), CXCR3(G025H7)/APC-Cy7 (Biolegend, San Diego, US), TNFR2(MR2-1)/
FITC (Hycult, Uden, Netherlands), TNFR2(#22235)/APC (R&D, Minneapolis, US), 
and Fix-viable-Dye labeled with APC-eFluo780 (eBioscience, Vienna, Austria). For 
intracellular staining, FOXP3(PCH101) /eFluo660 and Helios(22F6)/AlexFluo647 
(both from eBioscience) were used after fix-perm-treatment of cells, according to the 
manufacturer’s description. 
For intracellular cytokine staining, cells were stimulated for 4 h with phorbolmyristate 
acetate (PMA, 12.5 ng/mL), ionomycin (500 ng/mL) and brefeldin A (5 ug/mL) before 
starting of FACS staining. These antibodies were used: IFNγ(45.B3)/Pe-Cy7, IL-
17A(eBio64DEC1) /Alexa488, IL-10 (JES3-19F1)/PE (all from BD Bioscience). 
Isotype matched antibodies were used to define marker settings. Flow cytometry 
data were analyzed using Kaluza software (Beckman-Coulter).
Protocols used for ex vivo Treg expansion
High purity FACS-sorted Treg (5 x 104) were stimulated with anti-CD3/anti-CD28 
mAb-coated microbeads (Invitrogen, Bleiswijk, Netherlands) in a 1:2 bead-to-cell 
ratio and exogenous rhIL-2 (200 U/mL, Proleukine, Amsterdam, Netherlands). 
TNFR2 agonist mAb (2.5 µg/mL, Hycult, Uden, Netherlands) and/or rapamycin 
(1µM, Sigma, Zwijndrecht, Netherlands) was added at the start of the cultures. Cells 
were harvested and analyzed as described at day 7.
Low purity MACS-isolated Treg (5 x 104) were stimulated with anti-CD3/anti-CD28 
mAb-coated microbeads (Invitrogen) in a 1:2 bead-to-cell ratio. TNFR2-agonist (2.5 
µg/mL) and/or rapamycin (1µM) was added at the start of the cultures. On day 2, 
exogenous rhIL-2 (750 U/mL) was added to the culture. Every 2 or 3 days the culture 
medium was replenished by fresh culture medium containing rapamycin (1µM) (until 
day 7) and 750 U/mL rhIL-2. On day 9, additional TNFR2-agonist (2.5 µg/mL) was 
supplemented. On day 16, cells were harvested and analyzed.
Co-culture suppression assays
The suppressor capacity of expanded-Treg was studied using co-culture suppression 
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assays. Treg were expanded for 7 (FACS-sorted Treg) or 16 (MACS-isolated Treg) 
days under the conditions described. Thereafter, Treg were collected, washed and 
added at different ratio’s to CFSE-labeled CD4+CD25- responder T-cells (Tresp) 
together with anti-CD3/anti-CD28 mAb-coated beads (1:5 bead-to-cell ratio) for 3 
days. Proliferation of Tresp was determined by analyzing CFSE dilution as described 
previously (33).  
FOXP3 gene methylation
The FOXP3 methylation status was analyzed by bisulphate sequencing as 
described previously (34). In brief, geneGenomic DNA was isolated from either 
MACS-isolated CD4+CD25+ Treg or expanded Treg under each treatment group 
using the QIAamp DNABloodMini kit (Qiagen, Venlo, Netherlands), Bisulfite 
converted  and amplified using bisulfite-specific polymerase chain reaction 
(PCR) (forward 59 TGGATATTTGGTTAGAGT TAAGAAT 39 and reverse 59 
ACCTAACACTCTCAAAACTTCAAAC 39). The purified PCR product was sequenced 
on an ABI 3130 Genetic Analyzer (Applied Biosystems, Bleiswijk, Netherlands), and 
analyzed using Sequencing Analysis version 5.4 software (Applied Biosystems).
Humanized skin inflammation mouse model
The huPBL-SCID-hu Skin allograft mouse model used in this study has been described 
previously (35). In brief, human abdominal skin from healthy individuals obtained 
after elective surgery (Sannavisie Bodyclinic, Mill, Netherlands) was transplanted 
onto 6-8-week-old female B17.B6-PrkdcscidLyst bg/Crl (SCID/beige) mice, and allowed 
to engraft for 3 weeks. Next mice were intra peritoneally (i.p) injected with 10-40 x 
106 huPBMC in the absence or presence of  rapamycin expanded Treg (RapTreg) or 
Rapamycin plus TNFR2-agonist expanded Treg (R/TTreg) at a ratio huPBMC : Treg of 
1:1 or 1:2. Mice were sacrificed 3 weeks after injection of the human immune cells. 
Tissues of interest were collected, and the histological analysis of the grafts was 
performed thereafter. The use of human skin and peripheral blood were approved 
and in accordance with the regulations set by the Medical Ethical Committees for 
human research of the RUNMC. Human skin (from elective surgery) and buffy coats 
were from healthy donors, who gave written informed consent for scientific use.. 
Buffy coats were purchased from Sanquin Blood Bank, Nijmegen, Netherlands.
Histology & Immunohistochemistry
Human skin grafts were fixed in neutral buffered 4% formalin (Mallinckrodt Baker, 
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Inc Deventer, Netherlands) for 4 hours, processed and embedded in paraffin. Then, 
6 mm sections were cut and the slides were stained with Hematoxylin-Eosin (HE) or 
processed for immunohistochemical staining.
Monocolonal antibody against human CD3(clone7.2.38, Abcam, Cambridge, UK) 
was used to stain human CD3+ T cells. Antibody stainings were visualized using the 
Dako Cytomation EnVision+system-HRP (ABC) kit (DAKO, Glostrup, Copenhagen, 
Denmark) combined with 3,3’-diaminobenzidine tetrahydrochloride (DAB, brown) 
(Sigma-Aldrich, St. Louis, USA) or using that Labeled Streptavidin Biotin method 
(Universal LSAB Kit/AP; Dako) combined with either Permanent Red (Dako) or 
5-Bromo-4-Chloro-3-Indolyl Phosphate/Nitro Blue Tetrazolium (BCIP/NBT) (Dako). 
Sections were photographed using a microscope (Axiokop2 MOT; Zeiss, Sliedrecht, 
Netherlands), digital camera (Axiocam MRc5; Zeiss) and AxioVision software (Zeiss).
Determination of epidermal thickness
Histologic assessment of the grafts was performed by light microscopy after 
transplantation of human skin. The mean epidermal thickness was calculated using 
the program Visiopharm Integrator System (VIS) (Visiopharm, Hørsholm, Denmark) 
as epidermal area divided by epidermal surface length.
Image analysis of immunohistochemistry
To enumerate huCD3+ T cells, representative pictures were made at 20× 
magnification. A representative region of interest (ROI) was drawn from the lowest 
epidermal papilla till 300 mm dept into the dermis. Cell quantification was performed 
by setting a threshold and relating this to a number of cells per mm2. For evaluation 
of number of CD3+ cells, positively stained cells were counted manually in CD3 
infiltrated areas of the tissues and the number was reported per mm2.
Statistics
Statistical analysis was tested using the GraphPad Prism software version 5.0 
(GraphPAd Software Inc., San Diego, US). For comparison, Mann Whitney t-Test 
or Wilcoxon paired t-Test (between two groups) and One-way ANNOVA plus turkey 
post test (more than two groups) were used, where appropriate.
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Results
Expansion of high purity FACS-sorted Treg in the presence of TNFR2-agonist 
and rapamycin preserves Treg suppressor function and stability. 
We began by examining the expression of TNFR2 on human CD4+ T cells. Based 
on the expression of CD25, CD4+ T cells were gated as CD25high, CD25intermediate, and 
CD25negative populations. The CD25high subset showed the highest expression levels 
of TNFR2, and as expected were FOXP3 positive and CD127low (Figure 1A). Next, 
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Figure 1: TNFR2-agonist preserves the expression of Foxp3, Helios and HLA-DR, markers associated 
with highly suppressive function. (A) Flow cytometry analysis of human CD4+ cells immediately after 
cell preparation. The lymphocytes gate is set based on the forward and side scatter. Right panels show 
the expression of TNFR2, FOXP3, and CD127 in different cell subsets, based on CD25 expression. (B) 
Schematic overview of FACS-sorted Treg expansion strategy, as described in Materials and Methods. 
(C) Flow cytometry of FACS-sorted high purity Treg before (input) and after cell expansion (day 7) under 
the indicated conditions. Dot plots show surface expression of HLA-DR and CD127, and intracellular 
expression of FOXP3 and Helios. Numbers within the gated regions show the percentage of positive 
cells. A representative experiment out of two different donors is shown. Rapa: rapamycin; Agonist: 
TNFR2-agonist.
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we studied the effect of additional TNFR2 agonist mAb (TNFR2-agonist) (29) 
stimulation on suppressor function and stability of highly purified Treg. To this end, 
high purity FACS-sorted human CD4+CD25high Treg were stimulated using anti-CD3/
CD28-mAb coated beads and rhIL-2, in the presence or absence of TNFR2-agonist 
and/or rapamycin, and cultured for a week (Figure 1B). Purity of the Treg population 
based on CD25 expression and no/low expression of CD127, was 95.6% ± 0.3 
(Mean ± SD), and 80.1% ± 2.5 (Mean ± SD) of these cells co-expressed Helios, 
which is in line with the literature (36) that states that Helios+ and Helios- subsets 
coexist within human FOXP3+ Treg. Upon stimulation, at day 7 of culture,  the 
majority of Treg cultured in the medium group lacked CD127 expression, preserved 
Helios expression, while lost FOXP3 expression. Interestingly, following culture in 
the presence of TNFR2-agonist plus rapamycin, a higher number (~94%) of Helios+ 
cells was observed (Figure 1C). Interestingly, the expression of HLA-DR, a molecule 
associated with potent Treg suppressive function (37), was highly enhanced by 
TNFR2-agonist. In accordance with Okubo et al (29), we observed that TNFR2 
stimulation resulted in a Treg population that hardly expressed the chemokine 
receptors CCR5, CCR6, CCR7, and CXCR3, while CD62L was expressed on the 
majority of these cells (Supplemental figure S1). An important feature of Treg is 
their suppressive capacity. We assessed this functional capacity in a CFSE-based 
co-culture suppression assay. Treg expanded with TNFR2-agonist plus rapamycin, 
as compared to the other stimulatory conditions, showed the highest suppressor 
capacity (Figure 2A). 
Previously, we and others described that Treg can lose their stability and start to 
produce pro-inflammatory cytokines(13, 14, 38). To analyze the stability of Treg that 
were expanded in the presence of TNFR2-agonist plus rapamycin, we analyzed 
their IL-17A and IFNγ producing potential. Treg expanded in the presence of TNFR2-
agonist plus rapamycin, as compared to the other groups, hardly revealed IL-17A 
or IFNγ producing capacity (Figure 2B). Taken together, this data suggest that the 
stability of Treg is well preserved by TNFR2-agonist plus rapamycin stimulation.
TNFR2-agonist promotes efficient ex vivo expansion of lower purity MACS-
isolated Treg into a highly stable homogenous Treg population
Then,  we further explored the effect of stimulation with the TNFR2-agonist using 
MACS-isolated, thus less pure but more easily obtainable, CD4+CD25+ human 
Treg. We employed a well established Treg expansion protocol (29) that includes 
anti-CD3/CD28 mAb coated microbead stimulation, high dose rhIL-2 and rapamycin 
(Figure 3A). To mimic the moderately pure Treg isolated using CliniMACS which is 
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Figure 2: TNFR2-agonist plus rapamycin expanded FACS-sorted Treg real a high suppressive capacity 
and less IL-17A and IFNγ producing potential. FACS-sorted high purity human Treg were stimulated 
as described in Material and Methods. At day 7 of the cell cultures, expanded Treg were harvested, 
washed, and analyzed for their suppressive capacity in a CFSE-based co-culture suppression assay. 
MedTreg,  RapTreg and  R/TTreg represent cells expanded in the medium, the presence of rapamycin 
only and TNFR2-agonist plus rapamycin, respectively. (A) Histograms show the inhibition of Tconv 
proliferation following the addition of graded doses of Treg. The ratio of Treg:Tconv is indicated on the 
top. (B) Flow cytometry of intracellular IL-17A and IFNγ of Treg before (day 0) and after expansion (day 
7) under the indicated conditions.. A representative experiment out of two different donors is shown. 
Rapa: rapamycin; Agonist: TNFR2-agonist.
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typically around 40-60% of CD4+CD25high  cells (4), we prepared human Treg by using 
laboratory based MiniMACS with a modified amount of CD25 beads, thus resulting 
in a lower purity of Treg, as analyzed by the expression of FOXP3 (66% ± 18, mean ± 
SD, Figure 3B). The expansion fold of MACS-isolated Treg in the combined presence 
of TNFR2-agonist plus rapamycin was significantly increased (12x expansion fold) 
as compared to that of rapamycin only (7.5x expansion fold)  or TNFR2-agonist only 
(9.2x expansion fold) (Figure 3C). Due to the usage of high amount of rhIL-2 in the 
expansion protocol, which has shown its critical role in the lineage maintenance of 
both murine (39, 40) and human (41, 42) Treg, FOXP3 expression in the medium 
group was largely preserved upon stimulation. Interestingly, Expansion with the 
TNFR2-agonist plus rapamycin prevented the loss of FOXP3 expression (Figure 
3D). Also, as observed with high purity FACS-sorted Treg (Figure 1C), expansion 
in the presence of TNFR2-agonist plus rapamycin led to highest percentages of 
Helios (89.1%) and HLA-DR (90.9%) expressing cells. Irrespective of the expansion 
conditions used, the expanded Treg showed low levels of CD127 (Figure 3D). 
Co-culture suppression assays showed that TNFR2-agonist plus rapamycin 
expanded MACS-isolated low purity Treg revealed a higher suppressive capacity as 
compared to Treg expanded in the presence of medium or rapamycin only (Figure 
4A). In addition, the TNFR2-agonist plus rapamycin expanded Treg hardly showed 
the potential to produce IL-17A and IFNγ (Figure 4B). Also, expansion of low purity 
MACS-isolated Treg in the presence of TNFR2-agonist plus rapamycin resulted in a 
homogenous Treg population that expressed CD62L and CD27, lacked expression 
of CCR5, CCR7 and CXCR3, while a limited percentage of cells expressed CCR6 
(Figure 4C). This homogenous Treg phenotype and their high suppressive functions 
were comparable to the observation derived from using high purity FACS-sorted 
Treg, suggesting that this protocol is of interest for the ex vivo expansion of low 
purity, but easily obtainable Treg for their clinical purposes.
As Treg stability and suppressor function critically depends on the stable expression 
of FOXP3, which in turn depends on hypo-methylation of a CpG rich region in the 
FOXP3 gene, called the TSDR (43), we hypothesized that stimulation by TNFR2-
agonist plus rapamycin of Treg promotes demethylation of the TSDR. To test this, 
low purity MACS-isolated Treg were expanded according to the protocols mentioned 
and the TSDR demethylation status was analyzed using bi-sulphite sequencing. 
The significant increase of TSDR demethylation is only observed in TNFR2-agonist 
plus rapamycin expanded cells, but not in case of rapamycin or TNFR2-agonist only 
group (Figure 4D). This combined TNFR2-agonist plus rapamycin induced hypo-
methylation of the FOXP3 gene likely explains the increased suppressor capacity 
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Figure 3: TNFR2-agonist facilitates ex vivo expansion of MACS-isolated low purity human Treg. (A) 
Schematic overview of MACS-isolated low purity Treg expansion strategy as described in the Materials 
and Methods. (B) Dot plots show a representative FOXP3 expression pattern after MACS Treg isolation, 
as shown in the cumulative data graph (N=10, right panel). (C) Cumulative graph show fold expansion 
of Treg that were stimulated as described in (A). (D) Flow cytometry of surface expression of HLA-DR 
and CD127, and intracellular expression of FOXP3 and Helios of  MACS-isolated Treg before (input) and 
after expansion (day 16) under the indicated conditions. Numbers within the gated regions show the 
percentage of positive cells. N = 4-14. Asterisks in C indicate significant differences. Rapa: rapamycin; 
Agonist: TNFR2-agonist.
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and high stability of Treg population expanded under these conditions. 
Previously, we showed that stimulation of human Treg in a pro-inflammatory 
environment enhances the IL-17A producing potential of Treg (13). Having established 
that Treg expansion in the presence of TNFR2-agonist plus rapamycin results in 
increased stability of the Treg population, we questioned whether re-stimulation of 
these cells in a pro-inflammatory environment can break the stability and promote 
the IL-17A producing potential. To examine this, low purity MACS-isolated Treg were 
cultured for 16 days in the presence of TNFR2-agonist plus rapamycin, and the 
resultant Treg were subsequently re-stimulated with anti-CD3/CD28 beads and rhIL-
2 in the absence or presence of the pro-inflammatory cytokines IL-1β or IL-23. Re-
stimulation of these expanded Treg in the presence of IL-1β or IL-23 neither led to 
the loss of FOXP3 expression, nor the increase in  IL-17A producing potential (Figure 
4E), further stressing the stability of these expanded Treg. In conclusion, 16 days 
expansion of low purity MACS-isolated Treg in the presence of TNFR2-agonist and 
rapamycin results in a highly pure, homogenous and very stable Treg population.
TNFR2-agonist plus rapamycin expanded Treg inhibit inflammation in a 
humanised mouse model
Next, using a pre-clinical humanised skin inflammation mouse model, we sought 
to establish whether TNFR2-agonist plus rapamycin expanded Treg can suppress 
inflammation in vivo. To this end, SCID mice were transplanted with a human 
skin graft, whereupon 21 days after engraftment of the human skin, allogeneic 
human PBMC (huPBMC) were injected intra peritoneally. Typically, this results in 
a strong inflammatory response of the human skin 3 weeks after infusion, which 
is characterized by thickening of the epidermis and influx of human lymphocytes 
(35). Systemic repopulation of human lymphocytes is observed as indicated by the 
increased size and weight of mouse spleen (Figure 5B).  In vivo suppressive capacity 
of TNFR2-agonist plus rapamycin expanded Treg was proven as co-infusion of 
these cells with huPBMC at a ratio of 1:1 inhibited skin inflammation, as indicated 
by a reduction of epidermal thickening and human T cells influx (Figure 5C). Treg 
co-infusion also inhibited systemic repopulation of human lymphocytes (Fig. 5D). 
Discussion 
An important issue for Treg-based immunotherapy is to maintain stability and 
suppressive function of Treg during and after ex vivo expansion and following their 
transfer into patients. Although clinical grade high purity Treg isolation by GMP flow 
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cytometry is available in a few medical centers worldwide, most clinic centers use 
GMP qualified magnetic bead based isolation techniques that result in limited Treg 
purity. Hence, in this study we focussed on optimizing an ex vivo Treg expansion 
protocol that produces high numbers of stable potent human Treg starting with low 
purity magnetic bead isolated Treg. We found that combined use of TNFR2-agonist 
and rapamycin promotes Treg proliferation rates, enhances TSDR demethylation 
and increases both Treg stability and function in vitro. Low purity Treg expanded 
in the presence of TNFR2-agonist plus rapamycin suppressed inflammation in a 
humanized mouse model in vivo.
TNFα has both pro-inflammatory and anti-inflammatory effects. It binds to two 
structurally related but functionally distinct receptors TNFR1 and TNFR2. In general, 
TNFR1 is responsible for TNFα-mediated cell apoptosis, and TNFR2 for any function 
related to T cell survival. In contrast to the ubiquitous expression of TNFR1, TNFR2 
expression is more limited to myeloid and lymphoid cell lineages (23). Interestingly, 
human Treg, as opposed to CD25- Tconv cells, constitutively express high levels of 
TNFR2 (29, 31, 44, 45), and TNFR2+ Treg show the most potent suppressive capacity 
in mice and in humans (27, 31, 46, 47). The effect of TNFα on Treg suppressor 
Figure 4: TNFR2-agonist preserves the stability of MACS-isolated low purity Treg during ex vivo 
expansion. MACS-isolated low purity human Treg were cultured as described under Materials and 
Methods. Thereafter, the expanded Treg were harvested, washed, and  analyzed for their suppressor 
capacity in CFSE-based co-culture suppression assay. MedTreg,  RapTreg and  R/TTreg represent 
cells expanded in the medium, the presence of rapamycin only and TNFR2-agonist plus rapamycin, 
respectively. (A) Histograms show the inhibition of proliferation of Tconv following the addition of 
graded doses of Treg. The ratio of Treg:Tresp are indicated on the top. Cumulative data (N= 6) are 
shown in the bottom panel. (B) Flow cytometry of intracellular IL-17A and IFNγ of Treg at the start 
of the culture (day 0) and after expansion (day 16) under the indicated conditions. Dot plots show 
representative data of N = 4-7 individuals as shown in the cumulative data graph (right panel). Each line 
represents an experiment where Treg were expanded under the conditions described on the X-axis. 
(C) Expression of CXCR3, CCR5, CCR6, CCR7, CD62L and CD27 before (day 0) and after expansion (day 
16). (D) Bisulphite sequencing of the TSDR of expanded Treg. Each dot represents a single experiment. 
(E) Expanded Treg were harvested, rested overnight, and then restimulated with anti-CD3/anti-CD28 
beads in a 1:2 ratio of beads to cells, in the absence or presence of  IL-1β (50 ng/mL) and IL-23 (50 ng/
mL) for 2-days. Exogenous rhIL-2 (200 U/mL) was included in the cell cultures. Thereafter, intracellular 
production of IL-17A and IFNγ was analyzed using flow cytometry. Cumulative data derived from 
seven different donors are shown. Asterisks indicate significant differences. Rapa: rapamycin; Agonist: 
TNFR2-agonist.
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Figure 5: TNFR2-agonist plus rapamycin expanded Treg inhibit inflammation in a humanised mouse 
model. (A) Schematic overview of the humanised skin inflammation mouse model used. In brief, SCID 
mice were transplanted with a human skin graft, 21 days after engraftment allogeneic human PBMC 
(huPBMC) or huPBMC plus Treg (ratio 1:1) that were expanded in the presence of TNFR2-agonist 
plus rapamycin for 16-days (R/TTreg) were injected intra peritoneally. 26 days later the animals were 
sacrificed to analyze the mouse spleen and human skin grafts. (B) Representative photographs of 
mouse spleens. Cumulative data show the weight of spleens derived from N = 4 mice (right panel). 
(C) Representative photographs showing histology (HE staining) of human skin grafts. Left panel: 10 x 
magnification. Right panel shows the epidermal thickness (µm) of human skin grafts following infusion 
of huPBMC or huPBMC plus R/TTreg. Mean ± SEM, N = 6. (D) Immunohistochemistry of human CD3+ 
(brown) T cells infiltration in the human dermis. A representative photograph of N = 4 as presented 
in the cumulative data graph is shown (right panel). Top panel: 20x magnification; Low panel: 40x 
magnification. Asterisks indicate significant differences.
 143
TNFR2-agonist facilitates Treg expansion
5
function remains controversial. Some groups reported that TNFα/TNFR2 signalling 
inhibits human Treg suppressive function in vitro (44, 45) and in vivo (48, 49), other 
groups found that TNFα increases FOXP3 expression and suppressive activity (50, 
51), and that TNFR2 is crucial for sustaining FoxP3 expression and maintaining the 
stability of murine Treg in an inflammatory environment (27). Consistent with the 
latter observation, the majority of tumour-infiltrating Treg are found to be TNFR2 
positive and highly suppressive (52). It should be noted that a more recent study 
revealed that the nature of the TNFR2 antibodies used in these studies was likely 
different (agonistic versus antagonistic) (29).  In this study, we found that stimulation 
of human Treg with a TNFR2-agonist antibody preserved a stable Treg phenotype 
and function after ex vivo expansion. It is known that increase in NFκB activity 
promotes FOXP3 expression (53), and that TNFα induces a TNFR2/NFkB dependent 
pathway in human Treg (44). Using TNFR2-agonist only was enough to prevent 
the loss of FOXP3 expression during ex vivo expansion, whereas the maintenance 
of hypo-methylation status of TSDR required both rapamycin and TNFR2-agonist, 
suggesting that stabilization of Foxp3 expression requires both mTOR and NFκB 
signal pathways. One of the major concerns in Treg therapy is the plasticity of Treg, 
and the hypermethylation of TSDR is well correlated to loss of Treg stability (54). In 
vitro re-stimulation of TNFR2-agonist plus rapamycin expanded Treg neither led to 
the loss of FOXP3 expression nor the enhancement of IL-17 production, especially 
under the mimic pro-inflammatory conditions, suggesting a well preserved Treg 
stability. Importantly, this observation was further supported by the in vivo data that 
were acquired from a preclinical humanized mouse model. 
The clinical application of Treg based adoptive therapy in transplantation and 
autoimmunity is hampered by the paucity of peripheral Treg numbers, purity of 
clinical grade isolated Treg and  stability and function of ex vivo expanded Treg. 
Current protocols used for Treg ex vivo expansion commonly use anti-CD3 and 
anti-CD28 mAb stimulation in the presence of rhIL-2 (4, 6-11). This treatment alone 
typically results in a heterogeneous Treg population revealing inadvertent pro-
inflammatory (like IL-17A, IFNγ) cytokine producing potential (12-14). Moreover, 
Treg isolation using the GMP CliniMACS system leads to a moderately pure Treg 
population, with around 40-60% CD4+CD25high cells (4). Considering the intrinsic 
reduced ability of Treg to proliferate in vitro,  “contaminating” non-Treg cells might 
grow out during ex vivo expansion. One solution is to include rapamycin in the 
expansion culture. Rapamycin is a mTOR kinase inhibitor which preferentially 
inhibits effector T cell proliferation and cytokine production in both mice and humans 
(7), 18, 20). However, addition of rapamycin generally leads to lower overall cell 
yields (55). Consistent with the report that TNFR2/NFκB pathways stimulate human 
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Treg proliferation (44), combined usage of TNFR2-agonist and rapamycin resulted in 
efficient Treg proliferation. These fully expanded Treg were even more suppressive 
than cells expanded in the presence of rapamycin only. Previous studies showed 
that rapamycin leads to the inhibition of IL-17 and IFNγ production (56). Intriguingly, 
combined usage of TNFR2-agonist and rapamycin further prevented IL-17 and IFNγ 
production, as compared to rapamycin only treatment. Moreover, the percentage 
of CCR6 positive cells, a marker that identifies IL-17-producing cells derived from 
human Treg (13), was also low following the treatment with TNFR2-agonist plus 
rapamycin. A  recent study showed that TNFR2 knock out CD4 T cells had increased 
expression of RORγt and IL-17 production, which was dependent on the impairment 
of TNFR2-mediated activation of NFκB (57). We speculate that a similar process 
of regulation may exist in human Treg where TNFR2/NFκB signalling might act 
as a double edged sword to enhance FOXP3, but inhibit RORγt expression, thus 
contributing to the stabilization of Treg.
Earlier studies indicated that TNFR2 is more densely expression on human 
CD45RA-activated Treg (44). Therefore, stimulation with a TNFR2-agonist  might 
mainly induce the proliferation of a memory Treg subset. Indeed, one of the most 
notable surface markers that was up-regulated by stimulation in the presence 
TNFR2-agonist was HLA-DR, which identifies an effector Treg subset that exhibits 
higher FOXP3 expression and more potent suppression (37). HLA-DR positive 
effector Treg are reported to be more sensitive to apoptosis than HLA-DR negative 
Treg (58). However, in this study, re-stimulation of TNFR2-agonist plus rapamycin 
expanded Treg, which expressed high level of HLA-DR, had a similar cell viability 
as medium-expanded Treg that express few HLA-DR. Analysis of chemokine 
receptor expression showed that stimulation of the TNFR2-agonist led to reduced 
expression of the chemokine receptors CXCR3 and CCR6, which are linked to Th1 
and Th17 like cells, respectively. It has been demonstrated that Th1- and Th17-like 
Treg specifically regulate Th1 and Th17 responses in mice (59, 60). An implication 
of the lack of CXCR3 and CCR6 on the expanded Treg might suggest that these 
cells upon infusion fail to migrate to sites of Th1 and Th17 responses. However, 
all TNFR2-agonist expanded Treg showed CD62L expression, which might favour 
their trafficking to secondary lymphoid organs, where they might further expand and 
receive instruction with regard to tissue homing capacity (34).  
In conclusion,  we demonstrate the potential of additional TNFR2-agonist stimulation 
for ex vivo expansion of low purity Treg. Expansion of low purity MACS-isolated 
human Treg in the presence of TNFR2-agonist and rapamycin results in a stable 
homogenous FOXP3+, Helios+, CD127low Treg population that reveals profound 
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suppressor potential both in vitro and in vivo, in a preclinical humanized mouse 
model. Our findings further emphasize that expansion of bead-isolated Treg 
requires rapamycin for achieving a functional and stable Treg cell product. But the 
selection of an additional agent like TNFR2-agonist, can overcome the rapamycin-
mediated inhibition of Treg proliferation, and even further stabilize Treg based on 
the demethylation status of TSDR region. It is thus of great  interest to consider the 
combined usage of TNFR2-agonist and rapamycin for stable ex vivo Treg expansion 
for clinical application.
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Supplemental Figure S1: TNFR2-agonist down regulates the expression of CCR6, CXCR3, and CCR7. 
Flow cytometry of FACS-sorted Treg after cell expansion under the indicated conditions . Dot plots 
show surface expression of CXCR3, CCR5, CCR6, CCR7, CD62L and CD27 at day 7 of the cell cultures. 
Numbers within the quadrant show the percentage of positive cells. A representative experiment out 
of two different donors is shown. Rapa: rapamycin; Agonist: TNFR2-agonist.
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Abstract
Regulatory Tcells(Treg) are crucial for immune homeostasis and prevention of 
immune pathology. Yet, Treg may lose Foxp3 and start secreting IL-17, dependent 
on environmental cues. Our previous data revealed that Treg from severe psoriasis 
patients are particularly prone to such conversion. The question of how to maintain 
Treg stability in the context of inflammation awaits immediate resolution. The 
pan-PKC inhibitor sotrastaurin has shown efficacy in clinical trials of psoriasis. 
Here, we show that sotrastaurin inhibited effector T cell responses, whereas the 
regulatory response was enhanced. Sotrastaurin prevented TCR/CD28-induced 
T-cell activation and pro-inflammatory cytokine production, but preserved a stable 
Treg phenotype as evidenced by maintenance of suppressive capacity, high Foxp3 
and CD25 expression, and lack of IL-17A and IFNγ production. Moreover, in both 
circulating and dermal psoriatic Treg, prone to rapid induction of IL-17, sotrastaurin 
enhanced Foxp3 expression and prevented IL-17A and IFNγ production even when 
stimulated in the presence of  the Th17-enhancing cytokines IL-1β or IL-23. Thus, 
pharmacological inhibition of PKC may serve as a powerful tool to concurrently 
inhibit effector T cells and to facilitate Treg, thereby showing therapeutic potential for 
the treatment of psoriasis.
Short Title: sotrastaurin preserves Treg in psoriasis
Abbreviations: Treg, regulatory T-cells; Tconv, conventional T-cells; Th, Helper 
T-cells; PKC, protein kinase C.
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Introduction
Regulatory T-cells(Treg) are crucial for maintaining immune homeostasis. Their 
significance was demonstrated in a variety of preclinical autoimmunity models 
and their clinical relevance was proven by demonstrating that the suppressive 
function of Treg was hampered in autoimmunity and allergy(Buckner 2010). This 
knowledge is currently exploited for the development of new therapeutic designs 
in the management of human chronic-inflammatory diseases. However, recent 
insights point to the notion that human Treg may lose the expression of the Treg-
master transcription factor Foxp3 and convert into less suppressive and even IL-
17 producing phenotypes under pro-inflammatory environmental stimuli(Koenen 
et al. 2008; Beriou et al. 2009; Voo et al. 2009). IL-17 is considered an important 
mediator in psoriatic disease. Recently, we demonstrated that Treg of psoriasis 
patients revealed a remarkably high propensity to differentiate into IL-17A-secreting 
cells, with enhanced loss of Foxp3 and a higher RORyt expression(Bovenschen et 
al. 2011). The concurrent presence of IL-17+Foxp3+CD4+ Treg in human psoriatic 
skin lesions led us to believe that this relative Treg instability may contribute to 
perpetuation of skin inflammation. Thus, the question of how to maintain human Treg 
stability under in vivo inflammatory conditions awaits immediate resolution, and the 
search for pharmaceutical agents that may realize such a feat has only just started. 
Foxp3 expression is under tight epigenetic control(Huehn et al. 2009; Lal et al. 2009) 
and pharmaceutical agents such as DNA methyl-transferase (DNMT) inhibitors and 
histone-deacetylase (HDAC) inhibitors were shown to maintain Foxp3 expression 
in human Treg(Koenen et al. 2008; Polansky et al. 2008). In contrast, many of the 
early T-cell activation inhibitors such as calcineurin inhibitors have disabling effects 
on Treg function. 
In 2008, a proof-of-concept clinical study in psoriasis patients using the pan-PKC 
inhibitor sotrastaurin (AEB071) was reported; Sotrastaurin significantly reduced the 
clinical severity of psoriasis by affecting several immune cells(Skvara et al. 2008). 
To date, sotrastaurin has shown evidence of efficacy in phase II clinical trials in 
both psoriasis as well as renal transplantation(Friman et al. 2011; Wagner et al. 
2011). Sotrastaurin is a low-molecular-weight (LMW) immunosuppressant that 
selectively targets PKC including the PKCα, β and θ isoforms(Evenou et al. 2009). 
PKCθ, a serine/threonine kinase belonging to the calcium-independent novel 
PKC subfamily, is the most abundant isoform in T-cells. TCR and CD28 signaling 
trigger PKCθ catalytic activation and membrane translocation to the immunological 
synapse, leading to activation of NFκB, AP-1, and NFAT in effector T-cells. Studies 
in PKC-knockout (KO) mice have shown that PKCθ is required for productive 
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Th2(Marsland et al. 2004) and Th17(Tan et al. 2006) responses, but is dispensable 
for Th1 responses. More recently, the function of PKCθ in Treg has become the 
focus of attention. Selective inhibition of PKCθ using a LMW inhibitor enhanced 
Treg function, suggesting that PKCθ signaling negatively regulates Treg cells via an 
unknown mechanism(Zanin-Zhorov et al. 2010).  
Yet, most knowledge on the differential role of PKCθ in T-cell biology relies on studies 
in mice. Little is known about regulation and function of PKCθ in human T-cells. Here, 
we investigated the in vitro effects of sotrastaurin on human effector and regulatory 
T-cell subsets. Sotrastaurin significantly inhibited T-cell effector function and the 
production of inflammatory cytokines. Importantly, sotrastaurin was found to preserve 
human Treg suppressive function and prevent IL-17A production. In Treg from 
psoriasis patients with impaired Treg stability, treatment with sotrastaurin restored 
a bona fide Treg phenotype and prevented Treg differentiation into inflammatory 
effector cells. Thus, pharmacological targeting of PKC in T cells by LMW inhibition 
might be a powerful means to simultaneously control effector T cells and adequate 
Treg function. 
Results
AEB071 inhibits effector function of conventional T cells, but preserves the 
Treg phenotype even under pro-inflammatory conditions 
First, we established the effect of the PKC inhibitor sotrastaurin (AEB071) on human 
conventional CD4+CD25- cells (Tconv) from healthy individuals. We observed a 
clear dose-dependent inhibition of the proliferative capacity of Tconv by AEB071 
following anti-CD3/anti-CD28 mAb-coated bead stimulation (Figure S1a). To exclude 
the possibility that the observed proliferation inhibition was due to induction of cell 
apoptosis, cells were stained for the active form of Caspase 3, a central mediator 
of apoptosis. No obvious differences in the percentages of Caspase 3 positive cells 
between untreated and treated groups were noted (Figure S1b). 
Then, cells were stimulated with anti-CD3/anti-CD28 mAb-coated beads in the 
presence or absence of AEB071 or Rapamycin and phenotypically analyzed by 
flowcytometry over a 6-days culture period. AEB071 prevented the expression of the 
T-cell activation markers CD69, CD25 and HLA-DR (Figure 1a). Expression of the 
negative co-stimulatory molecules PD-1 and CTLA-4 during T-cell activation was 
also prevented by AEB071. Activated human CD4+CD25- cells may transiently 
express Foxp3, but stable expression of Foxp3 is correlated with suppressor function 
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in Tregs(Tran et al. 2007). In our Tconv cultures the transient expression of Foxp3 
peaked at day 3 of culture. AEB071 treatment not only significantly prevented the 
increase in the number of Foxp3 positive cells (Figure 1a), but also the expression 
level of Foxp3 (Mean Fluorescence Intensity (MFI), data not shown). Foxp3 
expression was low at day 6 of culture in both the treated and untreated conditions, 
implying that inhibition of PKC does not favor the generation of induced Treg from 
Tconv. Subsequently, we established that addition of AEB071 to cultures of activated 
Tconv significantly inhibited the production of IL-17A (Figure 1b) and IFNγ (Figure 
S1c) at both day 3 and 6. Addition of Rapamycin also completely inhibited IL-17A 
secretion. 
We next assessed the effect of AEB071 on Treg from healthy individuals. As a 
comparator, we included Rapamycin which is known to harness human Treg function 
both in vitro and in vivo(Tresoldi et al. 2011). AEB071 dose-dependently inhibited 
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Figure 1: AEB071 inhibits Tconv cell activation and IFNγ/IL-17A production. CD4+CD25- Tconv 
were stimulated with anti-CD3/anti-CD28 mAb-coated beads with or without AEB071(10 μM) or 
Rapamycin(200 nM) and phenotypically analyzed at day 1/3/6. (a) Representative dot-plots showing 
CD69, HLA-DR, CD25, PD-1, CTLA-4 and Foxp3 expression at day 6 of culture (left panel) and cumulative 
data showing the frequency of each marker analyzed (right panel). n=6. (b) Presence of IL-17A in cell 
culture supernatants at day 3 and 6 as measured by Luminex. Each data point represents a separate 
experiment performed with CD4+CD25- cells obtained from different healthy blood donors. n=6. 
*P<0.05; **P<0.01, ***P<0.001.
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Treg proliferation following stimulation with either anti-CD3/anti-CD28 mAb-coated 
beads or PMA/soluble anti-CD28 mAb in the presence of exogenously added rhIL-2 
(Figure 2a). The IC50 of AEB071 was 0.09 mM under the stimulation with CD3/CD28/
rhIL-2 and 0.15 mM when PMA/CD28/rhIL-2, a PKC-skewing activation method, was 
used(Smeets et al. 2012). Rapamycin was less potent in the inhibition of Treg 
proliferation as compared to Tconv, 30% (Treg, Figure 2a) vs 70%(Tconv, Figure 
S1a). Higher concentrations of Rapamycin did not result in further inhibition of Treg 
proliferation. Furthermore, AEB071-treated Treg did not show increased apoptosis 
(Figure S1d), indicating that the compound does not affect Treg cell viability by 
apoptosis induction. Rapamycin treatment also did not affect Treg apoptosis 
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Figure 2: AEB071 preserves Treg phenotype and prevents Treg from producing IFNγ/IL-17A. FACS-
sorted CD4+CD25high Treg were stimulated with anti-CD3/anti-CD28 mAb-coated beads or PMA/
anti-CD28 mAb plus rhIL-2 in the presence of a graded dose of AEB071(red line) or Rapamycin(blue 
line). (a) Proliferation of Treg was measured by [3H]-thymidine incorporation during the last 6 h of a 
7-days culture. n=5. (b) Flowcytometry of Treg cultured for 7-days as described above in the presence 
of AEB071(1μM), Rapamycin (200nM) or C20(1μM). Representative dot-plot showing CD25+Foxp3+ 
expression (left panel) and cumulative data showing the frequency and MFI of CD25+ and Foxp3+ 
cells (right panel). n=3. (c, d) Presence  of IFNγ and/or IL-17A in cell culture supernatant at day 7 as 
measured by Luminex. IL-1β was added to the culture where indicated. (e) Cumulative data showing 
the frequency of RORγt+ cells. All experiments were performed with Treg obtained from different 
healthy blood donors. Mean + SEM are shown, n=3. ns: not significant ; *P<0.05; **P<0.01.
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induction.
To evaluate the impact of PKC inhibition on Treg phenotype, the expression of Foxp3 
and CD25 was analyzed upon stimulation with CD3/CD28/rhIL-2 or PMA/CD28/rhIL-
2. For comparison and confirmation purposes, we used the selective PKCθ inhibitor 
C20. Similar to Rapamycin, inhibition of PKC using either AEB071 or C20 largely 
preserved the expression of Foxp3 and CD25 (both percentage and MFI) regardless 
of the stimulation protocol (Figure 2b). Notably, the administration of Rapamycin 
significantly enhanced the MFI of CD25.
Recent studies provided evidence for functional heterogeneity and lineage plasticity 
within the Treg compartment. Under certain conditions, Treg may acquire an effector 
phenotype including the ability to produce IFNγ and/or IL-17A. Here, we measured 
the amount of IFNγ and IL-17A produced by Treg after treatment with AEB071, C20 or 
Rapamycin. In the absence of any inhibitors, Treg did produce somewhat IFNγ upon 
stimulation. Interestingly, AEB071 almost completely blocked this IFNγ production 
(Figure 2c). A similar inhibition was seen in the presence of Rapamycin or C20. In 
line with several reports(Koenen et al. 2008; Voo et al. 2009), IL-17A was produced 
by Treg stimulated with CD3/CD28/rhIL-2 and its production was enhanced by the 
pro-inflammatory cytokine IL-1β (Figure 2d). In contrast, IL-17A was hardly detected 
following treatment with AEB071, C20 or Rapamycin. Importantly, AEB071, similar 
to Rapamycin, successfully prevented Treg from producing IL-17A, even in the 
presence of IL-β (Figure 2d). It has been suggested that the ratio of Foxp3/RORgt 
determines the Treg/Th17 plasticity(Bettelli et al. 2006). However, we were unable to 
find any significant change of Foxp3 (Figure 2b) and RORgt (Figure 2e) expression 
in our set up. 
To explore the effect of PKC inhibition on Treg suppressor function, Treg were 
stimulated with anti-CD3/anti-CD28/rhIL-2 for a week in the presence/absence of 
AEB071, Rapamycin or C20. Thereafter, viable expanded Treg were co-cultured 
with CFSE-labeled CD4+CD25- responder T-cells (Tresp) at different ratio’s of 
Treg:Tresp and the dilution of CFSE was determined after 3-days of culture. 
According to expectation(Coenen et al. 2006; Tresoldi et al. 2011), Treg expanded in 
the presence of Rapamycin demonstrated preserved suppressor function when 
compared to the untreated condition (Figure 3a-b). Interestingly, treatment with 
AEB071 proved just as successful in maintaining suppressor function (Figure 3a-b), 
similar to C20 treatment (Figure 3c). At a ratio of 1:1 (Treg:Tresp), the proliferation of 
Tresp was inhibited more than 80% under all conditions tested, including Treg treated 
with AEB071. At a ratio of 1:2(Treg:Tresp), still over 50% inhibition of Tresp 
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proliferation was observed in the AEB071 treated condition. 
AEB071 preserves phenotype and function of circulating Treg from  psoriasis 
patients 
Previously, we showed that, as compared to healthy controls, Treg from psoriasis 
patients upon stimulation exhibit enhanced loss of Foxp3, the master transcription 
factor associated with suppressor function, and increased production of IL-
17A(Bovenschen et al. 2011). This was particularly so when stimulated in the 
presence of IL-23 or IL-1β. So, having established that in healthy Treg AEB071 
preserves Treg function and phenotype, we explored whether AEB071 may  improve 
Treg function in psoriasis patients. We isolated either CD4+ lymphocytes or 
CD4+CD25high Treg from patient PBMCs, and stimulated the cells with anti-CD3/anti-
CD28 mAb-coated beads plus rhIL-2 in the presence/absence of AEB071 or 
Rapamycin for a week. Th17 polarizing cytokines IL-1β or IL-23 were also 
administrated to the cell culture. In the total psoriatic CD4+ T-cell pool, the addition 
of AEB071 or Rapamycin resulted in enhanced Foxp3+ cell numbers as compared 
to the standard stimulation, especially in the presence of IL-23 (Figure 4a). More 
importantly, under these conditions AEB071 significantly inhibited both IL-17A and 
IFNγ production (Figure 4b). Then we analyzed FACS-sorted Treg from patient 
peripheral blood. Confirming our previous results (Bovenschen et al. 2011), these 
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Figure 3: Inhibition of PKC preserves Treg 
suppressive function. CFSE-based co-culture 
suppression assay of CD4+CD25high Treg that 
were stimulated with anti-CD3/anti-CD28/rhIL-2 in 
the absence or presence of AEB071(1 μM), C20(1 
μM), or Rapamycin(200 nM). (a, c) A representative 
overlay histogram of CFSE-based suppression assay 
is shown on day 3 of co-culture. (b) Cumulative data 
showing %-inhibition of Tresp proliferation induced 
by expanded Treg that were cultured according to 
the conditions mentioned. All experiments were 
performed with CD4+CD25high and CD4+CD25- 
cells obtained from different healthy blood donors. 
n=5 (a, b) or 3 (c). Mean + SEM are shown. ns: not 
significant. Tresp: responder T-cells.
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cells showed a markedly diminished expression of Foxp3 following stimulation, 
which was enhanced by the addition of IL-1β or IL-23 (Figure 4c, upper part left 
panel). Whereas in healthy Treg AEB071 treatment maintained a similar level of 
Foxp3+ cells (Figure 2) as compared to the untreated condition, in patient Treg, 
treatment with AEB071 or Rapamycin not only prevented the loss of Foxp3, but 
slightly enhanced it, even  in the presence of IL-1β or IL-23 (Figure 4c). Moreover, 
this feature was accompanied by a reduced production of IL-17A (Figure 4d). 
ba
d
Figure 4
FS
Foxp3
+ IL1β                                          + IL23 
46.2% 22.3%
54.5% 61.8%
65.2% 57.0%
Untreated
AEB071
Rapamycin
c
U
nt
re
at
ed
AE
B0
71
R
ap
am
yc
in    
U
nt
re
at
ed
AE
B0
71
R
ap
am
yc
in    
U
nt
re
at
ed
AE
B0
71
R
ap
am
yc
in
0
300
600
900
900
7000
+ IL-1β + IL-23
*** ** *** **
IF
N
γ  
(p
g/
m
L)
U
nt
re
at
ed
AE
B0
71
R
ap
am
yc
in    
U
nt
re
at
ed
AE
B0
71
R
ap
am
yc
in    
 
U
nt
re
at
ed
AE
B0
71
R
ap
am
yc
in
0
10
20
30
40
+ IL-1β + IL-23
**
*
*
*
**
%
Fo
xp
3+
 c
el
ls
U
nt
re
at
ed
A
E
B
07
1
R
ap
am
yc
in   
U
nt
re
at
ed
A
E
B
07
1
R
ap
am
yc
in   
U
nt
re
at
ed
A
E
B
07
1
R
ap
am
yc
in
0
100
200
300
300
1000
+ IL-1β + IL-23
* ** *** ** ** *
IL
-1
7A
 (p
g/
m
L)
U
nt
re
at
ed
AE
B0
71
R
ap
am
yc
in    
U
nt
re
at
ed
AE
B0
71
R
ap
am
yc
in    
U
nt
re
at
ed
AE
B0
71
R
ap
am
yc
in
0
25
50
75
100
+ IL-1β + IL-23
*
*
*
*
*
%
Fo
xp
3+
 c
el
ls
U
nt
re
at
ed
AE
B0
71
R
ap
am
yc
in
U
nt
re
at
ed
AE
B0
71
R
ap
am
yc
in
U
nt
re
at
ed
AE
B0
71
R
ap
am
yc
in
0
500
1000
1500
+ IL-1β + IL-23
*
*
*
IL
-1
7A
 (p
g/
m
L)
93.7%
90.4%
93.5%
87.3%
89.8%
89.2%
PAT 1 PAT 2
Figure 4: AEB071 prevents the extensive loss of Foxp3 and inhibits IFNγ/IL-17A production by 
peripheral Treg from psoriasis patients. CD4+ T-cells or CD4+CD25high Treg isolated from psoriasis 
peripheral blood were stimulated with anti-CD3/anti-CD28 mAb-coated beads in the absence/presence 
of AEB071(1 μM) or Rapamycin(200 nM) for 7 days. IL-1β or IL-23 was included where indicated. In 
case of Treg, rhIL-2 was also administrated to the cultures. (a) Cumulative data showing the frequency 
of Foxp3+ cells as measured by flowcytometry. n=11. (b) Cumulative data showing the amount of 
IFNγ and IL-17A in the culture supernatants of patient CD4+ cells as measured by Luminex. n=11. 
(c) Representative dot-plots showing Foxp3 expression on Treg from 2  different psoriatic patients 
following stimulation as described above for 7-days. Cumulative data showing the frequency of 
Foxp3+ cells (right panel). n=7. (d) Cumulative data showing the amount of IL-17A in psoriatic patient 
Treg cell culture supernatants at day 7 of culture. Each data point represents a separate experiment, 
performed with cells isolated from a different psoriasis patient.  n=7. *P<0.05; **P<0.01; ***P<0.001. 
PAT: Patient.
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AEB071 prevents IL-17A and IFNγ production by skin-resident T-cells  
Recruitment of T-cells into the skin and their effector responses are considered to be 
key features in the pathogenesis of psoriasis. We therefore investigated the effect of 
AEB071 on skin-resident T-cells. Single dermal cell populations were prepared from 
skin biopsies from lesional skin of psoriasis patients (n=5) or skin from healthy 
individuals (n=3). Figure 5a shows the percentage of cutaneous lymphocyte antigen 
(CLA) and Foxp3 positive cells in the CD3+  population thus obtained (Figure 5a). 
Culture strategies are outlined in Figure 5b. First, we stimulated freshly isolated 
primary dermal T cells with anti-CD3/anti-CD28 mAb-coated beads plus rhIL-2 and 
IL-1β for 12 days, in the presence or absence of AEB071. Similar to its effect on 
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Figure 5: AEB071 prevents IL-
17A and IFNγ production by 
skin-resident T-cells. Punch skin 
biopsies obtained from healthy 
individuals and psoriasis patients 
were used for preparation of the 
single dermal cell populations as 
described in Material&Methods. 
Thereafter, cells were either 
analyzed by FACS analysis  for 
CD3, CLA and Foxp3 expression, 
or cultured as schematically 
indicated (b) with or without 
AEB071(10 µM). (a) Dot-plots 
showing the expression of CLA 
and Foxp3 based on the CD3+ 
gated derma cell population 
at day 0. Dot-plots show one 
representative healthy donor and 
one merged dot-plot of 3 patients. 
(c) Cumulative data showing 
the percentage of Foxp3+ cells 
after the first round of 12-days 
stimulation (Primary(D12)) or after the second round of 7-days stimulation (Expanded(D19)) (d) 
Cumulative data showing the percentage of IL-17A and IFNγ positive cells at day 12 and 19 of culture. 
In total, 3 healthy and 5 patient skin biopsies were used.
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blood-derived circulating T-cells (Figure S1a), and as compared to the non-treated 
condition, AEB071 strongly inhibited proliferation of primary dermal T-cells in both 
samples from psoriasis patients and those from healthy controls (data not shown). 
Since very few dermal T-cells proliferated in the presence of AEB071, hampering 
more extensive analysis, we employed an alternative strategy to investigate the 
effect of AEB071 on dermal T-cells. First, we expanded primary dermal T-cells with 
anti-CD3/anti-CD28/rhIL-2 for 12-days. Thereafter, expanded dermal T-cells were 
collected and re-challenged in the presence/absence of AEB071 for another 7-days 
before performing the phenotypic analysis. Consistent with our observation in 
circulating Treg, AEB071 enhanced Foxp3 expression in dermal T-cells derived from 
both healthy individuals and patients (Figure 5c). Also patient derived dermal T-cells 
(primary and expanded) showed enhanced capacity to lose Foxp3 expression upon 
stimulation, which was largely prevented by treatment with AEB071 (Figure 5c). 
Again similar to circulating Treg, upon stimulation, psoriasis patient derived dermal 
T-cells produced more IL-17A than those from healthy individuals. Also, AEB071 
clearly diminished the percentage of IL-17A as well as IFNγ producing cells in 
patients (Figure 5d).
Discussion
IL-17 is an important mediator in the pathogenesis of psoriasis. Previously, we 
reported that Treg of psoriasis patients have an enhanced propensity to convert into 
an inflammatory phenotype and start producing IL-17(Bovenschen et al. 2011). We 
also found evidence for these IL-17 producing Treg in psoriatic plaques. Recently, the 
importance of defining agents that can prevent this type of conversion was highlighted 
in view of improved therapeutic regimens for the management of (auto)inflammatory 
processes(Soler and McCormick 2011). We here hypothesized that the pan-PKC 
inhibitor sotrastaurin (AEB071), now used in clinical trials to diminish clinical symptoms 
in psoriasis patients(Skvara et al. 2008), might be such an agent. Indeed, our study 
provides evidence that sotrastaurin preserves the stability of human Treg; in vitro 
treatment with sotrastaurin prevented circulating Treg of both psoriasis patients and 
healthy controls from producing IFNγ and IL-17A, even in the presence of the IL-17-
driving-cytokine IL-1β. Also, Treg that were cultured in the presence of sotrastaurin, 
similar to Rapamycin, efficiently suppressed the proliferation of responder T-cells, 
indicating that both compounds favor the maintenance of suppressor function. 
Moreover, also in dermal T cells from lesional skin sotrastaurin preserved Foxp3 
expression and inhibited IL-17A and IFNγ production upon stimulation, features that 
may contribute to the clinical effects observed upon treatment. 
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Based on data obtained in PKCθ KO mice, contrasting roles for PKCθ in the 
development and function of thymus derived Treg were reported: while Treg numbers 
were reduced, Treg suppressor function proved intact(Gupta et al. 2008). The recent 
finding that the PKCθ specific inhibitor C20 increases the suppressor activity of 
human Treg(Zanin-Zhorov et al. 2010) is in line with our findings and suggests that 
therapeutic strategies designed to inhibit PKC in T-cells may hold promise for the 
treatment of autoimmune conditions. Sotrastaurin is a LMW immunosuppressant 
selectively targeting PKC(Evenou et al. 2009). In patients with moderate-to-severe 
psoriasis, sotrastaurin resulted in a mean reduction up to 69% for the PASI score 
compared to baseline after 2-weeks of treatment(Skvara et al. 2008), suggesting the 
efficacy of sotrastaurin in T-cell mediated diseases. Indeed, sotrastaurin markedly 
prolonged graft survival times in experimental heart and kidney allo-transplantation 
animal models(Weckbecker et al. 2010; Bigaud et al. 2012). Although a phase II 
clinical trial using sotrastaurin plus MPA in renal transplant recipients was associated 
with increased rejection from week 4 onwards, this calcineurin inhibitor-free regimen 
showed an acceptable safety profile and improved renal function(Friman et al. 
2011), which support further study of sotrastaurin as a component of multidrug 
immunosuppressive regimens. 
Several studies revealed that under pro-inflammatory environmental stimuli human 
Treg may lose Foxp3 and convert into less suppressive and even inflammatory 
phenotypes(Koenen et al. 2008; Beriou et al. 2009; Voo et al. 2009). Here, we showed 
that sotrastaurin maintained the regulatory phenotype of Treg as characterized 
by the expression of Foxp3 and CD25 and preserved suppressor function. More 
importantly, upon stimulation of Treg, sotrastaurin, similar to Rapamycin(Yurchenko 
et al. 2012), not only preserved expression of Foxp3 and CD25, it also prevented Treg 
from producing IL-17A. The stabilizing effect of sotrastaurin was found in Treg from 
healthy individuals as well as from those of psoriasis patients, even in the presence 
of the Th17-enhancing cytokines IL-1β or IL-23. Since psoriatic Treg are far more 
prone to convert into IL-17 producers and being in an inflammatory environment, 
this stabilizing feature is of particular relevance in the treatment of psoriasis patients.
The mechanism by which PKC affects Treg fate and function is largely unclear. In 
effector T cells, PKCθ is recruited to the IS with the specific purpose of destabilizing 
the connection and possibly allowing for subsequent antigen encounter thereby 
favoring Th2 and Th17 development(Yokosuka et al. 2008). In contrast, mouse studies 
revealed that in Treg the PKC/CARMA/NFkB complex was found localized outside 
of the IS(Zanin-Zhorov et al. 2011). This implies that inhibition of PKC-mediated 
activation of NFkB/Ap1 is beneficial during Treg activation, whereas inhibition of 
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the NFkB/Ap1-mediated inflammatory pathway is detrimental for (Th2 and Th17) 
effector function. The fact that Rapamycin is able to stabilize Treg suggests that 
multiple pathways are likely involved. Treg stability through Rapamycin-mediated 
inhibition of mTOR may be achieved in a direct way through inhibition of protein 
synthesis or indirectly by modulating cellular metabolism via Akt. This is underlined 
by the phenomenon that effector T-cells and Treg require distinct metabolic programs 
to support their functions: Th1, Th2 and Th17 cells are highly glycolytic whereas 
Treg have high lipid oxidation rates in vitro(Michalek et al. 2011). Importantly, 
hypoxia-inducible factor 1 (HIF-1), a key metabolic sensor, was shown to control 
the balance between the reciprocally regulated Th17 and Foxp3+Treg cell lineage, 
which appeared to be dependent on mTOR(Dang et al. 2011; Shi et al. 2011). Thus, 
the data imply that pharmacological inhibition targeting either PKC or mTOR (by 
sotrastaurin and Rapamycin respectively) may be used to control Treg and Tconv 
specific functions in inflammatory disease. 
Further, we found that different IC50s of sotrastaurin were obtained for Tconv and Treg 
subsets, and under different stimulation conditions (e.g. CD3/CD28 and PMA/CD28). 
Some of this can be explained by our previous finding that PMA/CD28-induced 
T-cell stimulation is highly dependent on the PKCθ pathway whereas CD3-mediated 
pathways are dependent on both Lck and PKCθ signal transduction(Smeets et al. 
2012). Although sotrastaurin dose-dependently inhibited both Tconv and Treg cell 
proliferation, the IC50 for Treg was always lower than that for Tconv regardless of 
the stimulus provided. This may be explained by: 1/ differences in expression of 
environmental sensors and ensuing signal transduction pathways involved in Treg 
and Tconv subsets, 2/ differences in PKCθ  cellular concentrations and cellular 
localization as reported recently for Treg and Tconv. Higher sensitivity of Treg to 
PKC inhibition may be favourable for preventing Treg reprogramming in vivo. More 
studies are needed to establish optimal dosing of PKC inhibitors for stabilizing Treg 
function while maintaining T-cell homeostasis.
In conclusion, here, we showed that sotrastaurin inhibited effector T cell responses 
whereas the regulatory response was enhanced, a feature observed even in the 
presence of IL-1β. In addition, we provide evidence for the role of PKC in the balance 
of Treg and Th17 differentiation and show that this mechanism also holds true for 
both circulating and skin-derived T cells from psoriasis patients. Inhibition of PKC 
thus appears to control Treg fate by preventing Treg differentiation into inflammatory 
effector T-cells. Pharmacological inhibition of PKC may thus add to strategies for 
Treg facilitation in the treatment of autoimmune related disorders, such as psoriasis.
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Materials and Methods
Cell isolation and culture
Buffy coats were obtained from healthy blood donors (Sanquin Blood Bank, Region 
South-East, The Netherlands) upon written informed consent, according to the 
Declaration of Helsinki. In total 16 psoriasis patients were recruited to this study 
and peripheral blood was collected by vena puncture. The average PASI (Psoriasis 
Area and Severity Index) score was 10.3 ± 2.5 (Mean +/- SEM). Patients were either 
untreated(n=5) or treated with methotrexate(n=7), fumaric acid(n=3), or UVB(n=1). 
This study was carried out in RUMC in accordance with the applicable rules concerning 
the review of research ethics committees and upon written informed consent. 
PBMCs and CD4+ were isolated and cultured as described previously(He et al. 
2011). Briefly, The resultant CD4+ fraction was labeled with anti-CD25-PE(M-A251; 
BD Biosciences, Erembodegem, Belgium) and anti-CD4-PC5(13B8.2, Beckman-
Coulter, Mijdrecht, The Netherlands), conjugated monoclonal antibodies(mAbs); 
Thereafter, Tconv(CD4+CD25-) and Treg(CD4+CD25high) were sorted using an Altra 
or Aria cell-sorter(Beckman-Coulter). Cell purity was over 98%. 
CD4+CD25- Tconv were stimulated with anti-CD3/anti-CD28 mAb-coated beads 
(T Cell Expanders, Dynal Biotech, Oslo, Norway), in a bead:cell ratio of 1:5, 
in the absence/presence of the indicated concentrations of inhibitors for 4 days. 
CD4+CD25high Treg were stimulated with either anti-CD3/anti-CD28 mAb-coated 
beads, in a bead:cell ratio of 1:2, and recombinant human cytokines IL-2(rhIL-2, 
25 U/mL, Proleukine, Amsterdam, The Netherlands), or PMA(12.5 ng/mL), soluble 
CD28 mAb(1 μg/mL) and rhIL-2(25 U/mL) in the absence/presence of the indicated 
concentrations of inhibitors for a week. IL-1β(50 ng/mL) or IL-23(50 ng/mL) was 
added into cell cultures, where described.
Cell isolation from skin
Skin punch biopsies from healthy individuals were obtained from abdominal skin 
leftover of healthy individuals undergoing elective plastic surgery at the RUMC 
Department of Plastic Surgery after oral or written informed consent for scientific 
use. Skin punch biopsies from psoriasis patients (PASI score, 15.8 +/- 1.7,  n=5) 
were obtained from lesional skin at University of Essen Department of dermatology 
after oral or written informed consent for scientific use. The use of human skin 
was approved and in accordance with the regulations set by the Medical Ethical 
Committees for human research of the RUMC. 
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Biopsies(4 mm) were incubated in a 24-well plate in which each well contains 32 
mg/mL Dispase II (Roche, Woerden, The Netherlands) at 4°C,overnight for peeling 
off of the epidermis. Thereafter, biopsies were mechanically dissociated using 
gentalMACS tubes(Miltenyi Biotec, Leiden, The Netherlands) followed by the 
incubation with collagenase I(10 000 U/mL, Sigma-Aldrich) for 1h. After the addition 
of DNase I(5 MU/mL, Calbiochem, Amsterdam, The Netherlands) and one more 
cycle of mechanical dissociation, samples were filtered through a cell strainer to 
obtain the single dermal cell population, referred to as primary dermal T-cells in this 
manuscript.
Primary dermal T-cells were cultured with anti-CD3/anti-CD28 mAb-coated beads 
together with rhIL-2 for 12 days before either directly performing the phenotypic 
analysis, or used as expanded dermal T-cells for further analysis. At day 12 the 
expanded dermal T-cells were collected, and re-stimulated for another 7-days 
before phenotypic analysis. IL-1β(50ng/mL) and  AEB071(10 uM) were added where 
indicated.
Inhibitory compounds
AEB071 and C20 were kindly provided by Organon NV (now Merk Research 
Laboratories, MSD, Oss, The Netherlands) and Boehringer Ingelheim 
Pharmaceuticals, Inc. (Ridgefield, CT, USA), respectively. Rapamycin was purchased 
from Sigma(Zwijndrecht, The Netherlands). Cells were pretreated with indicated 
concentrations of the inhibitors or vehicle control for 30 min at 37°C. Thereafter, 
stimulators as indicated were added to the culture mixture. 
Cell proliferation assay
Typically 5x104 Tconv or 2x104 Treg per well were stimulated in the presence of 
graded doses of inhibitors. Cell proliferation was monitored by [3H]-thymidine 
incorporation using a Gas Scintillation Counter(Canberra Packard, Matrix 96 Beta-
counter, Meriden, CT) at day 4(Tconv) or 7(Treg). Percentage of cell proliferation 
inhibition was normalized to the control. The sigmoid curve was generated using 
GraphPad Prism5.0.
Antibodies and CfSE labeling
Cells were phenotypically analyzed by multi-colors flow cytometry (Beckman 
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-Coulter), using: anti-CD3-PeCy5(UCHT1), anti-CD4-PeCy5(T4), anti-CD8-
ECD(SFCI21Thy2D3), anti-CD69-ECD (TP1.55.3) and anti-CD62L-ECD(DREG56) 
(all from Beckman-Coulter), anti-CD25-PeCy7 (BC96; eBioscience), anti-HLA-
DR-FITC(L243) and anti-PD1-FITC(MIH4) (both from BD Bioscience) mAbs. Anti-
Foxp3-FITC or -eFluo450 (PCH101), anti-RORγt-PE or –APC(AFKJS-9) (both 
from eBioscience), and anti-CTLA4-APC(BNI3, BD Bioscience) were used after 
Fix-Perm-treatment (eBioscience). Appropriate isotype mAbs were used to define 
marker settings. Fixable viability dye(eBioscience) was used in some experiments. 
Data were analyzed using Kaluza software(Beckman-Coulter).
Cells(5 x 106 cells/mL) were labeled with 0.5 µM CFSE(Molecular Probes, Leiden, 
The Netherlands) to monitor cell division(Koenen et al. 2005).
Co-culture suppression assays
The suppressor capacity of expanded-Treg was studied in co-culture assays. 
Treg were expanded in the absence/presence of inhibitors for a week. Thereafter, 
viable Treg were collected, washed and added at different ratio’s to CFSE-labeled 
CD4+CD25- responder T-cells(Tresp) together with anti-CD3/anti-CD28 mAb-coated 
beads for 3-days. Proliferation of Tresp was determined by analyzing CFSE dilution 
as described previously(Koenen et al. 2005).  
Cytokine production
IL-17A and IFNγ were determined in the culture supernatants using Luminex cytokine 
assays (Invitrogen, Veenendaal, The Netherlands), according to manufacturer’s 
instructions. The lower level of detection(LLOD) of IFNγ was less than 5 pg/mL and 
the LLOD of IL-17A was less than 10 pg/mL.
Statistics
Results are presented as mean+/-SEM. P-values were determined by paired t-Test 
or one-way ANOVA, using the GraphPad Prism5.0 software. P values less than 0.05 
were considered statistically significant. 
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Supplemental Figure S1: AEb071 dose-dependently inhibitis cell proliferation of 
conventional and regulatory T-cells without affecting cell apoptosis. (a) CD4+CD25- 
Tconv were stimulated with anti-CD3/anti-CD28 mAb-coated beads in the presence of a 
graded dose of AEB071 or Rapamycin for 4-days. Cell proliferation was determined using
3H-incorporation as described in Material & Methods. Percentage of cell proliferation inhibition
was normalized to the condition of  non-treated i.e. medium as shown in the figure. Mean +/-
SEM are shown. n=6. (b) Percentage of apoptotic cells after stimulation of Tconv in the 
presence of AEB071 (1 or 10 µM) or Rapamycin (200 nM)  as indicated by Caspase-3 positivity, 
measured using flowcytometry at day 4. n=3. (c) Presence of IFNg in cell culture supernatants 
at day 3 and 6 as measured by Luminex. Each data point represents a separate experiment 
performed with Tconv obtained from different healthy blood donors. n=6. *P<0.05; **P<0.01. (d) 
CD4+CD25high Treg were stimulated with anti-CD3/anti-CD28 mAb-coated beads or PMA/anti-
CD28 mAb in the presence of rhIL-2. AEB071 or Rapamycin were included where indicated. 
Percentage of apoptotic Treg, as indicated by Caspase-3 positivity, was measured using 
flowcytometry at day 7 of culture. Drug concentration is indicated in parentheses in µM. All 
experiments were performed with cells obtained from different healthy blood donors. Mean +/- 
SEM are shown, n = 3.   
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Short Abstract 
We describe a protocol to efficiently isolate skin resident T cells from human skin 
biopsies. This protocol yields sufficient numbers of viable human skin resident 
lymphocytes for flow cytometric analysis and ex vivo culture.
Long Abstract 
Human skin has an important barrier function and contains various immune cells that 
contribute to tissue homeostasis and protection from pathogens. As the skin is relatively 
easy to access, it provides an ideal platform to study peripheral immune regulatory 
mechanisms. Immune resident cells in healthy skin conduct immunosurveillance, but 
also play an important role in the development of inflammatory skin disorders, such 
as psoriasis. Despite emerging insights, our understanding of the biology underlying 
various inflammatory skin diseases is still limited. There is a need for good quality 
(single) cell populations isolated from biopsied skin samples. So far, isolation 
procedures have been seriously hampered by a lack of obtaining a sufficient number 
of viable cells. Isolation and subsequent analysis have also been affected by the loss 
of immune cell lineage markers, due to the mechanical and chemical stress caused 
by the current dissociation procedures to obtain single cell suspension. Here, we 
describe a modified method to isolate T cells from both healthy and involved psoriatic 
human skin by combining mechanical skin dissociation using an automated tissue 
dissociator and collagenase treatment. This methodology preserves expression 
of most immune lineage markers such as CD4, CD8, Foxp3 and CD11c upon the 
preparation of single cell suspensions. Examples of successful CD4+ T cell isolation 
and subsequent phenotypic and functional analysis are shown.
Keywords: Skin biopsy, Immunity, Lymphocytes, CD4+, CD8+, Psoriasis, Lesional 
skin, Cell culture, Flow cytometry, Cytokines.
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Introduction 
The skin, as the primary interface between the body and the environment, provides 
the first line of defence against external physical, chemical and biological insults 
such as wounding, ultraviolet radiation and micro-organisms. Skin comprises two 
main compartments, the epidermis and the dermis, and contains a variety of immune 
cells including Langerhans cells, macrophages, dendritic cells (DCs), and about 20 
billion memory T cells, nearly twice the number present in the entire blood volume1,2. 
A growing body of data supports the notion that the skin has essential immunological 
functions, both during tissue homeostasis and in various pathological conditions. 
Immune cells resident in normal skin are thought to conduct immunosurveillance3 
and have been shown to play a role in the development of inflammatory disorders 
such as psoriasis4. In psoriatic lesional skin, both CD4+ and CD8+ infiltrated T cells 
were observed and it was shown that the ratio of the CD4 and CD8 varies depending 
on the disease status5. However, these populations of cells are difficult to study 
because existing techniques allow the isolation of only few cells.
The currently widely used techniques for T cell isolation from human skin combine 
mechanical skin dissociation with enzymatic treatment. Human skin biopsies are 
extensively minced and incubated with enzymes like trypsin, collagenase and/or 
EDTA6-8. Considering that skin is a barrier tissue which is highly resistant to tensile 
forces and mechanical disaggregation, the established methods of T cell isolation 
produced very few cells, and even lower numbers of viable cells, which makes ex 
vivo cell culture of these cell populations difficult and challenging. 
Here, we report a modified method to isolate lymphocytes from both healthy and 
involved psoriatic human skin by combining mechanical dissociation of the skin using 
an automated tissue dissociator instead of the established method of extensively 
mincing, together with enzymatic digestion using collagenase. Various viable 
immune cell subsets including DCs and T cells were observed after preparation of 
a single-cell suspension. Importantly the expression of the surface markers CD3, 
CD4 and CD8 was well preserved. Cells thus prepared, are ready for use in ex 
vivo cell cultures or flow cytometric analysis. This protocol has been successfully 
employed for the analysis of single skin biopsies (4mm) derived from lesional skin of 
psoriasis patients. Results showed that  skin resident patient T cells produced more 
inflammatory cytokines like IL-17 and IFNγ in comparison to healthy volunteers9. 
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Protocols
Note: Skin biopsies from healthy individuals were obtained from abdominal skin 
leftover of individuals undergoing elective plastic surgery after oral or written informed 
consent for scientific use. The use of human skin was approved and in accordance 
with the regulations set by the Medical Ethical Committees for human research of 
the Radboud university medical center, Nijmegen, the Netherlands and University of 
Essen, Germany. 
1. Preparation of single cell suspensions from human skin (Work sterile in a 
flow-cabinet if subsequent cell culture is required)
1.1. Prepare cell culture medium: RPMI 1640 + penicillin/streptomycin (final 
concentrations 100 units/ml and 100 mg/ml, respectively) + pyruvate (20 
mM) and glutamax (20 mM), with no serum added.
1.2. Prepare complete culture medium: culture medium prepared in step 1.1 + 
10% human pooled serum (HPS); store at 4˚C. Bring medium to 20˚C ± 2 
before using.
1.3. Obtain the skin biopsy using a 4mm round biopsy punch instrument and 
keep it in RPMI1640 complete culture medium at 20˚C ± 2 for upto 4 hours 
or at 4 ˚C over-night. Process the biopsy as soon as possible upon arrival 
in the laboratory. Longer storage of skin will influence the cell yield and cell 
viability.
1.4. Label a blue-capped dissociation tube and add 5 ml complete culture 
medium into the labelled tube.
1.5. Add 2 ml of complete culture medium into each well (in total 3 wells) of a 
sterile 6-well culture plate. Use sterile tools to place the biopsy into a single 
well, rinse, move it over to a second well and repeat this step one more 
time, thus achieving a total of three rinses. 
1.6. Transfer the well rinsed skin biopsy to a sterile petri dish, add 100 µl of 
complete culture medium on the top of biopsy, and carefully scrape off the 
subcutaneous fat tissue using a stainless steel disposable sterile scalpel. 
This is a critical step.
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1.7. Cut each skin biopsy into 4 smaller pieces on a sterile petri dish.
1.8. Transfer samples (upto four of 4 mm biopsies per tube) to the prepared 
dissociation tube containing 5 ml of complete culture medium.
1.9. Tightly close the tubes with the cap, and attach upside down to the sleeve 
of the automated tissue dissociator. Make sure that all sample material is 
located in the area of the rotor.
1.10. Start the dissociation process by running the “program m_spleen 
_01” (a pre-defined program provided by the instrument’s internal memory 
or by the accompanied program card) to dissociate the biopsy at the 
appropriate rotating speed for 56 seconds.
1.11. After processing, detach the dissociation tube from the dissociator and 
make sure that all the dissociated material is collected at the bottom of the 
tube.
1.12. Add 150 µl collagenase I-A (80 mg/ml) into the dissociation tube and 
incubate the sample in a shaking water bath at 37 ˚C for 60 min. Higher 
concentration of collagenase or longer incubation time will alter cell viability.
1.13. Add 100 µl of DNase I (5 MU/ml) into thedissociation tube, mix well.
1.14. Attach the dissociation tube to the sleeve of the automated tissue 
dissociator and run the “program m_ spleen _01” to dissociate the biopsy 
one more time.
1.15. Place a 70 mM nylon cell strainer on the top of a 50 ml Falcon tube. 
Apply dissociated sample materials to this cell strainer to remove cell 
clumps/tissue debris.
1.16. Wash cell strainer once with 5 ml of complete culture medium.
1.17. Centrifuge at 20 ˚ C ± 2, 450 x g for 10 min and aspirate supernatant.
1.18. Repeat the washing step one more time. 
1.19. Resuspend cell pellets in 300 ml of complete culture medium.
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1.20. Single-cell suspensions are ready for further analysis; continue with 
protocols for ex vivo cell culture or flow cytometry analysis. 
1.21. In case of further intracellular cytokine staining, please do firstly 
stimulate cells with PMA (12.5 ng/ml), Ionomycin (500 ng/ml) and Brefeldine 
A (5 µg/ml) for 4 hours at 37 ˚C, 5% CO2 incubator for 4 hours before 
performing flow cytometry analysis.
2. Polyclonal activation of skin-resident T-cells (ex vivo cell culture)
2.1. Aliquot 100 ml single-cell suspensions (prepared in step 1.19) into a round-
bottom 96-well plate. Note: For each of 4 mm skin biopsy, the acquired 
single-cell suspensions can be split into at least two wells of a 96-well plate.
2.2. Add anti-CD3/anti-CD28 mAb-coated microbeads (25000 beads per well), 
recombinant human cytokine rIL-2 (final concentration 25 U/ml) and rIL-1β 
(final concentration 50 ng/ml).
2.3. Cover the culture plate with a well-labelled plate lid, incubate in 5% CO2, 
100% humidity, 37 ˚C incubator.
2.4. Change medium when the medium colour turns to yellow. A clear cell colony 
can be observed from day 8 of cell culture.
3. Flow cytometry analysis of primary/cultured skin-resident T cells
3.1. Prepare FACS buffer: PBS + 0.2% BSA.
3.2. Transfer cells of interest into a v-bottom 96-well plate. 
3.3. Centrifuge at 20 ˚C ± 2, 450 x g for 2 min, and aspirate supernatant.
3.4. Resuspend the pellet in 100 ml of PBS. Centrifuge at 20 ˚C ± 2, 450 x g for 
2 min, and aspirate supernatant.
3.5. Stain cells with 100 µl of prepared eFluorescence780 conjugated fixable 
viability dye (1:1000 dilution using PBS) at 4 ˚C for 30 min.
3.6. Add 100 µl of FACS buffer, centrifuge at 20 ˚C ± 2, 450 x g for 2 min, and 
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aspirate supernatant.
3.7. Select required cell surface marker mAbs, for example: CD45-BV421 
(HI30, 1:20), CD3-ECD(UCHT1, 1:50), CD4-PC5.5(1388.2, 1:200), 
CD8-APC-AlexFluo700(B9.11, 1:400), CD14-FITC(TUK4, 1:50), CD19-
APC-AlexFluo750(13-119, 1:50), CD56-PE(MEM-188, 1:50), CD25-
PeCy7(BC96, 1:50), CD11c-PeCy7(BU15, 1:10), and CD1c-APC(AD5-
8E7, 1:10), prepare the mAbs-mixture using FACS buffer according to each 
mAb dilution factor tested. Isotype control of antibody together with non-
stain sample were used to define gate settings.
3.8. Add 25 µl of prepared mAbs-mixture into each well. Incubate 20 min at 20 
˚C ± 2,, protect from light.
3.9. Add 100 µl of FACS buffer, centrifuge at 20 ˚C ± 2, 450 x g for 2 min, and 
aspirate supernatant.
3.10. For samples that only require cell surface staining, continue with 
step 3.18. 
3.11. In case of intra-cellular Foxp3 staining: 
3.12. Prepare fixation and permeabilization buffer by mixing one part of 
concentrate with 3 parts of diluents. 
3.13. Prepare 1X permeabilization buffer: 1 part of 10X permeabilization 
buffer + 9 parts of sterilized H2O. 
3.14. Resuspend pellets in 100 µl of fixation and permeabilization buffer, 
mix well, and incubate at 4 ˚C for 30 min.
3.15. Add 100 µl permeabilization buffer to each well, centrifuge at 450 x 
g at RT for 2 min, and aspirate supernatant.
3.16. Wash cells with permeabilization buffer one more time.
3.17. Select required intracellular mAbs, for example, Foxp3-
eFluo450(PCH101, 1:50), IL-17A-AlexFluo488(eBio64DEC1, 1:50) 
and IFNγ-PeCy7(4S.B3, 1:400). Prepare the mAbs mixture using 
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permeabilization buffer containing 2% normal rat serum according to each 
mAb dilution factor tested. Isotype control of antibody together with non-
stain sample were used to define gate settings.
3.18. Add 20 ml of prepared mAb-mixture into each well. Incubate at 4 oC 
for 30 min, protect from light.
3.19. After 30 min incubation, add 100 ml of permeabilization buffer 
into each well. Centrifuge at 20 ˚C ± 2, 450 x g for 2 min, and aspirate 
supernatant.
3.20. Wash cells with permeabilization buffer one more time.
3.21. Resuspend pellet in 110 ml of FACS buffer, and transfer cell 
suspensions into microFACS tube.Sample is ready for measurement using 
10-colour Navios flow cytometry.
3.22.  In case of exact cell number required, please add 10 µl of well 
mixed uniform suspension of fluorospheres into each sample immediately 
before performing measurement on flow cytometry. 
Representative Results
The protocol presented here will yield between 2200 ± 615 (mean ± SD, skin of 
healthy volunteers) up to 178000 ± 760 (mean ± SEM, lesional skin of psoriasis 
patients) viable lymphocytes from human skin when using a single 4 mm skin biopsy. 
Different types of CD45+ cells were identified in single-cell suspensions derived from 
skin of healthy individuals including CD4+ T-cells (~ 45%), CD8+ T-cells (~ 30%), 
and CD11c+ DCs (~5%), whereas few B cells (CD19+), NK cells (CD56+CD3-), 
or monocytes/macrophages (CD14+ or CD1c+) were observed (Figure 1A). The 
methodology also allows for the analysis of CD4+CD25+Foxp3+  cells in human 
skin biopsies. By using intra-cellular staining after fixing and permeabilization, it 
is possible to demonstrate expression of the transcription factor Foxp3 in CD25+ 
T-cells (Figure 1A). 
Single-cell suspensions derived from human skin biopsies showed a high 
autofluorescence background in FL1 (FITC), FL2 (PE), FL3 (ECD), FL9 (pacific blue) 
and FL10 (chrome orange) channels using a cytometer (data not shown). For proper 
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analysis of the lymphocyte population, we therefore recommend the use of an anti-
human CD45 mAb conjugated with a Brilliant Violet 421 fluorochrome for gating of 
the lymphocyte population and exclusion of the autofluorescent cell population 
(Figure 1B). The majority of resident cells in human skin were CD3+ T cells (Figure 
1C). For cell viability analysis it is recommended to use a fixable viability dye to 
distinguish viable from dead/dying cells (Figure 1C). Typically this protocol results in 
65.3% ± 7.7 (Mean ± SD)viable cells. For further analysis of the flow cytometry data, 
it is advised to gate on the viable cell population, since dead or dying cells lose their 
cell membrane integrity, and can non-specifically bind conjugated antibody, thereby 
increasing background staining. 
T cells isolated by this protocol are well suited for further functional analysis. By 
using a single 4 mm biopsy of lesional skin of psoriasis patients,  it was shown that 
the biopsy derived T-cells produced IL-17A and IFNγ following 4 hours stimulation 
with PMA/ionomycin in the presence of Brefeldin A (Figure 2). 
Freshly prepared single-cell skin suspensions from involved psoriatic skin lesions 
can be used also for further ex vivo cell culture and subsequent functional analysis. 
Following expansion after polyclonal stimulation with anti-CD3/anti-CD28 mAb-
coated microbeads in the presence of the pro-inflammatory cytokines IL-1β or IL-23 
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Figure 1: Different types of leucocytes are identified in single-cell suspensions derived from skin of 
healthy individuals. Skin resident lymphocytes isolated using the protocol described in the text were 
stained with the fluorochrome-conjugated mAbs of interest plus fixable viability dye and immediately 
analysed by flow cytometry. (A) Flow cytometric detection of the monocytes (CD14), DCs (CD11c), 
B cells (CD19), NK cells(CD56+CD3-), CD4+, CD8+ and CD25+Foxp3+ subsets within skin resident 
lymphocytes. Anti-Human CD45/BV421 mAb distinguishes lymphocytes from autofluorescent cells. 
The gating strategies used for CD45+ cells was shown in (B). (C) Percentage of viable CD45+CD3+ T 
cells after isolation. Number shows the percentage of positive cells . A representative experiment out 
of three different experiments/donors is shown.
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for 8 days, the cells can e.g. be analysed for their cytokine producing capacity (Figure 
3). By doing so, a clear difference between the cytokine producing potential of cells 
derived from skin of healthy and psoriatic individuals was observed. T cells from 
psoriatic individuals showed a much higher capacity to produce the psoriasis 
associated cytokines IL17A and IFNγ. This implies that even after ex vivo culture a 
prototypic psoriasis cytokine phenotype is maintained, absent in case of healthy 
controls.
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Figure 2: T-cells derived from lesional skin of psoriasis patients can produce IL-17A and IFNγ. A single 
4 mm skin biopsy was taken from the lesional skin of psoriasis patient upon orally or written informed 
consent for scientific use. The skin resident T cells were isolated using the protocol described in the 
text. Production of IL-17A and IFNγ by skin resident T cells. Intracellular accumulation of cytokines in 
response to 4 hours stimulation with PMA/ionomycin in the presence of Brefeldin A was measured 
by flow cytometry. Percentage of cytokine-positive cells is shown. Data of three different patients are 
shown.
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Figure 3: Skin-resident T cells are capable to produce 
IL-17A and IFNγ following ex vivo polyclonal 
stimulation. Skin resident cells derived from a 4 mm 
skin biopsy of healthy or psoriasis patient were 
prepared using the protocol described in the text. 
Thereafter, cells were stimulated with anti-CD3/anti-
CD28 mAb-coated microbeads in the presence of 
either IL-1β(50 ng/ml, A) or IL-23 (50 ng/ml, B) for 8 
days. Next, the cells were stimulated for 4 hours with 
PMA/ionomycin in the presence of Brefeldin A and 
thereafter analyzed for intracellular cytokine 
production by flow cytometry. A representative 
example out of three independent experiments/
donors is shown.
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Discussion
Here, we present a protocol to efficiently isolate skin resident T cells from human skin 
biopsies. The advantage of this protocol is the isolation of relatively high numbers 
of viable lymphocytes, and expressing relevant surface markers. The cell subsets 
identified were: CD11c+ DCs, CD4+ and CD8+ T cells and Foxp3+CD25+ cells. 
Importantly, ex vivo culture of isolated skin resident T cells was very well feasible and 
allowed for subsequent functional analysis. 
Human skin can be dissociated into single-cell suspensions by combining mechanical 
dissociation with enzymatic degradation of the extracellular adhesion proteins which 
function to maintain the structural integrity of tissues. Although dispase based layer 
separation of the epidermis and dermis  is a widely used method to determine cell 
infiltration in these respective skin layers, we noticed that dispase treatment led to 
a major reduction of cell surface expression of the CD25 and CD27(not shown). As 
these markers are important to characterize lymphocyte subsets, we believe that 
dispase treatment influences subsequent immunophenotyping. It is not likely that the 
removal of the dermis is responsible for the observed  reduction in CD25 or CD27 
expressing cells, since in  skin of healthy individuals the majority of T cells is localized 
in the dermis while minute T cell numbers are present in the epidermis 10-12. The 
detrimental effect of dispase on the proliferation capacity of isolated keratinocytes 
has been reported previously13. Therefore, prudent use of dispase is warranted if 
cell function is aim of study. In our protocol we have been using Collagenase type I 
to obtain single cell suspension of skin biopsies. Although Collagenase I  has high 
tryptic activity over Collagenase IV and thus is more harsh, we have chosen this 
particular Collagenase because it has been tested for  its suitability for cell culture. 
The use of a Collagenase IV that is suitable for cell culture might be a future step to 
further optimize our current protocol.
Due to its nature, the skin is highly resistant to tensile forces and mechanical 
disaggregation. So far, a comprehensive analysis of immune cells in human skin 
has been hampered by technical challenges in obtaining enough cell numbers when 
using relatively harsh digestion protocols. As a consequence, most studies published 
to date rely on immunohistochemical analyses. The direct isolation of CD4+ T cells 
from skin biopsies is generally considered cumbersome. An alternative would be the 
use of skin explant crawl out cultures10. However, these take 2-3 weeks of culture, 
and the skin explant culture medium contains a set selected of cytokines and 
chemokines, which might lead to preferential crawling out of specific T cell subsets. 
In addition the culture period might affect the phenotype of the cells. The current 
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protocol does not make use of added cytokines or chemokines, and expression of 
CD4 (and also other cell markers) is well preserved after the isolation, enabling both 
phenotypic and functional study of T cell populations directly after isolation. 
A commercially available automated tissue dissociator is used for the dissociation of 
skin fragments before their incubation with collagenase, required for the degradation 
the extracellular matrix. For the subsequent release of the cells from the extracellular 
matrix, the automated dissociator is used again. Although extensive manual 
cutting of skin can yield similar cell numbers (data not shown), the results are less 
consistent and are more dependent on the performer’s experience. Dissociation of 
skin using the pre-defined procedure offered by the instrument will yield much more 
reproducible results. Consistent with previous studies showing that skin contains 
various leukocytes subsets2,14, CD11c+ DCs, CD8+ and CD4+ T cells, and Foxp3+ 
cells were observed in single-cell populations prepared by the protocol presented 
here. Importantly, the protocol yields a relatively high yield of viable lymphocytes. Due 
to the efficiency of the protocol, it particularly useful when studying patient material, 
where often only a single 4 mm skin biopsy can be obtained. Using the method, we 
were able to show that T cells isolated from the lesional skin of psoriasis patients 
showed a higher capacity to produce IL-17A and IFNγ as compared to healthy skin9. 
Depending on the research question, it may be necessary to further purify certain 
cell subsets after the preparation of single cell suspensions. In this case, larger 
pieces of skin can be used to ensure the yield of sufficient cells for subset analyses. 
When doing so, make sure that the skin should be cut into smaller pieces of around 
2 mm x 2 mm before starting the isolation protocol. 
In conclusion, the present protocol offers an improved way to isolate skin resident 
cells, facilitating meaningful phenotypic and functional analysis on a single cell level, 
thereby improving our insight in skin immune responses. 
Critical steps in the current protocol are the proper removal of subcutaneous fat 
tissue and the cutting of skin into smaller pieces, especially when processing more 
than one biopsy in a dissociation tube. Fat tissue and/or large tissue pieces will 
cause the dissociator to work improperly, asking for re-runs. This will seriously harm 
cell viability. The limitation of the techinique is that cell numbers derived from a single 
4mm skin biopsy are not enough for subsequent isolation of subsets of cells.
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Induction of immunologic tolerance is essential for successful treatment of autoimmune 
diseases, solid organ and hematopoietic stem cell transplantation. Current strategies 
to induce immune tolerance include the usage of immunosuppressive drugs (ISDs) 
which cause functional deletion or inhibition of effector T cells and cell-based 
immunotherapy (1, 2). The backbone of ISDs treatment in solid organ transplantation 
remains calcineurin inhibitors mostly in association with short-time steroid treatment 
plus MMF or rapamycin (3). The drug-related toxicities and side effects have limited 
their clinical usage. The general strategy using a combination of synergistic ISDs (at 
lower dosages of the individual drugs) to maximize efficacy while minimizing toxicity, 
has resulted in a low rate of acute allograft rejection. In spite of the success of this 
strategy in acute allograft rejection, combination therapy does not adequately prevent 
chronic allograft rejection, one of the major causes of graft loss. The alternative 
option is to harness the regulation of the immune system thus controlling the effector 
immune responses. Ample immune cells, including CD4+FOXP3+ Treg, regulatory 
B-cells, tolerogenic DCs and MSCs, possess regulatory capacity that can promote 
tolerance induction. The underlying rational for using cell-based immunotherapy 
is to tip the balance from predominant pro-inflammatory cells towards a more 
balanced immune cell population enriched of regulatory cells thus promoting the 
immune homeostasis. One of the most studied regulatory cells are Treg.However, a 
number of fundamental questions need to be answered to optimize the application 
of Treg-based forms of therapy in human patients, considering the low frequency of 
circulating Treg and the functional plasticity of Treg. The aim of this thesis was to 
obtain more insight into T cell activation pathways and to unravel the molecular cues 
involved in optimal Treg expansion, while preserving a stable Treg phenotype and 
facilitating their clinical application.
We begin the study from exploring the molecular pathways that involved in the 
activation of human CD4+ T cells (chapter 2). Depending on distinct signals that 
cells have received, naïve CD4+ T cells may differentiate into Th1, Th2, Th17 or 
iTreg subsets. We used comprehensive transcriptome analyses of Jurkat T cells 
and purified human CD4+ T cells, which were stimulated with various stimuli in the 
presence of distinct pathway inhibitors, to identify genes and pathways involved 
in the differentiation towards Th1 and Th2 subtypes. We found that PMA/CD3 
stimulation enhanced a Th1-like response in a Lck and PKCθ dependent fashion, 
whereas PMA/CD28 stimulation, which induced neither calcium influx nor activation 
of NFAT, resulted in a Th2-like phenotype independent of the proximal TCR-tyrosine 
kinase Lck. Our finding that a PKCθ inhibitor blocked the PMA/CD28-induced Th2-
like gene expression profile, suggests that CD28 signalling is functionally linked with 
the PKCθ/NFκB pathway. This result is in line with the report that CD28 stimulation 
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triggers the intracellular activation of NFκB via PKCθ/CARMA-1/Bcl10 (4). Additional 
data derived from mice studies revealed that inhibition of NFκB activation prevented 
GATA-3 expression and Th2 cytokine production in developing Th2 cells (5), and 
that Th2-mediated inflammation is more PKCθ dependent as compared to Th1-
mediated inflammation (6). Interestingly, we found that PMA/CD3 stimulation 
significantly enhanced IL-17 production when compared to PMA/CD28 stimulation. 
This observation is in agreement with the previous report that IL-17 expression 
was dependent on signalling via the Itk kinase, a component of the TCR signalling 
pathway (7). This data reveals that not only various cytokines including IL-1β, IL-6 (8), 
and TGFβ/IL-2 (9, 10), but also TCR ligation (11) contributes to Th17 development 
at certain stages of human T cell differentiation. Many evidences point out that Treg 
are not a stable cell subset that could lose the suppressor functions and show IL-
17 producing potential, which is dangerous for the clinical therapy of autoimmune 
diseases and transplant patients. It would be very interesting to distinguish the effect 
of TCR/CD3 and PMA/CD28 stimulation on the Treg plasticity. We speculate that it is 
possible to manipulate T cell differentiation and Treg stability by selective targeting of 
the signals downstream of signal 1 (TCR) and signal 2 (CD28 costimulation). 
A growing body of evidences indicates that the ability of T cells to proliferate, activate 
or die isc ontrolled by their ability to take up nutrients and to regulate the energy 
metabolisms. Inhibition of the biosynthesis of guanine nucleotides (GTP and dGTP) 
by the immunosuppressant MMF and its active ingredient MPA is thought to be the 
main mechanism underlying the inhibition of T cell proliferation in vitro and in vivo. 
However, MMF inhibited T cell proliferation without lowering intracellular levels of 
dGTP and GTP in kidney transplant patients (12). Moreover, the positive effect of 
MMF-based therapy on circulating Treg was reported in liver transplant recipients 
(13). In chapter 3, we present a novel insight into the mechanisms underlying MPA-
associated suppression of human CD4+ T cells. By using human CD4+CD25- T cells 
that were stimulated with anti-CD3/anti-CD28, we showed that MPA did not affect 
the expression of CD25 and cytokine IL-2 production, nor did it affect early T cell 
apoptosis. Although MPA was reported to induce cell apoptosis in several cell lines 
(14, 15) and in an in vivo mouse model (16), it would infer from our findings that the 
induction of apoptosis by MPA is limited to specific cell types. Signaling via IL-2 in 
general increases STAT5 phosphorylation, which is an important step in controlling 
cell proliferation and survival (17). Interestingly, MPA treatment dramatically reduced 
STAT5 phosphorylation, without affecting the expression of CD25 and the levels 
of IL-2. Thus, it seems that in the presence of MPA, cells are unresponsive to IL-2 
signalling, thereby preserving a hyporesponsive state.
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Phenotypic analysis showed that MPA enhanced the expression of PD1, CTLA-4, 
CD70 and FOXP3, whereas CD25 expression was unaffected. The unique feature 
of MPA-induced CD70 expression on T cells may qualify as a pharmacodynamic 
biomarker, since it was not shared by other immunosuppressants like rapamycin or 
cyclosporine. CD70 is a DNA-methylation sensitive T cell gene (18). Combination 
of MPA and 5-Aza, a DNA methyltransferases (DNMTs) inhibitor, synergistically 
increased CD70 expression, suggesting MPA affects DNMTs activities directly 
or indirectly. Furthermore, we found that the addition of exogenous guanosine 
completely reversed MPA-enhanced CD70 expression. This indicates that reduction 
of GTP levels in T cells through IMPDH inhibition by MPA may thus affect the DNMTs 
enzyme activity, thereby enhancing the expression of CD70. Moreover, we found 
that MPA-induced CD70 expression on T cells was indeed functional. First, we 
observed that MPA-treated hyperblastoid cells had higher metabolic capacity and 
the expression of CD70 was correlated to hyperblasticity of cells. Second, ligation of 
CD70 restored the Akt/mTOR pathway and the phosphorylation of STAT5, particularly 
in the memory CD4+ T cell subset. Third, ligation of CD70 protected MPA-treated 
T-cells from cell apoptosis. In summary, our studies in chapter 3 revealed that the 
mechanisms of action underlying MPA-mediated immunosuppression of CD4+ T 
cells are multifaceted. Besides depletion of intracellular guanine nucleotides, MPA 
treatment downregulates the production of pro-inflammatory cytokines, induces 
the expression of negative co-stimulators and intrinsically modifies intracellular 
signalling events by suppressing the Akt/mTOR and STAT5 pathways. MPA thus 
modulates transcriptional activities relevant to metabolism and survival, leading to a 
T cell hyporesponsive state. Importantly, our data suggest that MPA treatment does 
not lead to irreversible effects on immune function and that optimal dosing of MPA 
may minimally impact homeostatic mechanisms and thereby maintain immunological 
balance (13). 
As we revealed in chapter 2 that the gene profile induced by PMA/CD28 is clearly 
distinct from the profile induced by CD3/CD28 stimulation of T cells, we undertook 
to study if a similar mechanism would apply to Treg. Treg constitutively express the 
CD28 costimulatory receptor, and previous studies show that CD28 is required for the 
thymic development of Foxp3+ Treg as CD28 or CD28-ligand deficient mice reveal 
severely reduced numbers of naturally occurring Treg and hence develop severe 
autoimmunity (19, 20). In addition, recent insights obtained from Treg-specific CD28 
conditional knockout mice supports the notion that CD28 stimulation also plays an 
important role in the proliferation and survival of peripheral Treg. Moreover, these 
animals develop severe autoimmunity, which can be prevented by supplementation 
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with CD28 sufficient Treg (21). These information have led us to hypothesize that CD28 
stimulation alone may be utilised to drive a stable expansion of human Treg in vitro. 
Within our expectation, single-CD28 stimulation of human circulating Treg, together 
with exogenously added rhIL-2 but in the absence of TCR/CD3 ligation, results in 
polyclonal expansion and preservation of a stable Treg phenotype and function as 
indicated by high FOXP3 expression, hyper demethylation of TSDR and profound 
suppressor function (chapter 4). Moreover, single-CD28 mediated stimulation of 
Treg, in contrast to anti-CD3+CD28 stimulation, results in increased Treg stability as 
indicated by the decreased potential to produce IL-17A and the inability to produce 
IFNγ. However, the expansion of Treg stimulated with conventional CD28-agonistic 
mAb and rhIL-2 lagged behind. To improve this aspect, we stimulated Treg with 
the commercial available CD28-superagonist (CD28 SA) mAb ANC28.1, a strong 
inducer of human conventional T cell proliferation (22). Indeed, stimulation with 
the CD28 SA mAb in the presence of exogenously added rhIL-2 results in superior 
polyclonal expansion of the Treg population, and the expanded Treg reveal high 
and stable FOXP3 expression, limited pro-inflammatory cytokine production, and 
profound suppressor capacity. It is interesting to point out that previously it has 
been reported that FACS-sorted high purity human Treg do not respond to ANC28.1 
stimulation when tested after 3 days of culture (22). Generally, it is known that highly 
pure, sorted Treg require more time as well as supplementation with exogenous 
rhIL-2 to enter cell division. In fact, we here demonstrate that prolonged (7 days) 
stimulation of high purity sorted Treg by a CD28 SA in the presence of exogenously 
added rhIL-2 results in vigorous proliferation of both naïve and memory FOXP3+ 
Treg cells. Mechanistically, we show that phosphoinositide3-kinase (PI3K) is needed 
for the stable FOXP3 expression of these CD28-expanded human peripheral Treg. 
Our results are in concert with the knowledge that CD28 activation enhances PI3K 
activity (23) and the PI3K/Akt/mTOR signal pathway is involved in regulation of 
Foxp3 expression (24).
Human FOXP3+ cells are known to be phenotypically and functionally heterogeneous. 
The stable and high FOXP3 expression is required for Treg suppressive function, and 
loss of FOXP3 during the cell cultures impairs their suppressive capacity, so called as 
exTreg (25). The difference between exTreg or non-regulatory CD45RO+FOXP3low 
T cells and suppressive FOXP3+ Treg is linked to the methylation status of the 
FOXP3 gene, which is completely demethylated in the bona fide Treg subset (26). 
Furthermore, human Treg could convert to pro-inflammatory cytokine (IL-17A and 
IFNγ) producing cells under certain cues dictated by IL-1β, IL-6 and IL-23 (27-29). 
Therefore, successful Treg-based immunotherapy not only depends on how efficient 
Treg are expanded but also how cells are well maintained as a stable functional 
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Treg population during their in vitro expansion. In chapter 4, we demonstrate that, 
CD28-superagonist might be a promising new avenue for the generation of stable 
polyclonal Treg intended for Treg-based immunotherapy. But CD28 is constitutively 
expressed on both Treg and non-Treg cells. CD28 superagonist will lead to the 
over growth of the left-over non-Treg cells, especially considering that the current 
techniques that applied for clinical grade isolation of Treg normally lead to a low 
purity of Treg. One possible solution for this dilemma is to include mTOR inhibitor 
rapamycin in the Treg culture mixture. We and others have shown that rapamycin 
allows for in vitro expansion of murine and human CD4+CD25+FOXP3+ Treg. It 
maintains Treg suppressor function, as well as promotes Treg de novo generation 
(30-32). Treg are less sensitive to rapamycin-mediated inhibition of cell proliferation 
(33). Furthermore, we realize that the demethylation of TSDR stimulation is not 
enhanced significantly following the stimulation with CD28 superagonist. Therfore, it 
is unclear whether the resultant Treg cell product is capable to preserve the potent 
suppressor function after the infusion into patients who generally possess a pro-
inflammatory environment, a condition known to drive Treg plasticity. It is worthwhile 
to perform further experiments to test the stability of these expanded Treg in vitro 
and in vivo. Recently, it is reported that Treg-expressed CD28 is important for the 
induction of CCR6 expression that is required for the skin homing (34). Exploring the 
expression pattern of chemokine receptors like CXCR3, CCR4, CCR6 and CCR7 on 
CD28-superagonist expanded Treg will also be very interesting to know more about 
their tissue distributions in vivo.
Although the transient expression of FOXP3 does occur in activated human non-
Treg cells, stable and high expression of FOXP3 is clearly a prerequisite for the 
maintenance of Treg suppressor function (25). Active transcription of the FOXP3 gene 
requires TCR signals, co-stimulatory molecules and cytokine receptors. The duration 
and strength of the TCR signals are crucial determinants of FOXP3 expression, as 
suboptimal TCR stimulation results in more efficient induction of Treg than strong TCR 
activation both in vitro and in vivo (35) and the inhibition of mTOR using rapamycin 
induces FOXP3 expression (36). In addition to TCR ligation, specific co-stimulatory 
signals are essential for FOXP3 expression in natural occurring and induced Treg 
cells. Treg constitutively express CD28 and other co-stimulatory molecules like 
CD27, GITR, ICOS, OX40, 4-1BB and TNFR2 (37-40). We have explored the effect 
of single-CD28 stimulation on Treg ex vivo expansion and Treg stability in chapter 4, 
and noticed that, in the absence of CD3, CD28 stimulation led to a reduced plasticity 
of Treg in vitro thus preserving the suppressor function. Another interesting co-
stimulatory molecule is TNFR2, the type II receptor for tumour necrosis factor alpha 
(TNFα). In contrast to TNFR1, TNFR2 is restricted to lymphocytes and mainly binds 
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membrane bound TNFα instead of soluble TNFα (41). The binding of TNFα to TNFR2 
provides costimulatory signals to T cells that enhance T cell proliferation (42, 43) and 
cell survival (44). Recent studies have shown that both murine and human Treg 
express TNFR2, and TNFR2+ Treg are maximally suppressive (39, 45). Additionally, 
surface expression of TNFR2 appears to positively correlate with CD25 and FOXP3 
expression in human Treg (46). The fact that TNFR2-agonist drives human Treg 
into a homogeneous population with potent suppressive capacity (40), indicates 
that TNFR2 is a valuable target for facilitating ex vivo expansion of human Treg. 
By using a specific TNFR2-agonist, we show, in chapter 5, that expansion of low 
purity MACS-isolated human Treg in the presence of TNFR2-agonist and rapamycin 
results in a stable homogenous FOXP3+, Helios+, HLA-DRhi and CD127low Treg 
population. Such expanded Treg reveal profound suppressor potential in vitro and 
in vivo in a preclinical humanized mouse model. Clinical usage of Treg is hampered 
by the paucity of Treg numbers. Current protocols used for Treg ex vivo expansion 
commonly use anti-CD3 and anti-CD28 mAbs in the presence of rhIL-2 together 
with or without rapamycin (30, 47-52). One of the reasons for using rapamycin is to 
inhibit potential contaminating Tconv in the isolated Treg population, while allowing 
preferential enrichment of Treg upon stimulation. Although Treg are less sensitive 
to mTOR inhibition by rapamycin as compared to Tconv (33), rapamycin-mediated 
inhibition of Treg proliferation has been reported (40, 53), which can be explained 
by the fact that Treg proliferation over time requires increased mTOR activity (54). In 
our studies, we also noticed that rapamycin inhibited Treg proliferation. Interestingly, 
combination usage of TNFR2-agonist and rapamycin significantly enhances Treg 
cell expansion fold as compared to rapamycin or TNFR2-agonist only. Importantly, 
these TNFR2-agonist plus rapamycin expanded Treg are even more suppressive for 
inhibition of proliferation of responder T cells than Treg expanded in the presence 
of rapamycin only. The significant increase of TSDR demethylation is only observed 
in TNFR2-agonist plus rapamycin expanded cells but not in case of rapamycin or 
the TNFR2-agonist only group. We hypothesize that such expanded Treg should be 
very stable upon a secondary stimulation. In vitro re-stimulation of TNFR2-agonist 
plus rapamycin expanded Treg makes cells insensitive to the destabilizing activity 
of IL-1β or IL-23, confirming our hypothesis of a firm preservation of Treg stability. 
We speculate that FOXP3 gene demethylation status might predict Treg phenotypic 
plasticity and functional stability, although further experiments are required to 
confirm if this holds true after their transfer to the in vivo environment. To test the 
stability of in vitro expanded Treg in vivo, we used a preclinical humanized mouse 
model designed to study human skin inflammation (55). Indeed, infusion of TNFR2-
agonist plus rapamycin in vitro expanded Treg suppressed skin inflammation in 
this humanized mice model. Altogether, these results suggest that combined use 
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of TNFR2-agonist and rapamycin not only optimize Treg proliferation rates but also 
maintains Treg stability and preserves their suppressive function.
As described in the previous section, in the laboratory, a combination of the CD4+, 
CD25high, and CD127low markers is used to FACS-sort high purity Treg. However, 
clinical grade Treg flow-sorting is restricted to only a few clinical centres worldwide. 
In contrast, magnetic bead isolation of CD4+CD25+ Treg using a GMP compliant 
closed system such as CliniMACS that results in low purity of Treg (47), can be more 
generally used. High purity Treg input is required for ex vivo expansion protocols as low 
purity Treg input will allow for an outgrowth of the contaminated non-Treg population 
in the commonly used anti-CD3/CD28/rhIL-2 expansion protocols. Interestingly, 
we found that irrespective of the purity of Treg input population, the resultant Treg 
expanded in the presence of TNFR2-agonist and rapamycin similarly express 
FOXP3 and Helios, and show a CD127low and HLA-DRhigh phenotype, which are all 
associated with the highly suppressive capacity of Treg (56-58). These data support 
the potential utility of the combined TNFR2-agonist and rapamycin approach for the 
ex vivo expansion of clinical grade low purity Treg. Of note, TNFR2-agonist plus 
rapamycin expanded Treg show a decreased expression of CCR6, a molecular that 
highly expressed on human Th17 cells (59), when compared to cells expanded in the 
absence of these reagents. However, CCR6 is also important for mediating Treg to 
migrate to the nonlymphoid tissues like skin and other inflammatory sites (60). It will 
be very interesting to further explore the tissue distributions of TNFR2-agonist plus 
rapamycin expanded Treg in vivo. Interestingly, it is shown that murine Treg specific 
deficient of CD28 impairs the induction of CCR6 and their trafficking to the skin (34). 
Unfortunately, we do not explore how CD28 stimulation affects the expression of 
CCR6 in human Treg although we do show that CD28 stimulation preserves Treg 
suppressor function (chapter 4). Assume that there is a similar effect between mans 
and mice that CD28 signals is important for the induction of CCR6 expression on 
Treg, it is then very interesting to notice that TNFR2-agonist preventing activated 
Treg to express CCR6 (chapter 5), because CD28 and TNFR2 share the same 
main downstream target NFκB. It seems that other mechanisms other than NFκB 
are involved in the regulation of CCR6 induction on Treg cells.
Treg exert their function in secondary lymphoid tissues as well as in the periphery. 
Recently, we demonstrated that the majority of Treg in healthy human secondary 
lymphoid organs are activated, produce cytokines and proliferate, which is in contrast 
to the resting phenotype of peripheral blood and bone marrow Treg (61). Similarly, 
Treg localized in human skin have an activated memory phenotype, and in inflamed 
skin from psoriasis patients Treg produce the disease associated cytokine IL-17 
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(62). The balance between Treg and Th17 cells is an important regulator of psoriasis 
severity. Evidence also shows that Treg isolated from the blood and lesional skin 
demonstrate an impaired suppressor function (63), rapidly lose FOXP3 expression 
and easily gain expression of IL-17A in in vitro cultures (64), indicating that Treg in 
psoriasis patients are unstable. The question of how to maintain human Treg stability 
under in vivo inflammatory conditions is therefore of prime importance and the 
search for pharmaceutical agents that may realize such a feat has only just started. 
The recent proof-of-concept clinical study in psoriasis patients suggests that oral 
administration of the PKC inhibitor sotrastaurin might be a novel treatment option in 
psoriasis (65). Together with the knowledge that localization of PKCθ in the immune 
synapse of Tconv and Treg is different (66, 67), we hypothesized that targeting 
PKC using a pharmacological agent might modulate the balance between Treg and 
Tconv, thereby restoring immune tolerance. To test this hypothesis, in chapter 6, 
we explored the effect of sotrastaurin on human circulating as well as skin-localized 
Treg and Tconv cell subsets derived from healthy volunteers and psoriasis patients. 
We found that in vitro treatment with sotrastaurin prevents circulating Treg of both 
psoriasis patients and healthy controls from producing IFNγ and IL-17A, even in the 
presence of the IL-17-driving cytokine IL-1β. In addition, Treg that were cultured 
in the presence of sotrastaurin efficiently suppressed the proliferation of Tconv, 
indicating that the drug may act to maintain suppressor function. Moreover, also in 
dermal T cells from lesional psoriatic skin, sotrastaurin preserved FOXP3 expression 
and inhibited pro-inflammatory IL-17A and IFNγ production upon stimulation, 
features that may underlie the clinical effects observed after drug treatment (68). 
Our findings are in line with the literature reporting that the PKCθ-specific inhibitor 
C20 increases the suppressor activity of human Treg (69). Therefore, therapeutic 
strategies designed to inhibit PKC in T cells may hold promise for the treatment of 
autoimmune conditions.
Further, we showed that cells stimulated with PMA/CD28 were more sensitive to 
sotrastaurin than those stimulated using CD3/CD28. Some of this can be explained 
likely by our previous finding that PMA/CD28-induced T-cell stimulation is highly 
dependent on the PKCθ pathway, whereas CD3-mediated pathways are dependent 
on both the Lck and PKCθ signal transduction pathways (chapter 2). The mechanism 
by which PKC affects Treg fate and function is largely unclear. In Tconv, PKCθ 
is recruited to the immune synapse with the specific purpose of destabilizing the 
synapse as an essential step in the dynamics of T cell activation (66). In contrast, 
mouse studies revealed that, in Treg, the PKC/CARMA/NFkB complex was found 
to localize outside the immune synapse (67). Such a difference between Tconv and 
Treg implies that inhibition of PKC mediates differential effects in Tconv and Treg 
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and that PKC-mediated activation of NFκB/AP-1 is beneficial during Treg activation, 
whereas inhibition of the NFκB/AP-1 mediated inflammatory pathway is detrimental 
for effector function. The fact that the mTOR inhibitor rapamycin is also able to 
stabilize Treg suggests that multiple pathways are likely involved in the preservation 
of Treg stability. The studies performed in chapter 6 provide evidences for the role of 
PKC in the balance of Treg and Th17 differentiation and show that this mechanism 
also holds true for both circulating and skin-derived T cells from psoriasis patients. 
Pharmacological inhibition of PKC may thus add to strategies for Treg facilitation in 
the treatment of autoimmune-related disorders, such as psoriasis.
The skin is the largest organ of the body and often houses many immune cells 
including memory T cells and Treg (70). A good quality single cell population 
isolated from biopsied skin samples is crucial to study peripheral immune regulatory 
mechanisms, because it is known that immune cells localized in the skin conduct 
immunosurveillance and play an important role in the development of skin disorders 
(71). Due to its nature, the skin is highly resistant to tensile forces and mechanical 
disaggregation. So far, isolation procedures have been seriously hampered by 
the lack of obtaining sufficient numbers of viable cells. Isolation and subsequent 
analysis have also been affected by the loss of immune cell lineage markers, due to 
the mechanical and chemical stress caused by the currently available dissociation 
procedures to obtain single cell suspensions. We used a modified isolation protocol 
to isolate skin-resident lymphocytes from human skin. The method that enables 
the isolation of leucocytes from both healthy and lesional psoriatic human skin 
by combining mechanical skin dissociation using an automated tissue dissociator 
and collagenase treatment is described step by step in chapter 7. This protocol 
has the advantage of isolating relatively high numbers of viable lymphocytes while 
maintaining adequate expression of phenotypic surface markers. The resultant cells 
are suitable for ex vivo cell cultures and analysis directly using the flow cytometry. 
Concluding remarks and future plans
The ultimate goal for immunosppressive therapy in the clinic is to achieve immune 
tolerance/homeostasis while avoiding the need for life time span usage of deleterious, 
non-selective immunosuppressant drugs. Regulatory T cells are an optimal 
candidate for such an approach. Currently, one of the main issues for the successful 
application of Treg-based cell therapy is to address the stability of Treg during and 
after ex vivo expansion and following their transfer into patients. In this thesis, we 
show that current expansion protocols can be improved by the addition of strong 
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CD28 and/or TNFR2 signalling moieties. Single-CD28 stimulation results in vigorous 
proliferation of human Treg (chapter 4), which reveal high FOXP3 expression, 
limited pro-inflammatory cytokine producing potential and profound suppressor 
capacity. Treg expanded in the presence of TNFR2-agonist plus rapamycin remain 
stable and strongly suppressive and the presence of these two agents also allows 
the usage of the MACS-isolated low purity, but more easily obtainable Treg being the 
start population (chapter 5). 
It is clear that the balance of signals through TCR, CD28, mTOR as well as metabolic 
cues determines Treg differentiation and homeostasis. Tconv use the glycolytic 
metabolism while Treg preferentially use the lipid oxidation (72). Selective in vivo 
inhibition of metabolic processes (by agents such as rapamycin or MMF) may provide 
an effective means of inducing immune tolerance. The ideal immunosuppressive 
drugs should inhibit aggressive T cells and at the same time preserve or potentiate 
Treg. The pharmacological inhibition of PKC may serve as such a powerful tool since 
we found that sotrastaurin concurrently inhibits Teff and facilitates Treg (chapter 
6), as confirmed by its therapeutic potential for the treatment of psoriasis. Another 
potential candidate might be MMF as it is known that renal transplant patient 
receiving MMF showed significantly higher CD4+CD25hiFOXP3+ Treg compared to 
patients on other treatments. In vitro MPA treated human CD4+ T cells were anergic 
but possessed a high metabolic activity, and the expression of FOXP3 and CD70 
were enhanced (chapter 3). Interestingly, we did not observe the MPA-mediated 
enhancement of CD70 on human Treg. Within our expectation, neither CD25 nor 
FOXP3 expression was affected following MPA treatment (our unpublished data). 
But further experiments are needed to test whether MPA treatment affects the 
sensitivity of effector T cells to Treg-mediated suppression. 
Future studies should focus on further optimizing these protocols by combining the 
CD28 superagonist mAb, TNFR2-agonist mAb, rapamycin and cytokine rhIL-2 to 
maximize the proliferation while preserving the stability and suppressor capacity. 
Since the isolated Treg at GMP level in general are less pure, such approaches 
would be clinically feasible and would further enhance the efficacy of Treg therapy. 
Another interesting improvement would be to alter the time point for the addition of 
rapamycin in the existing protocols. Recently, mTOR was reported to play a dual role 
during Treg proliferation: where mTOR activation (high metabolic rate) determines 
Treg hyporesponsiveness but the activation of mTOR is also required for Treg 
expansion at later time points (54). Therefore, it will be of interest to test rapamycin 
pretreatment of Treg and removal thereafter instead of the current protocols where 
Treg are expanded in the presence of rapamycin and rhIL-2 during the whole culture 
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period. 
In conclusion, this thesis describes our mission to explore novel ways to preserve 
a stable Treg phenotype/function, optimize the ex vivo expansion protocols for 
maximizing the proliferation of potent Treg, and unravel the mechanism underlying 
immunosuppressive agents that are used in the clinic. The knowledge obtained 
revealed molecular pathways for selective targeting will add to optimising Treg based 
forms of therapy for future clinical utility.
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Regulatoire T-cellen (Treg) zijn cruciaal voor de inductie en het in stand houden 
van immunologische tolerantie. Deze kennis wordt momenteel benut voor de 
ontwikkeling van nieuwe therapeutische behandelingen. Hierbij staat de infusie 
van grote aantallen ex vivo geëxpandeerde en zeer suppressieve Treg centraal. 
In preklinische transplantatie- en auto-immuniteit muismodellen is Treg gebaseerde 
immuuntherapie al succesvol gebleken. Er zijn al rapportages over klinische 
toepassingen om met Treg Graft versus Host ziekte bij stamceltransplantatie tegen 
te gaan en Diabetes Type 1 te behandelen. Onlangs is de ONE studie gestart, een 
multi-center Fase I / IIa klinische trial om de veiligheid en productiemogelijkheden 
van zeven verschillende regulerende celpopulaties, waaronder FOXP3+ Treg, te 
testen in levende nier- en levertransplantaties. De perifere bloed Treg populatie, 
die de basis van Treg therapie vormt, kent zowel heterogeniteit als plasticiteit en 
bevat naast stabiele en reeds gespecialiseerde, tevens nog niet stabiele en niet 
gespecialiseerde FOXP3+ cellen. Dit gegeven vormt de basis voor dit proefschrift. Het 
doel is humane Treg stabiliteit te borgen na ex vivo expansie met als doel, na in vivo 
infusie, te zorgen voor een veilige en effectieve Treg-gebaseerde immuuntherapie.
De reeds gespecialiseerde stabiele FOXP3+ Treg populatie onderscheidt zich door 
een uniek hoog expressie niveau van FOXP3 en een sterk gedemethyleerde FOXP3 
promotor regio. Uit eerder onderzoek blijkt ook dat een kleine populatie binnen 
deze Treg een hogere plasticitiet vertoont dan eerder aangenomen werd. Hierdoor 
gaat het stabiele fenotype verloren wat tevens gepaard gaat met epigenetische 
veranderingen. Dit is van belang omdat de isolaties voor klinische toepassingen 
van Treg met GMP systemen zoals CliniMACS®, meestal resulteren in minder 
zuivere Treg populaties met daarbij een hoger risico op een dergelijk verlies van 
fenotype en functie na expansie. Daarom geldt succesvolle ex vivo expansie van 
een stabiele Treg populatie in voldoende hoge aantallen nog steeds als een van de 
belangrijkste uitdagingen om volledige klinische toepasbaarheid te bereiken. Het 
standaard Treg expansie protocol met behulp van anti-CD3 en anti-CD28 mAbs in 
combinatie met rhIL-2 kan leiden tot Treg instabiliteit. Toevoeging van rapamycine 
aan dergelijke culturen voorkomt de groei van ongewenste niet-Treg cellen, 
maar schaadt tegelijkertijd de Treg proliferatie zelf ook. Een beter begrip van de 
moleculaire mechanismen betrokken bij T-cel activatie zal helpen een optimaal Treg 
expansie protocol te ontwerpen met voldoende aantallen zeer supressieve Treg 
cellen als resultaat. Hiervoor hebben we  we het systeem van signaaloverdracht 
in T-cellen verder in kaart gebracht en het belang van CD3 versus CD28 stimulatie 
bepaalt (hoofdstuk 2). PMA/CD3 stimulatie verbeterde de Th1- en Th17-achtige 
respons, terwijl PMA/CD28 stimulatie resulteerde in een Th2-fenotype op een 
PKCθ-afhankelijke, maar Lck-onafhankelijke wijze. Experimentele resultaten lieten 
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zien dat PMA/CD28 stimulatie resulteerde in een lagere IL-17 productie in humane 
T-cellen in vergelijking met PMA/CD3 stimulatie. Uit de literatuur blijkt dat CD28 een 
cel-intrinsieke rol speelt in Treg suppressor functie. Gebaseerd op deze gegevens 
beschrijven we in hoofdstuk 4 dat verhoogde activatie na CD28 stimulatie, in 
afwezigheid van TCR/CD3 liganden, resulteert in een sterke en efficiënte toename 
van stabiele ex vivo geëxpandeerde humane Treg. Dit bevestigt het belang van 
gebruik van een CD28 superagonist in het Treg expansie protocol voor Treg-
gebaseerde immuuntherapie. Gezien de veelheid aan co-stimulerende moleculen 
en het feit dat de combinatie van de tumor necrose factor receptor 2 (TNFR2) en 
CD25 zeer suppressieve Treg in humaan perifeer bloed identificeert, hebben we 
ook andere manieren voor Treg expansie onderzocht. Het protocol met toevoeging 
van de TNFR2-agonist, beschreven in hoofdstuk 5, leidde tot een efficiënte Treg 
expansie met een krachtige suppressieve functie en een verminderde IFNy en IL-
17A productie. Belangrijk is dat deze uitbreiding van het protocol het gebruik van 
minder zuivere, maar gemakkelijker verkrijgbare MACS®-geïsoleerde Treg fracties 
mogelijk maakt. Daarmee heeft deze aanvulling op het expansie protocol een hoge 
potentie voor ex vivo expansie van Treg voor klinische toepassingen.
Een aanvullende vraag voor succesvolle Treg-gebaseerde therapie is hoe klinische 
behandelingen met immunosuppressieve drugs (ISDs) de overleving en functie 
van Treg beïnvloeden. De impact van de huidige ISDs op Treg is onderzocht en 
beschreven, veelal in in vitro studies. Bijvoorbeeld calcineurineremmers zijn 
waarschijnlijk schadelijk voor Treg subpopulaties, terwijl rapamycine en  MMF 
zorgen voor in vivo Treg behoud. Het klinisch relevante antwoord zal komen uit de 
resultaten van de ONE studie, waarin Tregs zullen worden toegediend aan nier- of 
levertransplantatie patiënten met een standaard triple ISDs therapie (prednisolon, 
MMF en tacrolimus). In vitro tonen wij aan dat MPA (de actieve metaboliet van 
MMF) celproliferatie niet alleen remt via depletie van intracellulair GTP en dGTP 
depots, maar bij humane conventionele CD4+ T-cellen leidt tot een (reversibele) 
toestand van anergie en metabolische cellulaire herprogrammering (hoofdstuk 3). 
Deze gegevens suggereren dat een optimale dosering van MPA de homeostatische 
mechanismen en daarmee het immunologische evenwicht minimaal hoeven te 
beïnvloeden. 
Sotrastaurin (ook bekend als AEB071) werd gebruikt in een klinische trial om de 
klinische symptomen bij psoriasis patiënten verminderen. Beschreven is dat PKCθ 
een andere lokalisatie had in de immunologische synaps tussen regulerende T-cellen 
en conventionele T-cellen. Gebaseerd op de waarneming dat CD28 signalen cruciaal 
zijn voor Treg proliferatie en functie (hoofdstuk 4) en de kennis dat PKCθ een 
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van de belangrijkste downstream aangrijpingspunten van CD28 is (hoofdstuk 2), 
beschrijven we dat selectieve remming van PKC met de remmer sotrastaurin effector-
T-cel responsen blokkeert met behoud van een stabiel Treg fenotype (hoofdstuk 6). 
Sotrastaurin kan de conversie van zowel gezonde als psoriatische Treg naar IL-
17/IFNγ producerende cellen voorkomen, en een stabiel Treg fenotype stimuleren. 
Deze Treg behouden hun suppressieve capaciteit en een hoge FOXP3 en CD25 
expressie, zelfs in aanwezigheid van het cytokine IL-1β dat normaal gesproken zorgt 
voor een versterkt Th17 fenotype. Farmacologische remming van PKC kan dienen 
als een krachtig instrument voor het gelijktijdig remmen van effector T-cellen, terwijl 
de Treg expansie wordt bevorderd. Hierdoor wordt het therapeutisch potentieel voor 
de behandeling van auto-immuunziekten als psoriasis duidelijk zichtbaar.
Het uiteindelijke doel van immunosuppressieve therapie in de kliniek is om immuun 
tolerantie / homeostase te bereiken zonder het levenslange noodzakelijke gebruik 
van schadelijke, niet-selectieve immunosuppressieve geneesmiddelen. Regulatoire 
T-cellen zijn een optimale kandidaat voor een dergelijke benadering. Één van de 
belangrijkste pijnpunten voor de succesvolle toepassing van Treg-gebaseerde 
celtherapie is de stabiliteit van Treg tijdens en na ex vivo expansie en na de 
overdracht naar patiënten. In dit proefschrift laten we zien dat de huidige expansie 
protocollen kunnen verbeterd worden door de toevoeging van sterke CD28 en / of 
TNFR2 signalling groepen. Single-CD28 stimulatie resulteert in een sterke proliferatie 
van humane Treg die een hoge FOXP3 expressie hebben met een beperkt pro-
inflammatoir cytokine producerend potentieel en een sterke suppressie capaciteit. 
Treg geëxpandeerd in aanwezigheid van een TNFR2-agonist en rapamycine 
blijven stabiel en behouden hun suppressie capaciteit. De aanwezigheid van deze 
twee agentia laat ook toe om de Treg populatie verkregen via MACS isolatie te 
gebruiken, welke minder zuiver zijn maar makkelijker verkrijgbaar. De ideale 
immunosuppressieve medicatie moet agressieve T-cellen remmen en tegelijkertijd 
Treg behouden of versterken. De farmacologische remming van PKC kan hiervoor 
dienen. We toonden immers aan dat sotrastaurin gelijktijdig Teff remt en Treg 
bevordert.
213
Nederlandsesamenvatting
9

Chapter 10
Acknowledgement
216
Chapter 10
10
Coming to the last but not the least important chapter of the thesis, I would like to 
convey my deepest thanks to all of you.
First and foremost, Irma and Mieke. Thank you both for giving me a chance to 
walk into the field of immunology, considering that my experiences mainly focus 
on the molecular/cell biology. Thank you for the mentorship all these years. It is 
your invaluable tutoring that guide me through the beautiful world of immunology. I 
have learned a lot from the way you think the academic questions thus keeping the 
research “on the track”, the way you capture the points from complex data and always 
wrap them into a structural story. Also I have benefited so much from your enormous 
comments for all those academic writings. I love our “cut and paste” games.
My co-supervisors, Hans and Ruben. Thank you for patiently answering my 
innumerous naïve or difficult questions. Hans has never been upset when experiments 
were not proceeding smoothly, and Ruben is always my “signal pathway” supporter 
for helping design experiments and digest results. I am really appreciate your help to 
interpret unusual experiment outcomes, and to make “juicy” stories.
I am realy enjoy to work together with so many experienced analysts and researchers 
in LMI. I have learned all tricks & tips about the isolation of PBMCs/CD4/Treg cells 
from Esther F and Esther VR. I have asked Bram and Marina thousands of questions 
like “how to use…” and “where is …” I sincerely thank you guys for sharing your 
experiences and skills, and even carrying out some of my experiments. Henk, I 
thank you for generating the beautiful data of the demethylation of TSDR. Rob and 
Gaby, I appreciate you two help for cell sorting, which sometimes even performed 
out of the office hours.
My previous and current roommates, Jorieke, Diana, Clare, Vivian, Sip, Elena, Clive, 
Sija, Paulo, Dorien, Yessica, and all other LMI-ers especially Hans (Jacobs), Arnold, 
Jos, Kjeld, Urnie, Muriel, you have been such gracious friends by sharing the lab&life 
skills as well as the dutch cultural backgrounds. I also would like to thank the FCM-
ers from the laboratory of haematology, Romy and Peter from the department of 
dermatology, for all practical helps. 
Particularly, my sincere thanks to all (chinese) friends I met here. Thank you for 
being there to keep my (outside of the lab) life cheerful and colourful. Claire&Louis, 
it is amazing to meet you in Nijmegen. Hopefully we can still see eac other now 
and then, and I will try to vistit you in SG as well. I’d like to offer my special thanks 
to Lu&Bingbo, and Jianying&Qing. I really appreciate your babysitting during our 
217
Acknowledgement
10
difficult moments. 
亲爱的哥哥姐姐，谢谢你们一直以来对我的关爱包容与支持，让我成为世界上最幸
运的小妹。正是你们默默在背后的付出和照顾，使我能够一直追随自己的梦想，谢
谢你们为了咱们的大家庭所作出的奉献与牺牲。
亲爱的爸爸妈妈，感谢您们几十年来不辞辛劳抚育我们成长；感谢您们倾其所有支
持我的梦想；从您们勤苦劳作的背影和日常琐碎的唠叨中，我渐渐明白做人成功比
事业有成更重要。正是您们浓厚的爱支持着我一次次面对挑战，承受挫折；感谢您
们为我做的一切，祝愿您们健康平安。
Lovely Andy and Grace, you are the best gifts we ever had. You have enriched our 
lives so much. We are so glad to watch you growing up, through which to realise our 
joys and responsibilities. Papa and mama cherish you dearly.
Dear Xinhui, thank you for always being there for supporting and also bearing my 
(stupid) mistakes. We share the joys on our life journey and we support each other 
during the difficulty moments. We will face the life challenges together until we loss 
the black hair. Love.
218
List of Publications
10
List of Publications
He X, Landman S, Bauland CG, van den Dolder J, Koenen HJ, Joosten I. TNFR2 
agonist facilitates high purity expansion of human Treg starting from low purity 
isolated Treg. (Submitted for publication)
He X, Smeets RL, van Rijssen E, Boots AM, Joosten I, Koenen HJ. Single CD28 
stimulation induces stable and polyclonal expansion of human regulatory T cells. 
(Submitted for publication) 
He X, de Oliveira VL, Keijsers R, Joosten I, Koenen HJ. Lymphocyte isolation from 
human skin for phenotypic analysis and ex vivo cell culture. (Accepted by Journal of 
Visualized Experiments, in press)
He X, Koenen HJ, Smeets RL, Keijsers R, van Rijssen E, Koerber A, van de Kerkhof 
PC, Boots AM, Joosten I. Targeting PKC in human T cells using sotrastaurin (AEB071) 
preserves regulatory T cells and prevents IL-17 production. J Invest Dermatol. 2014 
Apr;134(4):975-83.
Smeets RL, He X‡, Fleuren WW‡, Vink PM, Wijnands F, Gorecka M, Klop H, 
Bauerschmidt S, Garritsen A, Koenen HJ, Joosten I, Boots AM, Alkema W. 
Molecular pathway profiling of T lymphocyte signal transduction pathways; Th1 and 
Th2 genomic fingerprints are defined by TCR and CD28-mediated signaling. BMC 
Immunol. 2012 Mar 14;13:12. (‡Authors contributed equally to this paper.)
He X, Smeets RL, Koenen HJ, Vink PM, Wagenaars J, Boots AM, Joosten I. 
Mycophenolic acid-mediated suppression of human CD4+ T cells: more than mere 
guanine nucleotide deprivation. Am J Transplant. 2011 Mar;11 (3):439-49.
S. Dinkla, B. van Cranenbroek, W.A. van der Heijden, X. He, R. Wallbrecher, I.E. 
Dumitriu, A.J. van der Ven, G.J.C.G.M. Bosman, H.J.P.M. Koenen, and I. Joosten.
Platelet-derived microparticles inhibit IL-17 production by regulatory T cells through 
P-selectin. DOI: http://dx.doi.org/10.1182/blood-2015-04-640300. Blood. In print.
Khoo AL, Joosten I, Michels M, Woestenenk R, Preijers F, He XH, Netea MG, van 
der Ven AJ, Koenen HJ. 1,25-Dihydroxyvitamin D3 inhibits proliferation but not the 
suppressive function of regulatory T cells in the absence of antigen-presenting cells. 
Immunology. 2011 Dec;134(4):459-68.
219
List of Publications
10
Cui ZJ, He XH. The pre-synaptic blocker toosendanin does not inhibit secretion in 
exocrine cells. World J Gastroenterol. 2002 Oct;8(5):918-22.
220
Curriculum Vitae
10
Curriculum Vitae
Xuehui He, daughter of Jintian He (father) and Xiuying Wu (mother), was born on 8 
November 1978 in Henan, China. She graduated from Henan University in Kai-Feng, 
China with the degree of bachelor of science in 1999. She furthered her study at the 
Institute of Cell Biology, College of Life Science at Beijing Normal University and got 
her master degree of science in 2002 under the supervision of prof. dr. Zongjie Cui. 
She moved to Germany in 2003 to continue her PhD study at Faculty of Medicine – 
Internal Medicine IV in University Hospital Tuebingen and Eberhard Karls University 
Tuebingen, Germany. There, she received a systemic training in the area of 
molecular cell biology, finished her project titled “The modulation of insulin signalling 
by focusing on the PKB/Akt kinase binding proteins and phosphorylated substates” 
under the supervision of PD dr. rer. nat. Reiner Lammers. She received her doctoral 
degree of science in 2007. 
In January 2008, she started to work as a post-doc together with prof. dr. Irma 
Joosten and dr. Hans Koenen at LMI at the Radboud university medical center 
Nijmegen. The initial project she performed was to explore the therapeutic inhibition 
of human CD4+ T cells using a pharmaceutical compound based research approach. 
Then she switched the topic to reveal the effect of immunosuppressive drugs on 
the maintenance and activation of human regulatory T cells. She accepted a PhD 
position on this topic in 2012 and furthered her research in finding ways to preserve 
a stable Treg phenotype and function, thus favouring their clinical applications. 
She is married to Xinhui Wang. They have a son Andy, born in 2011 in Nijmegen, and 
a daughter Grace, born in 2015 in Nijmegen. 
221
Curriculum Vitae
10
